PARP-1 degrading agent and use thereof
A novel PARP-PROTAC compound effectively addresses drug resistance and side effects of current PARP inhibitors by selectively degrading PARP-1 protein, enhancing clinical efficacy and safety.
Patent Information
- Application Number
- JP2024523825
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2022-10-13
- Filing Date
- 2022-10-21
- Publication Date
- 2024-11-06
- Estimated Expiration
- 2042-10-21
AI Technical Summary
Current PARP inhibitors face challenges such as drug resistance, rapid recovery of PARP protein activity after drug cessation, and side effects like hematologic toxicity, necessitating the development of more effective and safer PARP inhibitors.
Development of a novel PARP-PROTAC compound that selectively degrades PARP-1 protein through a covalent bond with an E3 ubiquitin ligase binding moiety, utilizing a PARP-1 target binding moiety and a chemical linking moiety to form a covalent bond, thereby inhibiting PARP-1 activity.
The PARP-PROTAC compound demonstrates high PARP-1 inhibition selectivity, safety, and improved pharmacokinetic characteristics, offering potential for clinical efficacy with reduced side effects.
Smart Images

Figure 2024540970000001_ABST
Abstract
Description
[Technical field]
[0001] The present invention belongs to the pharmaceutical field, and specifically relates to a small molecule compound having PARP-1 degrading activity, its stereoisomer, pharma- ceutically acceptable salt, solvate, cocrystal or deuterated product, and its use in the manufacture of a medicament for treating related diseases. [Background technology]
[0002] Approximately 5% of breast cancer patients are associated with BRCA1 / 2 gene germline gene mutations (BRCA1 gene 3%, BRCA2 gene 2%). The majority of breast cancers caused by BRCA1 mutations are triple-negative breast cancers (70%), while BRCA2 mutations are more likely to cause estrogen receptor-positive breast cancers (70%). BRCA1 / 2 genes are tumor suppressor genes and play an important role in repairing DNA damage, normal cell growth, etc. The gene mutation suppresses normal repair ability after DNA damage, causing homologous recombination deficiency (HRD), i.e., functional loss of BRCA or mutations or functional loss occurring in other homologous recombination-related genes, which makes it impossible to repair double-stranded DNA breaks by homologous recombination repair (HRR), ultimately resulting in canceration.
[0003] PARP1, an abbreviation for poly(ADP-ribose) polymerase 1, was first reported over 50 years ago and has since been found to play important roles in DNA repair, maintaining genome integrity, and regulating various metabolic and signaling processes. PARP1 can catalyze the transfer of ADP-ribose residues from NAD+ to target substrates and build poly(ADP-ribose) (PAR) chains. PARP plays an important role in the excision and repair process of DNA single-stranded bases. In HRD tumor cells, DNA double strands cannot be repaired, and PARP inhibitors block the repair of single strands, thereby forming a "synthetic lethal" effect and causing tumor cell death.
[0004] PARP inhibitors have a "trap" effect on PARP protein, which results in the PARP protein binding to damaged DNA being trapped in the DNA, which in turn prevents other DNA repair proteins from binding, ultimately causing cell death. However, conventional PARP small molecule inhibitors cannot affect the content of PARP protein, and once the drug is stopped, the PARP protein can quickly regain activity, making drug resistance prone to occur. In addition, some side effects of PARP inhibitors, including blood toxicity such as thrombocytopenia, may also be related to such a "trap" effect. PARP-PROTACs can prevent PARP1 trapping by blocking the catalytic and scaffolding functions of PARP1. Summary of the Invention [Problem to be solved by the invention]
[0005] The development of druggable PARP-PROTACs remains an unmet clinical need. [Means for solving the problem]
[0006] The present invention has developed a novel PARP-PROTAC, which can effectively solve the problems existing in current PARP inhibitors, has good efficacy, high safety, few side effects, high PARP1 inhibition selectivity and good pharmacokinetic characteristics, and has good prospects for clinical development.
[0007] A PARP-1 degrading agent of formula (I), its stereoisomer, deuterated form, solvate, pharma- ceutically acceptable salt or co-crystal, [ka] where ULM is an E3 ubiquitin ligase binding moiety, L is a bond or chemical linking moiety that covalently couples the PTM and ULM; the PTM is a PARP-1 target binding moiety; L according to the present invention forms a covalent bond with PTM and ULM at any site, including a bond by a single covalent bond or a bond by multiple covalent bonds. A single covalent bond, for example, means that L replaces one H in PTM to form one covalent bond. Multiple covalent bonds include bonds of two, three, and the like. The form of bonding by two covalent bonds includes, for example, L replacing two H or other groups at the same atom of PTM to form a double bond, or L replacing two H or other groups at different atoms of PTM to form a ring, and the ring includes a monocyclic ring, a fused ring, a spiro ring, and the like. The form of bonding by three covalent bonds includes, for example, L replacing three H at the same atom of PTM to form a triple bond, or L replacing three H at different atoms of PTM to form a bridged ring, and the like. In some specific embodiments, the PTM has a structure of formula (I-1), and the L forms a single bond covalent bond with the PTM by replacing any one of H in (I-1), or L forms a 4- to 7-membered heterocycloalkyl group containing 1 to 2 N atoms and 0 to 2 heteroatoms selected from S and O together with R4, R5 and the N atom to which they are connected, thereby covalently bonding to the PTM; [ka] In some specific embodiments, the PTM has a structure of formula (I-1) or (I-2), and the L forms a single bond covalent bond with the PTM by replacing any one of H in (I-1) or (I-2), or L forms a 4- to 10-membered heterocycloalkyl group containing 1 to 2 N atoms and 0 to 2 heteroatoms selected from S and O together with R4, R5 and the N atom to which they are connected, and is covalently bonded to the PTM; [ka] In some specific embodiments, the PTM has a structure represented by formula (I-1), (I-2), (I-3) or (I-4), and the L forms a single bond covalent bond with the PTM by replacing any one of H in (I-1), (I-2), (I-3) or (I-4), or the L forms a 4- to 10-membered heterocycloalkyl group containing 1 to 2 N atoms and 0 to 2 heteroatoms selected from S and O together with R4, R5 and the N atom to which they are connected, thereby covalently bonding to the PTM; [ka] In the present invention, the "1 to 2 N atoms" mentioned in "L, together with R4, R5 and the N atom to which they are bonded, forms a 4 to 10-membered heterocycloalkyl group containing 1 to 2 N atoms and 0 to 2 heteroatoms selected from S and O" means that the heterocycloalkyl group further contains 0 to 1 additional N atom in addition to the N atoms bonded to R4 and R5, In some specific embodiments, the PARP-1 degrading agent has formula (II), formula (III) or formula (IV): [ka] The structure is In some specific embodiments, the PARP-1 degrading agent is represented by Formula (II), Formula (III), Formula (IV), (V), (VI) or (VII): [ka] The structure is In some specific embodiments, the PARP-1 degrading agent is represented by formula (II-1), formula (III-1), formula (IV-1), formula (II-2), formula (III-2) or formula (IV-2): [ka] The structure is In some specific embodiments, the PARP-1 degrading agent is represented by formula (II-1), formula (III-1), formula (IV-1), formula (II-2), formula (III-2), formula (IV-2), (V-1), (VI-1), (VII-1), (V-2), (VI-2) or (VII-2): [ka] The structure is In some specific embodiments, the structure of formula (I-1), (I-2), (II), (III), (IV), (II-1), (III-1), (IV-1), (II-2), (III-2), (IV-2), (V-1), (VI-1), (VII-1), (V-2), (VI-2), or (VII-2) is X1, X2, X3, X4 and X5 are independently N or CR6, and in some specific embodiments, X1, X2, X3, X4 and X5 are independently N or CH, and in some specific embodiments, X1, X3, X4 are N, X2 is CH and X5 is N or CH; Ring A is a 4-12 membered heterocycloalkyl group containing 1-2 N atoms and 0-2 heteroatoms selected from S and O. In the present invention, the "1-2 N atoms" referred to in "ring A is a 4-12 membered heterocycloalkyl group containing 1-2 N atoms and 0-2 heteroatoms selected from S and O" means that the heterocycloalkyl group further contains 0-1 additional N atom in addition to the one N atom shown in ring A, or the heterocycloalkyl group further contains 0-1 additional N atom in addition to the one N atom shown in ring A. and further includes the case where X3 is an N atom, in which case the heterocycloalkyl group further contains 0 additional N atoms. In some specific embodiments, ring A is a 4-12 membered monocyclic heterocycloalkyl group, a spirocyclic heterocycloalkyl group, a bridged cyclic heterocycloalkyl group or a fused cyclic heterocycloalkyl group containing 1-2 N atoms and 0-2 heteroatoms selected from S and O. In some specific embodiments, ring A is a piperidine ring, a piperazine ring, a tetrahydropyrrolyl ring, [ka] And so on. R1 is H, C 1-4 Alkyl group, halogen, CN or C 3-6 and cycloalkyl groups, the alkyl and cycloalkyl groups being optionally substituted with 1 to 3 groups selected from halogen, OH, NH2, and COOH; in some specific embodiments, R1 is H or C 1-3 an alkyl group, the alkyl group being optionally selected from F, Cl, Br, I, OH, NH, C 1-4 alkoxy and COOH; and in some specific embodiments, C 1-3 the alkyl group is a methyl group, an ethyl group, a propyl group, or an isopropyl group; R2 is H, C 1-4 Alkyl group, C 1-4alkoxy groups, halogens, OH or NH2, the alkyl and alkoxy groups being optionally halogens, OH, NH2, COOH and C 3-6 In some specific embodiments, R2 is substituted with 1 to 3 groups selected from a cycloalkyl group, H, C 1-3 Alkyl group, C 1-3 In some specific embodiments, R2 is H; in some specific embodiments, C 1-3 The alkyl group is a methyl group, an ethyl group, a propyl group, or an isopropyl group. 1-3 the alkoxy group is a methoxy group, an ethoxy group, a propoxy group, or an isopropoxy group; R3 is H, C 1-4 Alkyl groups, halogens, C 1-4 alkoxy groups or NH2, the alkyl and alkoxy groups being optionally selected from halogen, OH, NH2, COOH and C 3-6 In some specific embodiments, R is substituted with 1 to 3 groups selected from a cycloalkyl group, H, C 1-3 Alkyl group, C 1-3 In some specific embodiments, R is an alkoxy group, F, Cl, Br, or I; in some specific embodiments, R is H; and in some specific embodiments, C 1-3 The alkyl group is a methyl group, an ethyl group, a propyl group, or an isopropyl group. 1-3 the alkoxy group is a methoxy group, an ethoxy group, a propoxy group, or an isopropoxy group; R4 is H, C 1-4 Alkyl group, C 3-6 A cycloalkyl group or a 4-7 membered heterocycloalkyl group containing 1-3 heteroatoms selected from N, S and O, wherein the alkyl group, cycloalkyl group and heterocycloalkyl group are optionally selected from halogen, OH, NH2, COOH and C 3-6 cycloalkyl groups, in some specific embodiments, R4 is H, a methyl group, an ethyl group, a propyl group, a cyclopropyl group, a cyclobutyl group, and the like; R5 is H, C 1-4 Alkyl group or C 3-6 a cycloalkyl group, the alkyl group and the cycloalkyl group being optionally substituted with 1 to 3 groups selected from halogen, OH, NH2 and COOH; in some specific embodiments, R5 is H, a methyl group, an ethyl group, a propyl group, a cyclopropyl group, a cyclobutyl group, etc.; Optionally, R4 and R5 together with the N atom to which they are attached form a 4-7 membered heterocycloalkyl group containing 1-3 heteroatoms selected from N, S and O, said heterocycloalkyl group optionally being selected from halogen, OH, NH2, COOH and C 3-6 or optionally R4 and R5 together with the N atom to which they are attached form a 4-10 membered heterocycloalkyl group containing 1-3 heteroatoms selected from N, S and O, said heterocycloalkyl group optionally being substituted with halogen, OH, NH2, COOH and C 3-6 cycloalkyl group, and in some specific embodiments, R4 and R5 together with the N atom to which they are attached form a 4-6 membered monocyclic heterocycloalkyl group, a 7-10 membered bicyclic spirocyclic heterocycloalkyl group containing 1, 2 or 3 heteroatoms selected from N, S and O; Each R6 is independently H, C 1-4 Alkyl group, halogen, CN or C 3-6 a cycloalkyl group, the alkyl group or the cycloalkyl group optionally being selected from halogen, OH, NH, C 1-4 alkoxy group, COOH; and in some specific embodiments, R6 is independently H; M is -NR5- or [ka] wherein ring B is a 4-10 membered heterocycloalkyl group containing 1-2 N atoms and 0-2 heteroatoms selected from S and O, * is a linking end with the left side, in the present invention, the "1-2 N atoms" mentioned in "ring B is a 4-10 membered heterocycloalkyl group containing 1-2 N atoms and 0-2 heteroatoms selected from S and O" means that the heterocycloalkyl group further contains 0-1 additional N atom in addition to the one N atom shown in ring B, in some specific embodiments, M is -NH- or a 4-10 membered monocyclic heterocycloalkyl group or spirocyclic heterocycloalkyl group containing 1-2 N atoms and 0-2 heteroatoms selected from S and O, in some specific embodiments, M is a piperidine ring, a piperazine ring, a tetrahydropyrrolyl ring, an azetidinyl group, [ka] and the ring N atom is the end of the link to the PTM, Each R L are independently -NR N -, C 1-3 Alkylene group, -CO-, -O-, -S-, C 3-6 A cycloalkylene group, a phenyl group, a 5- to 6-membered heteroaryl group containing 1 to 3 heteroatoms selected from N, S, and O, a 4- to 10-membered heterocycloalkylene group containing 1 to 3 heteroatoms selected from N, S, and O, 2-6 Alkenylene group, C 2-6 and an alkynylene group, wherein the alkylene group, alkenylene group, alkynylene group, cycloalkylene group, phenyl group, heteroaryl group, and heterocycloalkylene group are optionally selected from the group consisting of C 1-4 Alkyl groups, halogens, CN, C 1-4 Alkoxy and halogenated C 1-4 In some specific embodiments, each R L are independently -NH-, C 1-3 Alkylene group, -CO-, -O-, C 3-6A cycloalkylene group, a phenyl group, a 5- to 6-membered heteroaryl group containing 1 to 3 heteroatoms selected from N, S, and O, a 4- to 10-membered heterocycloalkylene group containing 1 to 3 heteroatoms selected from N, S, and O, 2-6 Alkenylene group, C 2-6 and the alkylene, alkenylene, alkynylene, phenyl, heteroaryl, cycloalkylene and heterocycloalkylene groups are optionally selected from the group consisting of: 1-3 Alkyl groups: F, Cl, Br, I, CN, C 1-3 Alkoxy and halogenated C 1-3 In some specific embodiments, each R L are independently -NR N -, C 1-3 Alkylene group, -CO-, -O-, -S-, C 3-6 a cycloalkylene group, a phenyl group, a 4- to 7-membered heterocycloalkylene group containing 1 to 3 heteroatoms selected from N, S, and O, and the alkylene group, the cycloalkylene group, the phenyl group, and the heterocycloalkylene group are optionally selected from C 1-4 Alkyl groups, halogens, CN, C 1-4 Alkoxy and halogenated C 1-4 In some specific embodiments, each R L are independently -NH-, C 1-3 Alkylene group, -O-, C 3-6 a cycloalkylene group, a phenyl group, a 4- to 7-membered heterocycloalkylene group containing 1 to 3 heteroatoms selected from N, S, and O, and the alkylene group, phenyl group, cycloalkylene group, and heterocycloalkylene group are optionally selected from C 1-3 Alkyl groups: F, Cl, Br, I, CN, C 1-3 Alkoxy and halogenated C 1-3 In some specific embodiments, each R Lare independently a methylene group, an ethylene group, a propylene group, NH, CO, O, S, a piperidinylene group, a piperazinylene group, a tetrahydropyrrolene group, an azetidinylene group, [ka] and the linking sites are any two non-H atoms, which may be the same or different, of the group, and in some specific embodiments, each R L are independently a methylene group, an ethylene group, a propylene group, NH, CO, O, a piperidinylene group, a piperazinylene group, a tetrahydropyrrolene group, an azetidinylene group, [ka] a phenyl group, a pyrazolyl group, an imidazolyl group, a pyridyl group, a thiazolyl group, a thienyl group, a pyridazinyl group, a pyrazinyl group, a pyrimidinyl group, a vinylene group, a propenylene group, an ethynylene group, or a propynylene group, and the linking sites are any two non-H atoms, which may be the same or different, of said groups; The condition is -M-(R L )n-, two identical -NR N -, -O- or -S- is not present; R N is H or C 1-4 In some specific embodiments, R N is H, a methyl group, an ethyl group, or a propyl group, n is an integer from 0 to 10, in some specific embodiments, n is an integer from 2 to 10, in some specific embodiments, n is 0, 1, 2, 3, 4, 5, 6, 7, or 8, in some specific embodiments, n is 1, 2, 3, 4, 5, 6, or 7, in some specific embodiments, n is 2, 3, 4, 5, 6, 7, or 8, in some specific embodiments, n is 2, 3, 4, 5, 6, or 7; the ULM is selected from U1, U2, U3, U4, U5, U6, U7, and in some embodiments, the ULM is selected from U1, U2, or U3; [ka] In some specific embodiments, ULM is [ka] is selected from In some specific embodiments, ULM is [ka] is selected from m is 1, 2, or 3; in some specific embodiments, m is 1 or 2; R7 is H, halogen, CN, NH2, OH, C 1-4 Alkyl group or C 1-4 an alkoxy group, the alkyl or alkoxy group being optionally substituted with 1 to 3 groups selected from halogen, CN, NH2 and OH; in some specific embodiments, R7 is H, F, Cl, Br, I, CN, NH2 or OH; R8, R9 are H or taken together to form =O.
[0008] As a specific first technical solution of the present invention, a PARP-1 decomposing agent of formula (I), its stereoisomer, deuterated product, solvate, pharma- ceutically acceptable salt or cocrystal is provided, [ka] where ULM is an E3 ubiquitin ligase binding moiety, L is a bond or chemical linking moiety that covalently couples the PTM and ULM; The PTM has a structure represented by formula (I-1), (I-2), (I-3) or (I-4), and the L forms a single bond covalent bond with the PTM by replacing any one of H in (I-1), (I-2), (I-3) or (I-4), or the L forms a 4- to 10-membered heterocycloalkyl group containing 1 to 2 N atoms and 0 to 2 heteroatoms selected from S and O together with R4, R5 and the N atom to which they are linked, thereby covalently bonding to the PTM; [ka] X1, X2, X3, X4 and X5 are independently N or CR6; Ring A is a 4-12 membered heterocycloalkyl group containing 1-2 N atoms and 0-2 heteroatoms selected from S and O; R1 is H, C 1-4 Alkyl group, halogen, CN or C 3-6 and cycloalkyl groups, the alkyl and cycloalkyl groups being optionally selected from halogen, OH, NH, C 1-4 substituted with 1 to 3 groups selected from an alkoxy group and COOH; R2 is H, C 1-4 Alkyl group, C 1-4 alkoxy groups, halogens, OH or NH2, the alkyl and alkoxy groups being optionally halogens, OH, NH2, COOH and C 3-6 substituted with 1 to 3 groups selected from cycloalkyl groups; R3 is H, C 1-4 Alkyl groups, halogens, C 1-4 alkoxy groups or NH2, the alkyl and alkoxy groups being optionally selected from halogen, OH, NH2, COOH and C 3-6 substituted with 1 to 3 groups selected from cycloalkyl groups; R4 is H, C 1-4 Alkyl group, C 3-6A cycloalkyl group or a 4-7 membered heterocycloalkyl group containing 1-3 heteroatoms selected from N, S and O, wherein the alkyl group, cycloalkyl group and heterocycloalkyl group are optionally selected from halogen, OH, NH2, COOH and C 3-6 substituted with 1 to 3 groups selected from cycloalkyl groups; R5 is H, C 1-4 Alkyl group or C 3-6 a cycloalkyl group, the alkyl group and the cycloalkyl group being optionally substituted with 1 to 3 groups selected from halogen, OH, NH2 and COOH; Optionally, R4 and R5 together with the N atom to which they are attached form a 4-10 membered heterocycloalkyl group containing 1-3 heteroatoms selected from N, S and O, the heterocycloalkyl group optionally being selected from halogen, OH, NH2, COOH and C 3-6 substituted with 1 to 3 groups selected from cycloalkyl groups; Each R6 is independently H, C 1-4 Alkyl group, halogen, CN or C 3-6 a cycloalkyl group, the alkyl group or the cycloalkyl group optionally being selected from halogen, OH, NH, C 1-4 It is substituted with 1 to 3 groups selected from an alkoxy group and COOH.
[0009] As a second technical solution of the present invention, there is provided a PARP-1 decomposing agent, its stereoisomer, deuterated product, solvate, pharma-ceutically acceptable salt or cocrystal, wherein the PARP-1 decomposing agent has a structure of formula (II) or formula (III): [ka] wherein ring A is a 4-12-membered monocyclic heterocycloalkyl group, a spirocyclic heterocycloalkyl group, a bridged cyclic heterocycloalkyl group, or a fused cyclic heterocycloalkyl group containing 1-2 N atoms and 0-2 heteroatoms selected from S and O; M is -NR5- or [ka] wherein ring B is a 4-10 membered heterocycloalkyl group containing 1-2 N atoms and 0-2 heteroatoms selected from S and O, and * is a linking end to the left side, Each R L are independently -NR N -, C 1-3 Alkylene group, -CO-, -O-, -S-, C 3-6 a cycloalkylene group, a phenyl group, a 4- to 7-membered heterocycloalkylene group containing 1 to 3 heteroatoms selected from N, S, and O, and the alkylene group, the cycloalkylene group, the phenyl group, and the heterocycloalkylene group are optionally selected from C 1-4 Alkyl groups, halogens, CN, C 1-4 Alkoxy and halogenated C 1-4 substituted with 1 to 3 groups selected from alkoxy groups; The condition is -M-(R L )n-, two identical -NR N -, -O- or -S- is not present; R N is H or C 1-4 is an alkyl group, n is an integer from 0 to 10, and more preferably an integer from 2 to 10; ULM is U1, U2 or U3: [ka] is selected from m is 1, 2 or 3; R7 is H, halogen, CN, NH2, OH, C 1-4 Alkyl group or C 1-4 an alkoxy group, the alkyl or alkoxy group being optionally substituted with 1 to 3 groups selected from halogen, CN, NH2 and OH; R8, R9 are H or taken together to form =O.
[0010] As a third technical solution of the present invention, there is provided a PARP-1 decomposing agent, its stereoisomer, deuterated product, solvate, pharma-ceutically acceptable salt or cocrystal, wherein the PARP-1 decomposing agent has a structure of formula (II), formula (III) or formula (IV): [ka] wherein ring A is a 4-12-membered monocyclic heterocycloalkyl group, a spirocyclic heterocycloalkyl group, a bridged cyclic heterocycloalkyl group, or a fused cyclic heterocycloalkyl group containing 1-2 N atoms and 0-2 heteroatoms selected from S and O; M is -NR5- or [ka] wherein ring B is a 4-10 membered heterocycloalkyl group containing 1-2 N atoms and 0-2 heteroatoms selected from S and O, and * is a linking end to the left side, Each R L are independently -NR N -, C 1-3 Alkylene group, -CO-, -O-, -S-, C 3-6 A cycloalkylene group, a phenyl group, a 5- to 6-membered heteroaryl group containing 1 to 3 heteroatoms selected from N, S, and O, a 4- to 10-membered heterocycloalkylene group containing 1 to 3 heteroatoms selected from N, S, and O, 2-6 Alkenylene group, C 2-6 and an alkynylene group, wherein the alkylene group, alkenylene group, alkynylene group, cycloalkylene group, phenyl group, heteroaryl group, and heterocycloalkylene group are optionally selected from the group consisting of C 1-4 Alkyl groups, halogens, CN, C 1-4 Alkoxy and halogenated C 1-4 substituted with 1 to 3 groups selected from alkoxy groups; The condition is -M-(R L )n-, two identical -NR N -, -O- or -S- is not present; R N is H or C1-4 is an alkyl group, n is an integer from 0 to 10, ULM is U1, U2 or U3: [ka] is selected from m is 1, 2 or 3; R7 is H, halogen, CN, NH2, OH, C 1-4 Alkyl group or C 1-4 an alkoxy group, the alkyl or alkoxy group being optionally substituted with 1 to 3 groups selected from halogen, CN, NH2 and OH; R8, R9 are H or taken together to form =O.
[0011] As a fourth technical solution of the present invention, there is provided a PARP-1 decomposing agent, its stereoisomer, deuterated product, solvate, pharma-ceutically acceptable salt or cocrystal, wherein the PARP-1 decomposing agent has a structure represented by formula (II), formula (III), formula (IV), (V), (VI) or (VII): [ka] wherein ring A is a 4-12-membered monocyclic heterocycloalkyl group, a spirocyclic heterocycloalkyl group, a bridged cyclic heterocycloalkyl group, or a fused cyclic heterocycloalkyl group containing 1-2 N atoms and 0-2 heteroatoms selected from S and O; M is -NR5- or [ka] wherein ring B is a 4-10 membered heterocycloalkyl group containing 1-2 N atoms and 0-2 heteroatoms selected from S and O, and * is a linking end to the left side, Each R L are independently -NR N -, C 1-3 Alkylene group, -CO-, -O-, -S-, C 3-6A cycloalkylene group, a phenyl group, a 5- to 6-membered heteroaryl group containing 1 to 3 heteroatoms selected from N, S, and O, a 4- to 10-membered heterocycloalkylene group containing 1 to 3 heteroatoms selected from N, S, and O, 2-6 Alkenylene group, C 2-6 and an alkynylene group, wherein the alkylene group, alkenylene group, alkynylene group, cycloalkylene group, phenyl group, heteroaryl group, and heterocycloalkylene group are optionally selected from the group consisting of C 1-4 Alkyl groups, halogens, CN, C 1-4 Alkoxy and halogenated C 1-4 substituted with 1 to 3 groups selected from alkoxy groups; The condition is -M-(R L )n-, two identical -NR N -, -O- or -S- is not present; R N is H or C 1-4 is an alkyl group, n is an integer from 0 to 10, ULMs are U1, U2, U3, U4, U5, U6, U7: [ka] is selected from m is 1, 2 or 3; R7 is H, halogen, CN, NH2, OH, C 1-4 Alkyl group or C 1-4 an alkoxy group, the alkyl or alkoxy group being optionally substituted with 1 to 3 groups selected from halogen, CN, NH2, and OH; R8, R9 are H or taken together to form =O.
[0012] As a fifth technical solution of the present invention, there is provided a PARP-1 decomposing agent according to the second or third technical solution, its stereoisomer, deuterated product, solvate, pharma-ceutically acceptable salt or cocrystal, wherein the PARP-1 decomposing agent is represented by formula (II-1) or formula (III-1): [ka] It has the structure:
[0013] As a sixth technical solution of the present invention, there is provided a PARP-1 decomposing agent according to the third technical solution, its stereoisomer, deuterated product, solvate, pharma-ceutically acceptable salt or cocrystal, wherein the PARP-1 decomposing agent is represented by formula (II-1), formula (III-1), (IV-1), (II-2), (III-2) or (IV-2): [ka] It has the structure:
[0014] As a seventh technical solution of the present invention, there is provided a PARP-1 decomposing agent, its stereoisomer, deuterated product, solvate, pharma-ceutically acceptable salt or cocrystal according to the third and fourth technical solutions, wherein the PARP-1 decomposing agent is represented by formula (II-1), formula (III-1), (IV-1), (II-2), (III-2), (IV-2), (V-1), (VI-1), (VII-1), (V-2), (VI-2) or (VII-2): [ka] [ka] It has the structure:
[0015] As an eighth technical solution of the present invention, there is provided a PARP-1 decomposing agent according to any one of the first to seventh technical solutions, a stereoisomer thereof, a deuterated product thereof, a solvate thereof, a pharma- ceutically acceptable salt thereof, or a cocrystal thereof, X5 is CH or N; R1 is H or C 1-3 an alkyl group, the alkyl group being optionally substituted with 1 to 3 groups selected from F, Cl, Br, I, OH, NH2 and COOH; R2 is H, C 1-3 Alkyl group, C 1-3 an alkoxy group, F, Cl, Br or I; R3 is H, C 1-3 Alkyl group, C 1-3an alkoxy group, F, Cl, Br or I; n is 0, 1, 2, 3, 4, 5, 6, 7 or 8, further 2, 3, 4, 5, 6, 7 or 8, further 1, 2, 3, 4, 5, 6 or 7, further 2, 3, 4, 5, 6 or 7; R5 is H; Ring B is a 4-10 membered monocyclic heterocycloalkyl group or spirocyclic heterocycloalkyl group containing 1-2 N atoms and 0-2 heteroatoms selected from S and O; Each R L are independently -NH-, C 1-3 Alkylene group, -O-, C 3-6 a cycloalkylene group, a phenyl group, a 4- to 7-membered heterocycloalkylene group containing 1 to 3 heteroatoms selected from N, S, and O, and the alkylene group, phenyl group, cycloalkylene group, and heterocycloalkylene group are optionally selected from C 1-3 Alkyl groups: F, Cl, Br, I, CN, C 1-3 Alkoxy and halogenated C 1-3 substituted with 1 to 3 groups selected from alkoxy groups; The condition is -M-(R L )n-, there are no two identical -NH- or -O- linked; R7 is H, C 1-3 an alkyl group, F, Cl, Br or I; R8, R9 are H or ═O; m is 1 or 2.
[0016] As a ninth technical solution of the present invention, there is provided a PARP-1 decomposing agent according to any one of the first to seventh technical solutions, a stereoisomer thereof, a deuterated product thereof, a solvate thereof, a pharma- ceutically acceptable salt thereof, or a cocrystal thereof, X5 is CH or N; R1 is H or C 1-3 an alkyl group, the alkyl group being optionally substituted with 1 to 3 groups selected from F, Cl, Br, I, OH, NH2 and COOH; R2 is H, C 1-3 Alkyl group, C 1-3an alkoxy group, F, Cl, Br or I; R3 is H, C 1-3 Alkyl group, C 1-3 an alkoxy group, F, Cl, Br or I; n is 1, 2, 3, 4, 5, 6 or 7; R5 is H; Ring B is a 4-10 membered monocyclic heterocycloalkyl group or spirocyclic heterocycloalkyl group containing 1-2 N atoms and 0-2 heteroatoms selected from S and O; Each R L are independently -NH-, C 1-3 Alkylene group, -CO-, -O-, C 3-6 A cycloalkylene group, a phenyl group, a 5- to 6-membered heteroaryl group containing 1 to 3 heteroatoms selected from N, S, and O, a 4- to 10-membered heterocycloalkylene group containing 1 to 3 heteroatoms selected from N, S, and O, 2-6 Alkenylene group, C 2-6 and the alkylene, alkenylene, alkynylene, phenyl, heteroaryl, cycloalkylene and heterocycloalkylene groups are optionally selected from the group consisting of: 1-3 Alkyl groups: F, Cl, Br, I, CN, C 1-3 Alkoxy and halogenated C 1-3 substituted with 1 to 3 groups selected from alkoxy groups; The condition is -M-(R L )n-, there are no two identical -NH- or -O- linked; R7 is H, C 1-3 an alkyl group, F, Cl, Br or I; R8, R9 are H or ═O; m is 1 or 2.
[0017] As a tenth technical solution of the present invention, there is provided a PARP-1 decomposing agent according to any one of the first to seventh technical solutions, a stereoisomer thereof, a deuterated product thereof, a solvate thereof, a pharma- ceutically acceptable salt thereof, or a cocrystal thereof, -M-(R L )n- or -(R L )n- is selected from one of the following structures, and * is the linking end to the left side, [ka] In some embodiments, -M-(R L )n- or -(R L )n- is [ka] [ka] is selected from one of the structures:
[0018] As an eleventh technical solution of the present invention, there is provided a PARP-1 decomposing agent according to any one of the first to tenth technical solutions, a stereoisomer thereof, a deuterated product thereof, a solvate thereof, a pharma- ceutically acceptable salt thereof or a cocrystal thereof, wherein the decomposing agent is [ka] [ka] [ka] is selected from one of the structures: Here, in each of the above structures, [ka] It is.
[0019] As a twelfth technical solution of the present invention, there is provided a PARP-1 decomposing agent, its stereoisomer, deuterated product, solvate, pharma-ceutically acceptable salt or co-crystal according to the first to tenth technical solutions, wherein the decomposing agent is selected from one of the structures in Table A.
[0020] [Table 1-1] [Table 1-2] [Table 1-3] [Table 1-4] [Table 1-5] [Table 1-6] [Table 1-7]
[0021] Next, the present invention further provides a pharmaceutical composition, which includes a PARP-1 decomposing agent described in the first to twelfth technical proposals, its stereoisomer, deuterated product, solvate, pharma- ceutically acceptable salt or cocrystal, and a pharma-ceutically acceptable carrier and / or excipient.
[0022] Further, the pharmaceutical composition or pharmaceutical preparation comprises 1-1500 mg of the compound described in any one of the above technical solutions, its stereoisomer, deuterated product, solvate, pharma- ceutically acceptable salt or cocrystal, and a pharma- ceutically acceptable carrier and / or excipient.
[0023] Moreover, the present invention further provides the use of any one of the above embodiments in the manufacture of a medicament for treating / preventing a PARP-1 mediated disease.
[0024] The PARP-1 mediated disease includes, but is not limited to, breast cancer, ovarian cancer, uterine cancer, or cervical cancer.
[0025] The present invention further provides a method for treating a disease in a mammal, the method comprising administering to a subject a therapeutically effective amount of the compound described in any one of the above technical solutions, its stereoisomer, deuterated product, solvate or pharma- ceutically acceptable salt or cocrystal, and a pharma-ceutically acceptable carrier and / or excipient, wherein the therapeutically effective amount is preferably 1-1500 mg, and the disease is preferably breast cancer, ovarian cancer, uterine cancer or cervical cancer.
[0026] The present invention further provides a method for treating a disease in a mammal, comprising administering to said mammal a therapeutically effective amount of a compound according to the present invention or a stereoisomer, deuterated form, solvate, pharma- ceutically acceptable salt or co-crystal thereof, or a pharmaceutical composition thereof. In some embodiments, the mammal according to the present invention comprises a human.
[0027] An "effective amount" or "therapeutically effective amount" as used herein includes the administration of a sufficient amount of a compound disclosed herein that relieves to some extent one or more symptoms of the disease or condition being treated. In some embodiments, the result is a reduction and / or alleviation of the signs, symptoms, or causes of a disease, or any other desired alteration of a biological system. For example, an "effective amount" for therapeutic use is the amount of a composition comprising a compound disclosed herein that is required to provide a clinically significant reduction in a disease symptom. Examples of therapeutically effective amounts include 1-1500 mg, 1-1400 mg, 1-1300 mg, 1-1200 mg, 1-1000 mg, 1-900 mg, 1-800 mg, 1-700 mg, 1-600 mg, 1-500 mg, 1-400 mg, 1-300 mg, 1-250 mg, 1-200 mg, 1-150 mg, 1-125 mg, 1-100 mg, 1-80 mg, 1-60 mg, 1-50 mg, 1-40 mg, 1-25 mg, 1-20 mg, 5-10 ... 500mg, 5~1000mg, 5~900mg, 5~800mg, 5~700mg, 5~600mg, 5~500mg, 5~400mg, 5~300mg, 5~250mg, 5~200mg, 5~150mg, 5~1 25mg, 5~100mg, 5~90mg, 5~70mg, 5~80mg, 5~60mg, 5~50mg, 5~40mg, 5~30mg, 5~25mg, 5~20mg, 10~1500mg, 10~1000mg, 10 ~900mg, 10~800mg, 10~700mg, 10~600mg, 10~500mg, 10~450mg, 10~400mg, 10~300mg, 10~250mg, 10~200mg, 10~150mg, 1 0~125mg, 10~100mg, 10~90mg, 10~80mg, 10~70mg, 10~60mg, 10~50mg, 10~40mg, 10~30mg, 10~20mg, 20~1500mg, 20~1000 mg, 20~900mg, 20~800mg, 20~700mg, 20~600mg, 20~500mg, 20~400mg, 20~350mg, 20~300mg, 20~250mg, 20~200mg, 20~15 0mg, 20~125mg, 20~100mg, 20~90mg, 20~80mg, 20~70mg, 20~60mg, 20~50mg, 20~40mg, 20~30mg, 50~1500mg, 50~1000mg,50-900mg, 50-800mg, 50-700mg, 50-600mg, 50-500mg, 50-400mg, 50-300mg, 50-250mg, 50-200mg, 50-150mg, 50-125mg, 50-100mg, 100-1500mg, 100-1000mg, 100-900mg, 100-800mg, 100-700mg, 100-600mg, 100-500mg, 100-400mg, 100-300mg, 100-250mg, 100-200mg, but are not limited thereto.
[0028] The present invention relates to a pharmaceutical composition or formulation, comprising a therapeutically effective amount of a compound according to the present invention or a stereoisomer, deuterated form, solvate, pharma- ceutically acceptable salt or co-crystal thereof, and a carrier and / or excipient. The pharmaceutical composition may be in the form of a unit dosage form (the amount of active ingredient in a unit dosage form is also referred to as the "formulation specification"). In some embodiments, the pharmaceutical composition contains 1-1500 mg, 5-1000 mg, 10-800 mg, 20-600 mg, 25-500 mg, 40-200 mg, 50-100 mg, 1 mg, 1.25 mg, 2.5 mg, 5 mg, 10 mg, 12.5 mg, 15 mg, 20 mg, 25 mg, 30 mg, 35 mg, 40 mg, 45 mg, 50 mg, 55 mg, 60 mg, 65 mg, 70 mg, 75 mg, 80 mg, 85 mg, 90 mg, 95 mg, 100 mg, 110 mg, 120 mg, 125 mg, 130 mg, 140 mg, 150 mg, 160 mg, 170 mg, 180 mg, 190 mg, 200 mg, 210 mg, 220 mg, 230 mg, 240 mg, 250 mg, 260 mg, 270 mg, 280 mg, 290 mg, 300 mg, 310 mg, 320 mg, 330 mg, 340 mg, 350 mg, 360 mg, 370 mg, 380 mg, 390 mg, 400 mg, 410 mg, 420 mg, 430 mg, 440 mg, 450 mg, 50 mg, 55 mg, 60 mg, 65 mg, 70 mg, 75 mg, 80 mg, 85 mg, 90 mg, 95 mg, 100 mg, 110 mg, 120 mg, 125 mg, 130 mg, 140 mg, 150 mg, 160 mg, 1
[0051] The present invention may be administered in an amount of 0.1 mg, 0.2 mg, 0.3 mg, 0.4 mg, 0.5 mg, 0.6 mg, 0.7 mg, 0.8 mg, 0.9 mg, 10 mg, 11 mg, 12 mg, 13 mg, 14 mg, 15 mg, or 16 mg of a compound of the present invention or a stereoisomer, deuterated form, solvate, pharma- ceutically acceptable salt, or co-crystal thereof, including, but not limited to, 220 mg, 230 mg, 240 mg, 250 mg, 275 mg, 300 mg, 325 mg, 350 mg, 375 mg, 400 mg, 425 mg, 450 mg, 475 mg, 500 mg, 525 mg, 550 mg, 575 mg, 600 mg, 625 mg, 650 mg, 675 mg, 700 mg, 725 mg, 750 mg, 775 mg, 800 mg, 850 mg, 900 mg, 950 mg, 1000 mg, 1100 mg, 1200 mg, 1300 mg, 1400 mg, or 1500 mg of a compound of the present invention or a stereoisomer, deuterated form, solvate, pharma- ceutically acceptable salt, or co-crystal thereof.
[0029] A method for treating a disease in a mammal, said method comprising administering to a subject a therapeutically effective amount of the compound of the present invention, its stereoisomer, deuterated product, solvate or pharma- ceutically acceptable salt or co-crystal, and a pharma- ceutically acceptable carrier and / or excipient, wherein the therapeutically effective amount is preferably 1-1500 mg, and said disease is preferably breast cancer, ovarian cancer, uterine cancer or cervical cancer.
[0030] A method for treating a disease in a mammal, the method comprising administering to a subject a pharmaceutical compound of the present invention, a stereoisomer, deuterated form, solvate or pharma- ceutically acceptable salt or co-crystal thereof, and a pharma- ceutically acceptable carrier and / or excipient in a daily amount of 1-1500 mg / day, the daily amount may be a single dose or a divided dose, and in some embodiments, the daily amount is 10-1500 mg / day, 20-1500 mg / day, 25-1500 mg / day, 50-1500 mg / day, 75-1500 mg / day, 100-1500 mg / day, 200-1500 mg / day, 10-1000 mg / day, 20-1000 mg / day, 25-1000 mg / day, 50-1000 mg / day, In some embodiments, the dose includes, but is not limited to, 75 to 1000 mg / day, 100 to 1000 mg / day, 200 to 1000 mg / day, 25 to 800 mg / day, 50 to 800 mg / day, 100 to 800 mg / day, 200 to 800 mg / day, 25 to 400 mg / day, 50 to 400 mg / day, 100 to 400 mg / day, and 200 to 400 mg / day. Daily doses include, but are not limited to, 1 mg / day, 5 mg / day, 10 mg / day, 20 mg / day, 25 mg / day, 50 mg / day, 75 mg / day, 100 mg / day, 125 mg / day, 150 mg / day, 200 mg / day, 400 mg / day, 600 mg / day, 800 mg / day, 1000 mg / day, 1200 mg / day, 1400 mg / day, and 1500 mg / day.
[0031] The present invention relates to a kit, which may comprise a composition in the form of a single dose or multiple doses, comprising a compound of the present invention or a stereoisomer, deuterated form, solvate, pharma- ceutically acceptable salt or co-crystal thereof, wherein the amount of the compound of the present invention or a stereoisomer, deuterated form, solvate, pharma- ceutically acceptable salt or co-crystal thereof is the same as that amount in said pharmaceutical composition.
[0032] In the present invention, the amounts of the compounds of the invention or their stereoisomers, deuterated forms, solvates, pharma- ceutically acceptable salts or cocrystals are in each case calculated in the form of the free base.
[0033] "Formulation specifications" refers to the weight of active ingredient contained in one unit dosage form, one tablet unit dosage form, or other unit dosage form.
[0034] Synthetic Route Patent documents such as WO 2021013735A1 describe methods for preparing PARP-1 inhibitors, and those skilled in the art can combine these documents with known organic synthesis techniques to prepare the compounds of the present invention, in which the starting materials are commercially available chemicals and / or compounds described in chemical literature. "Commercially available chemicals" are obtained from legitimate commercial sources, and suppliers include companies such as Taitan Technology, Ananji Chemical, Shanghai Demo, Chengdu Kelong Chemical, Shaoyuan Chemical Technology, Nanjing Yaoshi, Yaoming Kangde and Bailingwei Technology.
[0035] The PARP1-PROTAC of the present invention is produced by the following synthetic route: [ka] Each group is as defined above.
[0036] Reference texts and treatises in the field provide detailed introductions to the synthesis of reactants that can be used to prepare the compounds described herein, or provide texts describing such methods for reference. These references and treatises include: "Synthetic Organic Chemistry", John Wiley & Sons, Inc., New York; SRSandler et al., "Organic Functional Group Preparations," 2nd Ed., Academic Press, New York, 1983; "Chemistry", 2nd Ed., John Wiley & Sons, New York, 1992; J. March, "Advanced Organic Chemistry: Reactions, Mechanisms and Structure", 4th Ed., Wiley-Interscience, New York, 1992; Fuhrhop, J. and Penzlin G. "Organic Synthesis: Concepts, Methods, Starting Materials", Second, Revised and Enlarged Edition(1994)John Wiley & Sons ISBN:3-527-29074-5;Hoffman,RV "Organic Chemistry,An Intermediate Text" (1996)Oxford University Press,ISBN 0-19-509618-5;Larock,RC "Comprehensive Organic Transformations: A Guide to Functional Group Preparations" 2nd Edition(1999)Wiley-VCH,ISBN:0-471-19031-4;March,J.『Advanced Organic Chemistry:Reactions,Mechanisms,and Structure』4th Edition(1992)John Wiley & Sons,ISBN:0-471-60180-2;Otera,J.(editor)『Modern Carbonyl Chemistry』(2000)Wiley-VCH,ISBN:3-527-29871-1;Patai,S.『Patai’s 1992 Guide to the Chemistry of Functional Groups』(1992)Interscience ISBN:0-471-93022-9;Solomons,T.W.G.『Organic Chemistry』7th Edition(2000)John Wiley & Sons,ISBN:0-471-19095-0;Stowell,J.C.,『Intermediate Organic Chemistry』2nd Edition(1993)Wiley-Interscience,ISBN:0-471-57456-2;『Industrial Organic Chemicals:Starting Materials and Intermediates:An Ullmann’s Encyclopedia』(1999)John Wiley & Sons,ISBN:3-527-29645-X,in 8 volumes;『Organic Reactions』(1942-2000)John Wiley & Sons,in over 55 volumes;and 『Chemistry of Functional Groups』John Wiley & Sons,in 73 volumes.
[0037] Specific and similar reactants can be selectively identified by indexes of known chemicals produced by the Chemical Information Retrieval Service of the American Chemical Society, which are available in many public and university libraries and online. Chemicals that are known but not available in catalogs can optionally be produced by custom chemical synthesis businesses, many of which provide custom synthesis services, such as the companies listed above. A reference for producing and selecting pharmaceutical salts of the compounds described herein is PH Stahl & CG Wermuth "Handbook of Pharmaceutical Salts", Verlag Helvetica Chimica Acta, Zurich, 2002.
[0038] term Unless otherwise specified in the present invention, the terms used in the present invention have the following meanings.
[0039] Any carbon, hydrogen, oxygen, sulfur, nitrogen or halogen in the groups and compounds described herein includes its isotope, and any carbon, hydrogen, oxygen, sulfur, nitrogen or halogen in the groups and compounds described herein is optionally further replaced by one or more corresponding isotopes, where the carbon isotope is: 12 C and 13 C and 14 C; isotopes of hydrogen include protium (H), deuterium (D, also called heavy hydrogen), and tritium (T, also called tritium); isotopes of oxygen include 16 O and 17 O and 18 The isotopes of sulfur include 32 S and 33 S and 34 S and 36 S and the nitrogen isotopes are 14 N and 15 N and the fluorine isotope is 19 F, and the chlorine isotope is 35 Cl and 37 The isotopes of bromine include Cl and79 Br and 81 Includes Br.
[0040] As used herein, "halogen" refers to F, Cl, Br, I, or isotopes thereof.
[0041] "Halogenated" or "halogen substituted" refers to substitution with one or more selected from F, Cl, Br, I, or isotopes thereof, and the upper limit of the number of halogen substituents is equal to the sum of the replaceable hydrogens of the group to be substituted, and unless otherwise specified, the number of halogen substituents is any integer between 1 and the upper limit, and when the number of halogen substituents is greater than 1, they may be substituted with the same or different halogens. Usually, cases of 1 to 5 halogen substitutions, 1 to 3 halogen substitutions, 1 to 2 halogen substitutions, and 1 halogen substitution are included.
[0042] "Deuterium" refers to heavy hydrogen, an isotope of hydrogen (H).
[0043] The term "deuterated" or "deuterated compound" refers to a case where a hydrogen atom in a group such as an alkyl group, a cycloalkyl group, an alkylene group, an aryl group, a heteroaryl group, a mercapto group, a heterocycloalkyl group, an alkenyl group, or an alkynyl group is replaced with at least one deuterium atom, and the upper limit of the number of deuteration is equal to the sum of the numbers of hydrogen atoms that can be replaced in the groups to be substituted, and unless otherwise specified, the number of deuteration is any integer between 1 and the upper limit, for example, 1 to 20 deuterium atom substitutions, 1 to 10 deuterium atom substitutions, 1 to 6 deuterium atom substitutions, 1 to 3 deuterium atom substitutions, 1 to 2 deuterium atom substitutions, or 1 deuterium atom substitution.
[0044] "C x-y " group refers to a group containing x to y carbon atoms, e.g., "C 1-6 "Alkyl group" refers to an alkyl group containing from 1 to 6 carbon atoms.
[0045] "Alkyl group" refers to a monovalent linear or branched saturated aliphatic hydrocarbon group. Typically, the alkyl group has 1 to 20 carbon atoms, or 1 to 8 carbon atoms, or 1 to 6 carbon atoms, or 1 to 4 carbon atoms. Non-limiting examples include methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, neobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl, and the like, and the alkyl group may be further substituted with a substituent.
[0046] "Alkylene group" refers to divalent straight and branched chain saturated alkyl groups. Examples of alkylene groups include, but are not limited to, methylene groups, ethylene groups, and the like.
[0047] "Halogenated alkyl group" refers to the case where one or more hydrogens in an alkyl group are replaced with one or more halogen atoms (e.g., fluorine, chlorine, bromine, iodine or isotopes thereof), the upper limit of the number of halogen substituents is equal to the sum of the replaceable hydrogens in the alkyl group, and unless otherwise limited, the number of halogen substituents is any integer between 1 and the upper limit. Usually, the alkyl group is substituted with 1 to 5 halogens, or substituted with 1 to 3 halogens, or substituted with 1 to 2 halogens, or substituted with 1 halogen, and when the number of halogen substituents is greater than 1, they may be substituted with the same or different halogens, and specific examples include, but are not limited to, -CF3, -CH2Cl, -CH2CF3, -CCl2, CF3, etc.
[0048] An "alkoxy group" or an "alkyloxy group" refers to an -O-alkyl group. For example, -OC 1-8 Alkyl group, -OC 1-6 Alkyl group, -OC 1-4 Alkyl group or -OC 1-2Specific non-limiting examples include methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, sec-butoxy, tert-butoxy, n-pentyloxy, n-hexyloxy, cyclopropoxy, and cyclobutoxy, and the alkoxy groups may be optionally substituted with a substituent.
[0049] "Halogenated alkoxy group" refers to an -O-halogenated alkyl group. For example, -O-halogenated C 1-8 Alkyl groups, -O-halogenated C 1-6 Alkyl groups, -O-halogenated C 1-4 Alkyl group or -O-halogenated C 1-2 It is an alkyl group, and the upper limit of the number of halogen substituents is equal to the sum of the replaceable hydrogens of the substituted group. Unless otherwise specified, the number of halogen substituents is any integer between 1 and the upper limit, and is preferably 1 to 5 halogen substitutions, 1 to 3 halogen substitutions, 1 to 2 halogen substitutions, or 1 halogen substitution. When the number of halogen substituents is greater than 1, they may be substituted with the same or different halogens. Non-limiting examples include a monofluoromethoxy group, a difluoromethoxy group, a trifluoromethoxy group, a difluoroethyloxy group, etc.
[0050] The term "alkenyl group" refers to a straight-chain or branched-chain hydrocarbon group containing at least one carbon-carbon double bond (C=C), and typically contains 2 to 18 carbon atoms, for example, 2 to 8 carbon atoms, further for example, 2 to 6 carbon atoms, further for example, 2 to 4 carbon atoms, and examples thereof include a vinyl group, an allyl group, a 1-propenyl group, a 2-propenyl group, a 1-butenyl group, a 2-butenyl group, a 3-butenyl group, a 1-pentenyl group, a 2-pentenyl group, a 3-pentenyl group, a 4-pentenyl group, a 1-methyl-1-butenyl group, a 2-methyl-1-butenyl group, and a 2-methyl-3-butenyl group. , 1-hexenyl, 2-hexenyl, 3-hexenyl, 4-hexenyl, 5-hexenyl, 1-methyl-1-pentenyl, 2-methyl-1-pentenyl, 1-heptenyl, 2-heptenyl, 3-heptenyl, 4-heptenyl, 1-octenyl, 3-octenyl, 1-nonenyl, 3-nonenyl, 1-decenyl, 4-decenyl, 1,3-butadiene, 1,3-pentadiene, 1,4-pentadiene, and 1,4-hexadiene, and the like, wherein the alkenyl groups may be optionally further substituted with substituents.
[0051] "Alkenylene group" refers to a straight or branched chain divalent unsaturated hydrocarbon group containing at least one carbon-carbon double bond (C=C), and unless otherwise specified, an alkynylene group contains from 2 to 6 carbon atoms, preferably from 2 to 4 carbon atoms; non-limiting examples include ethynylene groups, which may be optionally substituted with substituents.
[0052] The term "alkynyl group" refers to a straight chain or branched chain hydrocarbon group containing at least one carbon-carbon triple bond (C≡C), and typically containing 2 to 18 carbon atoms, further containing 2 to 8 carbon atoms, further containing 2 to 6 carbon atoms, and further containing 2 to 4 carbon atoms. Examples include, but are not limited to, ethynyl, 1-propynyl, 2-propynyl, butynyl, 2-butynyl, 3-butynyl, 1-methyl-2-propynyl, 4-pentyl, 3-pentyl, 1-methyl-2-butynyl, 2-hexynyl, 3-hexynyl, 2-heptenyl, 3-heptenyl, 4-heptenyl, 3-octynyl, 3-nonynyl, and 4-decylalkynyl, which may be optionally substituted with a substituent.
[0053] "Alkynylene group" refers to a straight or branched chain divalent unsaturated hydrocarbon group containing a carbon-carbon triple bond (C≡C) and typically containing from 2 to 6 carbon atoms, and more typically containing from 2 to 4 carbon atoms, non-limiting examples include ethynylene, propynylene, and butynylene groups, which alkynylene groups may be optionally substituted with substituents.
[0054] "Cycloalkyl group" refers to a saturated or partially unsaturated, non-aromatic carbocyclic hydrocarbon group that does not contain a cycloheteroatom. Cycloalkyl groups may be monocyclic, bicyclic or polycyclic, which may be fused, spirocyclic, bridged or combinations thereof, and which may contain one or more aromatic rings, although the ring system as a whole does not have aromatic character and the linking site may be on an aromatic or non-aromatic ring. Typically, a cycloalkyl group contains 3 to 20 carbon atoms, further contains 3 to 8 carbon atoms, further contains 3 to 6 carbon atoms, if it is a monocyclic cycloalkyl group, it contains 3 to 15 carbon atoms, or 3 to 10 carbon atoms, or 3 to 8 carbon atoms, or 3 to 6 carbon atoms, if it is a bicyclic or polycyclic cycloalkyl group, it contains 5 to 12 carbon atoms, or 5 to 11 carbon atoms, or 6 to 10 carbon atoms, non-limiting examples are cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, butenyl, cyclopentenyl, cyclohexenyl, [ka] and the like, where cycloalkyl groups may be optionally substituted with substituents.
[0055] A "cycloalkylene group" is a divalent group of a cycloalkyl group.
[0056] "Aryl group" refers to a carbocyclic ring having aromatic character and containing no heteroatoms, including monocyclic aryl groups and fused ring aryl groups. Typically contains 6 to 13 carbon atoms, more preferably 6 to 9 carbon atoms, and more preferably phenyl groups, non-limiting examples include phenyl, naphthyl, anthryl, and phenanthryl groups, and aryl groups may be optionally substituted with substituents.
[0057] "Carbocycle" or "carbocyclic group" refers to a saturated, partially unsaturated, or aromatic carbocycle, the meaning of which includes aryl and cycloalkyl groups. A carbocycle may be monocyclic, bicyclic, or polycyclic, which includes bridged, fused, and spiro rings, and combinations thereof. A carbocycle typically has 3 to 12 carbon atoms, or 3 to 10 carbon atoms, or 3 to 6 carbon atoms. In non-limiting examples, monocyclic carbocycles include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, or phenyl, and the like, and bicyclic bridged rings include [ka] and the like, and the bicyclic fused ring is [ka] and the like, and the bicyclic spiro ring is [ka] etc., wherein the carbocycle may be optionally substituted with a substituent.
[0058] "Heterocycloalkyl group" refers to a saturated or partially unsaturated non-aromatic carbocyclic ring containing 1, 2, 3 or 4 heteroatoms selected from N, S and O. Heterocycloalkyl groups may be monocyclic, bicyclic or polycyclic, and bicyclic or polycyclic rings may be bridged, fused, spiro or combinations thereof, and bicyclic or polycyclic rings may contain one or more aromatic or heteroaromatic rings, but the ring system as a whole may not have aromaticity and the linking site may be on an aromatic or non-aromatic ring. Heterocycloalkyl groups are usually 3-20 membered rings, and when they are monocyclic heterocycloalkyl groups, they are usually 3-15 membered rings, or 3-10 membered rings, or 3-8 membered rings, or 3-6 membered rings, and when they are bicyclic or polycyclic heterocycloalkyl groups, they are usually 5-12 membered rings, or 5-11 membered rings, or 6-9 membered rings. Here, the heteroatoms N, S include their oxidation states. Non-limiting examples of heterocycloalkyl groups include azetidinyl, morpholinyl, piperazinyl, tetrahydropyrazine, piperidinyl, tetrahydropyranyl, oxetanyl, pyranyl, azacyclopentenyl, azacyclohexenyl, oxolyl, oxynyl groups, and the like, and heterocycloalkyl groups may be optionally substituted with substituents.
[0059] "Heteroaromatic ring" or "heteroaryl group", unless otherwise specified, refers to a ring containing 1 to 4 heteroatoms selected from N, O, or S and their oxidation states, and having aromaticity, which may be monocyclic, bicyclic, or polycyclic, and the bicyclic or polycyclic ring may be bridged, fused, spiro, or a combination thereof, and if bicyclic or polycyclic, may be a condensation of a heteroaryl group with an aryl group, or a condensation of a heteroaryl group with a heteroaryl group, where both the heteroaryl group or the aryl group may be linking moieties. Non-limiting examples include furyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, pyridyl, pyrimidine, pyridazinyl, pyrazinyl, indolyl, purinyl, [ka] and the like, wherein said heteroaryl groups may be optionally substituted with substituents.
[0060] "Heterocyclo" or "heterocyclo group" refers to a saturated or unsaturated aromatic or non-aromatic ring containing 1 to 4 heteroatoms selected from N, O, or S and their oxidation states, including heteroaryl and heterocycloalkyl groups. Heterocyclo includes monocyclic heterocyclo, bridged bicyclic heterocyclo, fused bicyclic heterocyclo, and spiro bicyclic heterocyclo or combinations thereof. Typically, it is a 3- to 12-membered heterocyclo or a 5- to 12-membered heterocyclo, or a 5- to 7-membered heterocyclo. Heterocyclo groups may be attached at a heteroatom or a carbon atom, non-limiting examples being oxiranyl, azacyclopropyl, oxetanyl, azetidinyl, 1,3-dioxolanyl, 1,4-dioxolanyl, 1,3-dioxanyl, piperazinyl, azacycloheptyl, pyridyl, furyl, thienyl, pyranyl, N-alkylpyrrolyl, pyrimidinyl, pyrazinyl, pyrazolyl, pyridazinyl, imidazolyl, piperidinyl, piperidyl, morpholinyl, thiomorpholinyl, 1,3-dithianyl, dihybridyl, cycloalkyl ... adrofuryl group, a dihydropyranyl group, a dithiolanyl group, a tetrahydrofuranyl group, a tetrahydropyrrolyl group, a tetrahydroimidazolyl group, an oxazolyl group, a dihydrooxazolyl group, a tetrahydrooxazolyl group, a tetrahydrothiazolyl group, a tetrahydropyranyl group, a benzimidazolyl group, a benzopyridyl group, a pyrrolopyridyl group, a benzodihydrofuryl group, an azabicyclo[3.2.1]octyl group, an azabicyclo[5.2.0]nonyl group, an oxatricyclo[5.3.1.1]dodecyl group, an azaadamantyl group, and an oxaspiro[3.3]heptyl group; [ka] and the like, heterocyclos may be optionally substituted with substituents.
[0061] A "heterocyclylene group" refers to a substituted or unsubstituted, saturated or unsaturated, aromatic or non-aromatic divalent heterocyclo group. Non-limiting examples include: [ka] etc.
[0062] "Spiro ring" refers to a polycyclic group in which the rings share one carbon atom (called a spiro atom), which may contain zero or more double or triple bonds and zero to five heteroatoms selected from N, O, S, P, Si and their oxidation states. Typically, the spiro ring is a 6-14 membered ring, or a 6-12 membered ring, or a 6-10 membered ring. Typically, the spiro ring is a 3 spiro 3 (representing a 3-membered spiro 3-membered ring), a 3 spiro 4, a 3 spiro 5, a 3 spiro 6, a 4 spiro 4, a 4 spiro 5, a 4 spiro 6, a 5 spiro 5, or a 5 spiro 6. Non-limiting examples of spiro rings are: [ka] wherein said spiro ring may be optionally substituted with a substituent.
[0063] "Fused ring" refers to a polycyclic group in which the rings share two adjacent ring atoms and one chemical bond, and may contain one or more double or triple bonds, and the fused ring may contain 0-5 heteroatoms selected from N, S, O, P, Si and their oxidation states. Usually, the fused ring is a 5-20 membered ring, or a 5-14 membered ring, or a 5-12 membered ring, or a 5-10 membered ring. Usually, the fused ring is a 3-parallel 4-ring (representing a fused ring formed of a 3-membered ring and a 4-membered ring; based on the IUPC naming rules, a fused ring with a 3-membered ring as the base ring is possible, and a fused ring with a 4-membered ring as the base ring is also possible, and the same applies below), a 3-parallel 5-ring, a 3-parallel 6-ring, a 4-parallel 4-ring, a 4-parallel 5-ring, a 4-parallel 6-ring, a 5-parallel 5-ring, a 5-parallel 6-ring, or a 6-parallel 6-ring. Non-limiting examples of fused rings include purine, quinoline, isoquinoline, benzopyran, benzofuran, benzothiophene, [ka] wherein said fused ring may be optionally substituted with a substituent.
[0064] "Bridged ring" refers to two rings sharing two non-adjacent ring atoms and may contain one or more double or triple bonds. Bridged rings may contain 0-5 heteroatoms selected from N, S, O, P, Si and their oxidation states. Typically, the bridged ring has 5-20, or 5-14, or 5-12, or 5-10 ring atoms. Non-limiting examples of bridged rings include adamantane, [ka] Includes.
[0065] "Substituted" or "substituent" means that, unless otherwise specified, any substitution occurs at any chemically permissible position, and the number of substituents complies with the rules of chemical bonding. Exemplary substituents are: 1-6 Alkyl group, C 2-6 Alkenyl group, C 2-6 Alkynyl group, C 3-8 Heteroalkyl groups, C 5-12 Aryl group, 5-12 membered heteroaryl group, hydroxy group, C 1-6 Alkoxy group, C 5-12 Aryloxy group, thiol group, C 1-6 Alkylthio group, cyano group, halogen, C 1-6 Alkylthiocarbonyl group, C 1-6 Alkylcarbamoyl group, N-carbamoyl group, nitro group, silyl group, sulfinyl group, sulfonyl group, sulfoxide, halogenated C 1-6 Alkyl groups, halogenated C 1-6 Alkoxy group, amino group, phosphonic acid, -CO2(C 1-6 alkyl group), -OC(=O)(C 1-6 alkyl group), -OCO2(C 1-6 alkyl group), -C(=O)NH2, -C(=O)N(C 1-6 alkyl group)2, -OC(=O)NH(C 1-6 alkyl group), -NHC(=O)(C 1-6 alkyl group), -N(C 1-6Alkyl group)C(=O)(C 1-6 alkyl group), -NHCO2(C 1-6 alkyl group), -NHC(=O)N(C 1-6 alkyl group)2, -HC(=O)NH(C 1-6 alkyl group), -NHC(=O)NH2, -NHSO2(C 1-6 Alkyl group), -SO2N(C 1-6 Alkyl group)2, -SO2NH(C 1-6 Alkyl group), -SO2NH2, -SO2C 1-6 These include, but are not limited to, alkyl groups and the like.
[0066] "Optionally" or "optionally" means that the subsequently described event or circumstance may, but does not necessarily, occur, and the description includes both cases where the event or circumstance occurs and cases where it does not occur. For example, "an alkyl group optionally substituted with F" means that the alkyl group may, but does not necessarily, have to be substituted with F, and indicates that the alkyl group is substituted with F and the alkyl group is not substituted with F.
[0067] "Pharmaceutically acceptable salts" refers to salts in which the compounds of the present invention retain the biological effectiveness and properties of the free acids or free bases and which are obtained by reaction of said free acids with non-toxic inorganic or organic bases, or by reaction of said free bases with non-toxic inorganic or organic acids.
[0068] A "pharmaceutical composition" refers to a mixture of one or more of the compounds herein or a stereoisomer, solvate, pharma- ceutically acceptable salt, or co-crystal thereof, with other components, wherein the other components include physiologically / pharmaceutical acceptable carriers and / or excipients.
[0069] The term "carrier" refers to a system that does not significantly stimulate the living body, does not eliminate the biological activity and properties of a given compound, and can change the administration form and distribution of a drug in the human body, control the release rate of the drug, and deliver the drug to a target organ. Non-limiting examples include microcapsules and microspheres, nanoparticles, liposomes, etc.
[0070] "Excipient" refers to a substance that is not a therapeutic agent itself, but is added to a pharmaceutical composition as a diluent, excipient, adhesive, and / or vehicle to improve its processing or storage properties, or to permit or facilitate the compound or pharmaceutical composition to form a dosage form for administration. As known to those skilled in the art, pharmaceutical excipients can serve a variety of functions and may be described as wetting agents, buffers, suspending aids, lubricants, emulsifiers, disintegrants, absorbents, preservatives, surfactants, colorants, flavoring agents, and sweeteners. Illustrative examples of pharmaceutical excipients include: (1) sugars, such as lactose, glucose, and sucrose; (2) starches, such as corn starch and potato starch; (3) cellulose and its derivatives, such as sodium carboxymethylcellulose, ethylcellulose, cellulose acetate, hydroxypropyl methylcellulose, hydroxypropyl cellulose, microcrystalline cellulose, and crosslinked carboxymethylcellulose (e.g., crosslinked sodium carboxymethylcellulose); (4) tragacanth powder; (5) malt; (6) gelatin; (7) talc; (8) excipients, such as cocoa butter, suppository wax; (9) oils, such as peanut oil, cottonseed oil, safflower oil, goa oil, olive oil, corn oil, and soybean oil; (10) glycols, such as propylene glycol, (11) polyols, such as glycerin, sorbitol, mannitol, and polyethylene glycol, (12) esters, such as ethyl oleate and ethyl laurate, (13) agar, (14) buffers, such as magnesium hydroxide and aluminum hydroxide, (15) alginic acid, (16) water for endotoxin testing, (17) isotonic saline, (18) Ringer's solution, (19) ethanol, (20) pH buffer solutions, (21) polyesters, polycarbonates, and / or polyanhydrides, and (22) other non-toxic, compatible substances used in pharmaceutical formulations.
[0071] "Stereoisomer" refers to isomers that result from different ways in which atoms are arranged in molecules, and includes cis-trans isomers, enantiomers and conformational isomers.
[0072] The compounds of the present invention further include tautomers thereof, for example, when a left-hand compound in which the pyrimidine ring is substituted with OH is described in the present invention, the right-hand tautomeric compound is also included. [ka]
[0073] The term "solvate" refers to a substance formed by intermolecular non-covalent bonding of the compound of the present invention or a salt thereof with a stoichiometric or non-stoichiometric solvent. When the solvent is water, it becomes a hydrate.
[0074] "Cocrystal" refers to a crystalline body formed by the association of an active pharmaceutical ingredient (API) and a co-crystal former (CCF) through the action of hydrogen bonds or other non-covalent bonds, where the API and CCF are both solids in their pure states at room temperature, and there is a fixed stoichiometric ratio between each component. Cocrystals are multi-component crystalline bodies, and include not only binary cocrystals formed between two neutral solids, but also multi-component cocrystals formed between a neutral solid and a salt or solvate. [Brief description of the drawings]
[0075] [Figure 1] FIG. 1 shows tumor growth curves of a mouse MDA-MB-436 subcutaneous in vivo transplanted tumor model. [Diagram 2] FIG. 1 shows the animal weight change curve of a mouse MDA-MB-436 subcutaneous in vivo transplanted tumor model. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0076] The present invention will be described in detail below with reference to examples. Unless specific conditions are specified in the examples, the experiments were carried out according to general conditions. The examples given are for better illustrating the present invention, and it should be understood that the present invention is not limited to the examples given. Non-essential improvements and adjustments made to the embodiments by those skilled in the art based on the above invention still fall within the scope of protection of the present invention. EXAMPLES
[0077] Detection Method The structures of the compounds are confirmed by nuclear magnetic resonance (NMR) and / or mass spectrometry (MS). NMR shifts (δ) are given in units of 10-6 (ppm). NMR measurements were performed using nuclear magnetometers (Bruker Avance III 400 and Bruker Avance 300), the solvents used were deuterated dimethylsulfoxide (DMSO-d6), deuterated chloroform (CDCl3), and deuterated methanol (CD3OD), and the internal standard was tetramethylsilane (TMS). The MS measurements were performed using Agilent 6120B (ESI) and Agilent 6120B (APCI). HPLC measurements were performed using an Agilent 1260DAD high pressure liquid chromatograph (Zorbax SB-C18 100 × 4.6 mm, 3.5 μM). Thin-layer chromatography silica gel plates are Yantai Yellow Sea HSGF254 or Qingdao GF254 silica gel plates. The silica gel plate specifications used in thin-layer chromatography (TLC) are 0.15mm~0.20mm, and the specifications used for separation and purification of finished products by thin-layer chromatography are 0.4mm~0.5mm. For column chromatography, Yantai Yellow Sea silica gel 200-300 mesh silica gel was generally used as the carrier.
[0078] Abbreviation TBSCl: tert-butyldimethylchlorosilane HATU: 2-(7-oxobenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate TBAF: Tetrabutylammonium fluoride TsCl: p-Toluenesulfonyl chloride DIPEA: N,N-diisopropylethylamine
[0079] Compound Production Example 1: N-(1'-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)-[1,4'-bipiperidine]-4-yl)-5-(4-((7-ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl)piperazin-1-yl)pyridine-2-formamide (Compound 1) [ka]
[0080] Step 1: Ethyl 6-methyl-5-nitronicotinate 1A (10 g, 47.6 mmol) and selenium dioxide (21.14 g, 190.5 mmol) were dissolved in 1,4-dioxane (100 ml) and refluxed at 100° C. overnight. After the reaction was completed, the mixture was filtered through a funnel packed with diatomaceous earth, the diatomaceous earth was washed with ethyl acetate, the filtrate was concentrated, and the resulting residue was separated and purified by silica gel column chromatography (eluent ratio: ethyl acetate:petroleum ether (v / v)=0%-40%) to obtain compound 1B (10.104 g, 94.7%).
number
[0081] Step 2: Sodium hydride (2.695 g, 112.3 mmol) was dissolved in anhydrous tetrahydrofuran (100 ml), stirred at 0° C., 2-phosphonobutyric acid triethyl (28.3 g, 112.3 mmol) was added dropwise, and after the addition was completed, the temperature was maintained at 0° C. and the mixture was stirred for 20 min. The temperature was raised to 40° C. and the mixture was stirred for 10 min. The mixture was transferred to a dry ice ethanol bath, and compound 1B (10.48 g, 46.8 mmol) was dissolved in anhydrous tetrahydrofuran (100 ml) and added dropwise to the reaction flask, and the dry ice ethanol bath was turned on. The mixture was stirred for 1 h, and after completion of the reaction, it was quenched by adding saturated ammonium chloride solution (100 ml), extracted by adding ethyl acetate (200 ml), the organic phase was separated, the aqueous phase was extracted with ethyl acetate (200 ml x 2), the organic phase was combined, dried over anhydrous sodium sulfate, concentrated, and the obtained residue was purified by silica gel column chromatography (eluent ratio: ethyl acetate:petroleum ether (v / v) = 0-10%) to obtain compound 1C (11.57 g, 76.8%), which is a mixture of two isomers.
[0082]
number
[0083] Step 3: Compound 1C (11.57 g, 35.9 mmol) was dissolved in ethanol (50 ml), 10% palladium carbon catalyst (1 g) was added, hydrogen gas was replaced three times, and the mixture was stirred at room temperature overnight. The mixture was filtered through a funnel packed with diatomaceous earth, the diatomaceous earth was washed with absolute ethanol, the filtrate was concentrated, 4M hydrochloric acid-dioxane solution (60 ml) was added to the obtained residue, the mixture was stirred at room temperature for 1 h, and the mixture was concentrated. Ethyl acetate (50 ml) was added to the obtained residue, the mixture was stirred, filtered, the filter cake was washed with ethyl acetate, and dried to obtain compound 1D (4.28 g, 42.0%). 1H NMR(400MHz,DMSO-d6)δ 10.39(s,1H),8.62(d,1H),7.75(s,1H),4.38 - 4.29(m,2H),3.24(dd,1H),2.97(dd,1H),2.62 - 2.53(m,1H),1.83 - 1.64(m,1H),1.45(tt,1H),1.33(dd,3H),0.94(t,3H).
[0084] Step 4: Compound 1D (4.28 g, 17.3 mmol) and 2,3-dichloro-5,6-dicyanobenzoquinone (4.309 g, 19.0 mmol) were dissolved in dioxane (86 ml) and reacted under reflux at 100 ° C for 3.5 h. After the reaction was completed, saturated sodium bicarbonate solution (40 ml) and ethyl acetate (120 ml) were added, the organic phase was separated, the aqueous phase was extracted with ethyl acetate (120 ml × 2), the organic phase was combined, dried over anhydrous sodium sulfate, concentrated, and the resulting residue was purified by silica gel column chromatography (eluent ratio: ethyl acetate: petroleum ether (v / v) = 0-50%) to obtain compound 1E (3.375 g, 79.5%).
number
[0085] Step 5: Compound 1E (3.375 g, 13.72 mmol) was dissolved in anhydrous tetrahydrofuran (150 ml) and stirred at -78 ° C. Lithium aluminum hydride (1.564 g, 41.16 mmol) was added in small portions, stirred at -78 ° C for 20 min, heated to -40 ° C, stirred for 20 min, and after the reaction was completed, 1M hydrochloric acid was added to adjust the pH of the system to neutral, the solvent was distilled off under reduced pressure, methanol / dichloromethane (1:10) (100 ml) was added to the obtained residue, the residue was dissolved, ultrasonically shaken for 10 min, filtered, the filtrate was collected, and the filter cake was dissolved again in methanol / dichloromethane (1:10) (100 ml), this process was repeated 8 times, the filtrate was combined and concentrated to obtain compound 1F (2.8 g, 100.0%). 1H NMR(400MHz,DMSO-d6)δ 11.86(s,1H),8.37(d,1H),7.72(d,1H),7.62(d,1H),5.44(t,1H),4.61(d,2H),2.57 - 2.51(m,2H),1.18(t,3H).
[0086] Step 6: Compound 1F (2.94 g, 14.4 mmol) was dissolved in dichloromethane (140 ml), N,N-dimethylformamide (1 ml) was added, and the mixture was stirred at 0°C. Thionyl chloride (6.29 ml, 86.4 mmol) was added dropwise to the reaction solution. After the addition was completed, the mixture was transferred to room temperature and stirred for 2 hours. After the reaction was completed, the mixture was concentrated to obtain compound 1G (3.20 g, 100.0%).
number
[0087] Step 7: Compound 1H (10 g, 46 mmol), N-Boc-piperazine (10.33 g, 56 mmol), (2-dicyclohexylphosphine-2',6'-diisopropoxy-1,1'-biphenyl)(2-amino-1,1'-biphenyl-2-yl)palladium methanesulfonate (Ruphos Pd G 3, 1.55 g, 1.85 mmol) and cesium carbonate (30.19 g, 93 mmol) were dissolved in dioxane (100 ml), purged with nitrogen gas three times, and refluxed at 100 ° C overnight. After the reaction was completed, the mixture was filtered through a funnel packed with diatomaceous earth, the diatomaceous earth was washed with ethyl acetate, the filtrate was washed with water (100 ml), dried over anhydrous sodium sulfate, and concentrated. The resulting residue was separated and purified by silica gel column chromatography (eluent ratio: ethyl acetate: petroleum ether (v / v) = 0% ~ 50%) to obtain compound 1I (9.53 g, 64.1%).
number
[0088] Step 8: Compound 1I (9.53 g, 29.7 mmol) was dissolved in methanol (100 ml), and 4 M hydrogen chloride-dioxane solution (100 ml) was added thereto. The mixture was stirred at room temperature for 1 h. After completion of the reaction, the mixture was concentrated to give compound 1J (8.70 g, 100.0%).
number
[0089] Step 9: Compound 1G (3.20 g, 14.4 mmol), compound 1J (4.23 g, 14.4 mmol), potassium iodide (478 mg, 2.88 mmol) and N,N-diisopropylethylamine (12.5 ml, 71.96 mmol) were dissolved in acetonitrile (150 ml) and refluxed at 80 ° C for 2 h. After the reaction was completed, the mixture was concentrated, extracted with water (80 ml), dichloromethane (150 ml) and methanol (15 ml), the organic phase was separated, the aqueous phase was extracted with dichloromethane (150 ml × 3), the organic phase was combined, concentrated, and the resulting residue was purified by silica gel column chromatography (eluent ratio: methanol: dichloromethane (v / v) = 0% to 15%) to obtain compound 1K (4.24 g, 72.1%).
number
[0090] Step 10: Compound 1K (4.24 g, 10.4 mmol) was dissolved in tetrahydrofuran (80 ml) and water (80 ml), lithium hydroxide (750 mg, 31.2 mmol) was added, and the mixture was stirred at room temperature for 2 h to react. After the reaction was completed, the pH of the system was adjusted to 4-5 with 1 M hydrochloric acid, and the mixture was concentrated. The resulting residue was purified by silica gel column chromatography (eluent ratio: methanol:dichloromethane (v / v) = 0%-15%) to obtain compound 1L (4.01 g, 100.0%).
number
[0091] Step 11: Compound 1L (1 g, 2.54 mmol) and 4-aminopiperidine-1-carboxylic acid tert-butyl ester (609 mg, 3.05 mmol) were dissolved in DMF (5 ml), benzotriazole-N,N,N',N'-tetramethyluronium hexafluorophosphate (962 mg, 2.54 mmol) was added, the mixture was purged with nitrogen gas three times, and the mixture was stirred at room temperature for 20 min. N,N-diisopropylethylamine (1.31 ml, 7.54 mmol) was added. mol) was added and the mixture was stirred at room temperature for 2 h to react. After the reaction was completed, water (10 ml) and ethyl acetate (12 ml) were added, the organic phase was separated, the aqueous phase was extracted with ethyl acetate (10 ml x 2), the organic phase was combined, dried over anhydrous sodium sulfate, and concentrated. The resulting residue was separated and purified by silica gel column chromatography (eluent ratio: methanol: dichloromethane (v / v) = 0% to 15%) to obtain compound 1M (563 mg, 38.5%).
number
[0092] Step 12: Compound 1M (563 mg, 0.98 mmol) was dissolved in dichloromethane (5 ml), trifluoroacetic acid (1 ml) was added, and the mixture was reacted at room temperature for 30 min. After the reaction was completed, the mixture was concentrated, and the resulting residue was purified by silica gel column chromatography (eluent ratio: methanol:dichloromethane (v / v) = 0-15%) to obtain compound 1N (351 mg, 75.5%).
number
[0093] Step 13: Compound 1O (5.0 g, 18.1 mmol) was dissolved in N-methylpyrrolidone (50 mL), azacyclobutan-3-ol (1.8 g, 18.1 mmol) and N,N-diisopropylethylamine (4.7 g, 45.0 mmol) were added, and the mixture was reacted at 90° C. for 2 h. The mixture was cooled to room temperature, water (50 mL) was added, and the mixture was extracted with ethyl acetate (50 mL×3), washed with water (50 mL×2), washed with saturated saline (50 mL×1), dried over anhydrous sodium sulfate, and concentrated to obtain crude product 1P (5.36 g, yield 90.0%).
number
[0094] Step 14: Compound 1P (5.36 g, 16.9 mmol) was dissolved in dichloromethane (120 mL), Dess-Martin oxidant (10.6 g, 25.2 mmol) was added, and the mixture was reacted at room temperature for 16 hours. The mixture was washed with saturated sodium thiosulfate (50 mL x 1), saturated sodium bicarbonate (50 mL x 1), and saturated saline (50 mL x 1), dried over anhydrous sodium sulfate, and concentrated to obtain crude product 1Q (5.33 g, 100.0% yield).
number
[0095] Step 15: Compound 1N (50 mg, 0.105 mmol) and compound 1Q (41 mg, 0.126 mmol) were dissolved in dry dichloroethane (5 ml), tetraisopropyl titanate (0.33 ml, 1.05 mmol) was added dropwise, and the mixture was stirred at room temperature for 24 h. The reaction solution was diluted with methanol (10 ml), sodium cyanoborohydride (35 mg, 0.55 mmol) was added, and the mixture was stirred for 15 min. The mixture was transferred to an ice-water bath and stirred, water (2 ml) was added dropwise, and the mixture was stirred for 10 min. The pH of the solution was adjusted to 7-8 using a saturated sodium bicarbonate solution, and the mixture was filtered through a funnel packed with diatomaceous earth, and the pH of the filtrate was adjusted to 6-7 with 1M hydrochloric acid, and the mixture was concentrated. The obtained residue was separated and purified by a liquid-phase separation column. Separation method by preparative HPLC: 1. Equipment: Waters 2767 separation liquid, Chromatography column: SunFire@ Prep C18 (19 mm x 250 mm). 2. The sample was filtered through a 0.45 μm filter to prepare a sample solution. 3. Conditions for preparative chromatography: a. Composition of mobile phases A and B: Mobile phase A: acetonitrile, Mobile phase B: water (containing 0.1% TFA). b. Gradient elution, with the content of mobile phase A being 5% to 50%. c. Flow rate is 12 mL / min. d. Elution time is 20 min. Retention time is 10.0 min, and the target compound (16 mg, 15.0%) was obtained.
number
[0096] Example 2: N-(1'-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)-[1,4'-bipiperidine]-4-yl)-5-(4-((7-ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl)piperazin-1-yl)pyridine-2-formamide (compound 2) [ka]
[0097] Step 1: Compound 1O (5.0 g, 18.1 mmol) was dissolved in N-methylpyrrolidone (50 mL), piperidin-4-ylmethanol (1.8 g, 18.1 mmol) and N,N-diisopropylethylamine (4.7 g, 45.0 mmol) were added, and the mixture was reacted at 90° C. for 2 hours. The mixture was cooled to room temperature, water (50 mL) was added, and the mixture was extracted with ethyl acetate (50 mL×3), washed with water (50 mL×2), washed with saturated saline (50 mL×1), dried over anhydrous sodium sulfate, and concentrated to obtain crude product 2B (6 g, 92% yield).
number
[0098] Step 2: Compound 2B (6 g, 16.8 mmol) was dissolved in dichloromethane (120 mL), Dess-Martin oxidant (10.6 g, 25.2 mmol) was added, and the mixture was reacted at room temperature for 16 hours. The mixture was washed with saturated sodium thiosulfate (50 mL x 1), saturated sodium bicarbonate (50 mL x 1), and saturated saline (50 mL x 1), dried over anhydrous sodium sulfate, and concentrated to obtain crude product 2C (6 g, 100% yield).
number
[0099] Step 3: Compound 2C (39 mg, 0.11 mmol) and 1N (50 mg, 0.105 mmol) were dissolved in dry dichloroethane (5 ml), tetraisopropyl titanate (0.33 ml, 1.05 mmol) was added dropwise, and the mixture was stirred at room temperature for 24 h. The reaction mixture was diluted with methanol (10 ml), sodium cyanoborohydride (35 mg, 0.55 mmol) was added, and the mixture was stirred for 15 min. The mixture was transferred to an ice-water bath and stirred, water (2 ml) was added dropwise, and the mixture was stirred for 10 min. The pH of the solution was adjusted to 7-8 using a saturated sodium bicarbonate solution, and the mixture was filtered through a funnel packed with diatomaceous earth, and the pH of the filtrate was adjusted to 6-7 with 1M hydrochloric acid, and the mixture was concentrated. The obtained residue was separated and purified by a liquid-phase separation column. Separation method by preparative HPLC: 1. Equipment: Waters 2767 separation liquid, Chromatography column: SunFire@ Prep C18 (19 mm x 250 mm). 2. The sample was filtered through a 0.45 μm filter to prepare a sample solution. 3. Conditions for preparative chromatography: a. Composition of mobile phases A and B: Mobile phase A: acetonitrile, Mobile phase B: water (containing 0.1% TFA). b. Gradient elution, with the content of mobile phase A being 5% to 50%. c. Flow rate is 12 mL / min. d. Elution time is 20 min. Retention time is 9.0 min, and target compound 2 (21 mg, 22.4%) was obtained.
number
[0100] Example 3: N-(1-((1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperidin-4-yl)methyl)piperidin-4-yl)-5-(4-((7-ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl)piperazin-1-yl)pyridine-2-formamide (compound 3) [ka]
[0101] Step 1: Compound 1O (5.0 g, 18.1 mmol) was dissolved in N-methylpyrrolidone (50 mL), piperidin-4-ylmethanol (2.1 g, 18.1 mmol) and N,N-diisopropylethylamine (4.7 g, 45.0 mmol) were added, and the mixture was reacted at 90° C. for 2 hours. The mixture was cooled to room temperature, water (50 mL) was added, and the mixture was extracted with ethyl acetate (50 mL×3), washed with water (50 mL×2), washed with saturated saline (50 mL×1), dried over anhydrous sodium sulfate, and concentrated to obtain crude product 3B (6 g, yield 89.6%).
number
[0102] Step 2: Compound 3B (6 g, 16.2 mmol) was dissolved in dichloromethane (120 mL), Dess-Martin oxidant (13.7 g, 32.4 mmol) was added, and the mixture was reacted at room temperature for 16 hours. The mixture was washed with saturated sodium thiosulfate (50 mL x 1), saturated sodium bicarbonate (50 mL x 1), and saturated saline (50 mL x 1), dried over anhydrous sodium sulfate, and concentrated to obtain crude product 3C (6 g, yield 100.0%).
number
[0103] Step 3: Compound 3C (81 mg, 0.22 mmol) and 1N (50 mg, 0.11 mmol) were added to ethanol (10 mL), then 1,2-dichloroethane (5 mL) was added, 6 drops of glacial acetic acid were added, and the mixture was reacted at 80 ° C for 12 hours, after which sodium cyanoborohydride (50 mg, 0.8 mmol) was added and the mixture was reacted at room temperature for 1 h. After spin drying, the mixture was separated and purified by a liquid-phase separation column (liquid-phase separation conditions: C18 reverse phase preparation column, mobile phase was deionized water (A) containing 0.1% trifluoroacetic acid, acetonitrile (B), gradient elution, B content = 5% to 50%, elution time 15 min, flow rate 12 mL / min, column temperature: 30 ° C), and the title compound 3 (30 mg, yield 33%, retention time about 6.0 min) was obtained.
number
[0104] Example 4: N-(1-((1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperidin-4-yl)methyl)azacyclobutan-3-yl)-5-(4-((7-ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl)piperazin-1-yl)pyridine-2-formamide (compound 4) [ka]
[0105] Step 1: Compound 1L (500 mg, 1.26 mmol) and 3-aminoazacyclobutane-1-carboxylic acid tert-butyl ester (259 mg, 1.51 mmol) were dissolved in DMF (5 ml), benzotriazole-N,N,N',N'-tetramethyluronium hexafluorophosphate (476 mg, 1.26 mmol) was added, the mixture was purged with nitrogen gas three times, and the mixture was stirred at room temperature for 20 min. N,N-diisopropylethylamine (486 mg, 3 .77 mmol) was added and the mixture was stirred at room temperature for 2 h to react. After the reaction was completed, water (5 ml) and ethyl acetate (6 ml) were added, the organic phase was separated, the aqueous phase was extracted with ethyl acetate (6 ml x 2), the organic phases were combined, dried over anhydrous sodium sulfate and concentrated, and the obtained residue was separated and purified by silica gel column chromatography (eluent ratio: methanol:dichloromethane (v / v) = 0% ~ 15%) to obtain compound 4A (313 mg, 45.0%).
number
[0106] Step 2: Compound 4A (313 mg, 0.57 mmol) was dissolved in dichloromethane (5 ml), trifluoroacetic acid (1 ml) was added, and the mixture was reacted at room temperature for 30 min. After the reaction was completed, the mixture was concentrated, adjusted to pH>7 with triethylamine, and purified by C18 column chromatography (acetonitrile:0.1% aqueous ammonia solution (v / v)=50%) to obtain compound 4B (155 mg, 60.5%).
number
[0107] Step 3: Compound 3C (81 mg, 0.22 mmol) and compound 4B (50 mg, 0.11 mmol) were added to ethanol (10 mL), then 1,2-dichloroethane (5 mL) was added, 3 drops of glacial acetic acid were added, and the mixture was reacted at room temperature for 1 hour. After that, sodium cyanoborohydride (50 mg, 0.8 mmol) was added and the mixture was reacted at room temperature for 1 hour. After spin drying, the mixture was separated and purified by a liquid-phase separation column (liquid-phase separation conditions: C18 reverse phase preparation column, mobile phase was deionized water (A) containing 0.1% ammonium bicarbonate, acetonitrile (B), gradient elution, B content = 5% to 50%, elution time 15 min, flow rate 12 mL / min, column temperature: 30 ° C.), and the title compound 4 (30 mg, yield 34.1%, retention time about 6.3 min) was obtained.
number
[0108] Example 5: N-(1-(1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperidin-4-yl)azacyclobutan-3-yl)-5-(4-((7-ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl)piperazin-1-yl)pyridine-2-formamide (compound 5) [ka]
[0109] Step 1: Compound 2C (81 mg, 0.22 mmol) and compound 4B (50 mg, 0.11 mmol) were added to ethanol (10 mL), then 1,2-dichloroethane (5 mL) was added, 3 drops of glacial acetic acid were added, and the mixture was reacted at room temperature for 1 hour. After that, sodium cyanoborohydride (50 mg, 0.8 mmol) was added and the mixture was reacted at room temperature for 1 h. After spin drying, the mixture was separated and purified by a liquid-phase separation column (liquid-phase separation conditions: C18 reverse phase preparation column, mobile phase was deionized water (A) containing 0.1% ammonium bicarbonate, acetonitrile (B), gradient elution, B content = 5% to 50%, elution time 15 min, flow rate 12 mL / min, column temperature: 30 ° C.), and the title compound 5 (30 mg, yield 34.7%, retention time about 6.2 min) was obtained.
number
[0110] Example 6: N-(1-((1-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)piperidin-4-yl)methyl)piperidin-4-yl)-5-(4-((7-ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl)piperazin-1-yl)pyridine-2-formamide (Compound 6) [ka]
[0111] Step 1: Compound 4-formylpiperidine-1-carboxylic acid benzyl ester 6A (5.0 g, 20.2 mmol) was dissolved in methanol (60 mL), trimethyl orthoformate (20 mL) and p-toluenesulfonic acid (500 mg) were added, and the mixture was reacted at room temperature for 4 hours. After concentration, water (50 mL) was added, and the mixture was extracted with ethyl acetate (50 mL x 3), washed with saturated aqueous sodium bicarbonate (50 mL x 2), washed with saturated saline (50 mL x 1), dried over anhydrous sodium sulfate, and concentrated to obtain crude product 6B (6 g, yield 100.0%).
number
[0112] Step 2: Compound 6B (6 g, 20.2 mmol) was dissolved in methanol (100 mL), palladium carbon (600 mg) was added, hydrogen gas was added at room temperature, and the mixture was reacted for 16 hours. After filtration, the mixture was dried and concentrated to obtain crude product 6C (3 g, yield 93.1%).
number
[0113] Step 3: Compound 6C (2 g, 12.6 mmol) and 5-fluoro-1(3H)-isobenzofuranone (1.9 g, 12.6 mmol) were added to dimethyl sulfoxide (40 mL), then N,N-diisopropylethylamine (3.3 g, 25.2 mmol) was added, and the mixture was reacted at 120° C. for 12 hours. After cooling to room temperature, water (50 mL) was added, and the mixture was extracted with ethyl acetate (50 mL×3), washed with water (50 mL×2), washed with saturated saline (50 mL×1), dried over anhydrous sodium sulfate, and concentrated. The mixture was then purified by silica gel column chromatography (petroleum ether:ethyl acetate (v / v)=20:100) to obtain product 6D (3 g, yield 81.2%).
number
[0114] Step 4: Compound 6D (3 g, 10.3 mmol) was dissolved in methanol (30 mL), water (30 mL) was added, sodium hydroxide (0.82 g, 20.6 mmol) was added, and the mixture was reacted at room temperature for 2 hours. The mixture was then adjusted to pH=5-6 with 1N hydrochloric acid, extracted with ethyl acetate (50 mL×3), washed with water (50 mL×1), washed with saturated saline (50 mL×1), dried over anhydrous sodium sulfate, and concentrated to obtain product 6E (2 g, yield 66.0%).
number
[0115] Step 5: Compound 6E (2g, 6.5mmol) was dissolved in methanol (30mL), ethyl acetate (30mL) was added, and the mixture was cooled to 0℃, followed by dropwise addition of trimethylsilane diazomethane (1.4g, 12.1mmol). The mixture was reacted at room temperature for 2 hours, and then extracted with ethyl acetate (50mL×3), washed with water (50mL×1), washed with saturated saline (50mL×1), dried over anhydrous sodium sulfate, concentrated, and then purified by silica gel column chromatography (petroleum ether:ethyl acetate (v / v)=20:100) to obtain product 6F (2g, yield 95.2%).
number
[0116] Compound 6F (0.9 g, 2.8 mmol) was dissolved in tetrahydrofuran (10 mL), triphenylphosphine (0.73 g, 2.8 mmol) was added, and the mixture was cooled to 0°C. Then, carbon tetrabromide (0.93 g, 2.8 mmol) was added dropwise. The mixture was reacted at room temperature for 1 hour, and then saturated ammonium chloride (20 mL) was added. The mixture was extracted with ethyl acetate (20 mL x 3), washed with saturated saline (50 mL x 1), dried over anhydrous sodium sulfate, and concentrated. The mixture was then purified by silica gel column chromatography (petroleum ether: ethyl acetate (v / v) = 15:100) to obtain product 6G (0.4 g, yield 37.0%).
number
[0117] Step 7: Compound 6G (0.4 g, 1 mmol) was dissolved in acetonitrile (10 mL), and 3-amino-2,6-piperidinedione (153 mg, 1.2 mmol) and N,N-diisopropylethylamine (194 mg, 1.5 mmol) were added. The mixture was reacted at 80° C. for 12 hours, concentrated, and then purified by silica gel column chromatography (methanol:dichloromethane (v / v) = 5:100) to obtain product 6H (0.25 g, yield 60.0%).
number
[0118] Step 8: Compound 6H (0.25 g, 0.6 mmol) was dissolved in tetrahydrofuran (10 mL), water (2 mL) and pyridinium p-toluenesulfonate (301 mg, 1.2 mmol) were added, and the mixture was reacted at 80° C. for 6 hours. Water (20 mL) was added, and the mixture was extracted with dichloromethane (20 mL×3), washed with saturated saline (50 mL×1), dried over anhydrous sodium sulfate, concentrated, and then purified by silica gel column chromatography (methanol:dichloromethane (v / v)=5:100) to obtain product 6J (0.21 g, yield 95.4%).
number
[0119] Step 9: Compound 6J (140 mg, 0.39 mmol) and compound 1N (50 mg, 0.11 mmol) were added to ethanol (10 mL), then 1,2-dichloroethane (5 mL) was added, 6 drops of glacial acetic acid were added, and the mixture was reacted at 80 ° C for 12 hours, after which sodium cyanoborohydride (50 mg, 0.8 mmol) was added and the mixture was reacted at room temperature for 1 h. After spin drying, the mixture was separated and purified by a liquid-phase separation column (liquid-phase separation conditions: C18 reverse phase preparation column, mobile phase was deionized water (A) containing 0.1% ammonium bicarbonate, acetonitrile (B), gradient elution, B content = 5% to 50%, elution time 15 min, flow rate 12 mL / min, column temperature: 30 ° C), and the title compound 6 (30 mg, yield 33.5%, retention time about 6.1 min) was obtained.
number
[0120] Example 7: N-(1-((1-(2-((3R,5R)-adamantan-1-yl)acetyl)piperidin-4-yl)methyl)piperidin-4-yl)-5-(4-((7-ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl)piperazin-1-yl)pyridine-2-formamide (compound 7) [ka]
[0121] Step 1: Adamantane acetic acid 7A (5.0 g, 25.8 mmol) was dissolved in N,N-dimethylformamide (50 mL), N,N,N',N'-tetramethyl-O-(7-azabenzotriazol-1-yl)uronium hexafluorophosphate (14.7 g, 38.7 mmol), 4-formylpiperidine (3 g, 25.8 mmol), N,N-diisopropylethylamine (16.6 g, 51.6 mmol) were added, and the mixture was reacted at room temperature for 12 hours. Water (50 mL) was added, and the mixture was extracted with ethyl acetate (50 mL x 3), washed with water (50 mL x 3), washed with saturated saline (50 mL x 1), dried over anhydrous sodium sulfate, and concentrated. The mixture was then purified by silica gel column chromatography (petroleum ether: ethyl acetate (v / v) = 20:100) to obtain product 7B (2 g, yield 26.6%).
number
[0122] Step 2: Compound 7B (95 mg, 0.33 mmol) and compound 1N (50 mg, 0.11 mmol) were added to ethanol (10 mL), then 1,2-dichloroethane (5 mL) was added, 6 drops of glacial acetic acid were added, and the mixture was reacted at 80 ° C for 12 hours, after which sodium cyanoborohydride (50 mg, 0.8 mmol) was added and the mixture was reacted at room temperature for 1 h. After spin drying, the mixture was separated and purified by a liquid-phase separation column (liquid-phase separation conditions: C18 reverse phase preparation column, mobile phase was deionized water (A) containing 0.1% ammonium bicarbonate, acetonitrile (B), gradient elution, B content = 5% to 50%, elution time 15 min, flow rate 12 mL / min, column temperature: 30 ° C), and the title compound 7 (28 mg, yield 34.1%, retention time about 6.3 min) was obtained.
number
[0123] Example 8: N-(1-((1-(4-(3-(2,4-dihydroxy-5-isopropylphenyl)-5-hydroxy-4H-1,2,4-triazol-4-yl)benzyl)piperidin-4-yl)methyl)piperidin-4-yl)-5-(4-((7-ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl)piperazin-1-yl)pyridine-2-formamide (Compound 8) [ka]
[0124] Step 1: Compound 8A (20.0 g, 60.6 mmol) was dissolved in ethanol (400 mL), palladium carbon (5 g) was added, and the mixture was reacted in hydrogen gas at 60° C. for 24 hours. The mixture was filtered and concentrated to give crude product 8B (9.5 g, 100.0% yield).
number
[0125] Step 2: Compound 8B (9.5 g, 60.6 mmol) was dissolved in DMF (200 mL), potassium O-ethyldithiocarbonate (12.6 g, 78.78 mmol) was added, and the mixture was reacted at 100°C for 12 hours under nitrogen gas protection. Cold water (200 mL) was added in an ice bath, and the pH was adjusted to 2-3 with 6N hydrochloric acid. After filtration, the filter cake was washed with water and dried to obtain crude product 8C (7 g, yield 52.0%).
number
[0126] Step 3: Compound 6C (9 g, 56.6 mmol) and p-nitrobenzyl bromide (12.2 g, 56.6 mmol) were added to dichloromethane (200 mL), then triethylamine (8.6 g, 84.9 mmol) was added, and the mixture was reacted at room temperature for 12 hours, followed by addition of water (200 mL). The mixture was extracted with dichloromethane (200 mL x 2), washed with saturated saline (200 mL x 1), dried over anhydrous sodium sulfate, and concentrated. The mixture was then purified by silica gel column chromatography (petroleum ether:ethyl acetate (v / v) = 20:100) to obtain product 8D (7.5 g, yield 45.4%).
number
[0127] Step 4: Compound 8D (7.5 g, 25.5 mmol) was dissolved in methanol (200 mL), and ammonium chloride (6.7 g, 127.5 mmol) and reduced iron powder (7.1 g, 127.5 mmol) were added. The mixture was reacted at 60°C for 24 hours, filtered, and the filtrate was washed with saturated sodium bicarbonate water (100 mL x 1), dried over anhydrous sodium sulfate, and concentrated to obtain crude product 8E (6 g, 100.0% yield).
number
[0128] Step 5: Compound 8C (7g, 30.7mmol) was dissolved in DMF (100mL), sodium 2-chloroacetate (5.4g, 46.5mmol), sodium bicarbonate (5.2g, 61.4mmol) were added, and the mixture was reacted at room temperature for 4 hours under the protection of nitrogen gas. Compound 8E (6g, 22.7mmol) was dissolved in DMF (10mL) and added. The mixture was reacted at 80°C for 5 hours under the protection of nitrogen gas, and then water (100mL) was added at room temperature. The mixture was extracted with ethyl acetate (200mL x 3), washed with water (200mL x 2), washed with saturated saline (200mL x 1), dried over anhydrous sodium sulfate, and concentrated to obtain crude product 8F (10g, yield 97.6%).
number
[0129] Step 6: Compound 8F (10.0 g, 21.8 mmol) was dissolved in tetrahydrofuran (100 mL), N,N'-carbonyldiimidazole (4.24 g, 26.16 mmol) was added, and the mixture was reacted at room temperature for 4 hours. Then, saturated ammonium chloride (100 mL) was added, and the mixture was extracted with ethyl acetate (200 mL x 3), saturated sodium bicarbonate (100 mL x 1), washed with saturated saline (50 mL x 1), dried over anhydrous sodium sulfate, and concentrated to obtain crude product 8G (11 g, yield 100.0%).
number
[0130] Step 7: Compound 8G (11.0 g, 21.8 mmol) was dissolved in ethanol (100 mL), and hydrazine hydrate (3.3 g, 65.4 mmol) was added. The mixture was reacted at room temperature for 12 hours, concentrated, and then purified by silica gel column chromatography (methanol:dichloromethane (v / v) = 5:100) to obtain product 8H (4.0 g, yield 38.1%).
number
[0131] Step 8: Compound 8H (1.4 g, 2.9 mmol) was dissolved in trifluoroacetic acid (7 mL), reacted at room temperature for 4 hours, adjusted to pH=7-8 with saturated sodium bicarbonate, filtered, and the filter cake was dried to obtain crude product 8J (1.2 g, yield 100.0%).
number
[0132] Step 9: Compound 8J (191 mg, 0.44 mmol) and compound 1N (50 mg, 0.11 mmol) were added to ethanol (10 mL), then 1,2-dichloroethane (5 mL) was added, 6 drops of glacial acetic acid were added, and the mixture was reacted at 80 ° C for 24 hours, after which sodium cyanoborohydride (50 mg, 0.8 mmol) was added and the mixture was reacted at room temperature for 1 h. After spin drying, the mixture was separated and purified by a liquid-phase separation column (liquid-phase separation conditions: C18 reverse phase preparation column, mobile phase was deionized water (A) containing 0.1% ammonium bicarbonate, acetonitrile (B), gradient elution, B content = 5% to 50%, elution time 15 min, flow rate 12 mL / min, column temperature: 30 ° C), and the title compound 8 (25 mg, yield 25.5%, retention time about 6.2 min) was obtained.
number
[0133] Example 9: N-(1-((1-(4-(3-(2,4-dihydroxy-5-isopropylphenyl)-5-hydroxy-4H-1,2,4-triazole -4-yl)benzyl)piperidin-4)-yl)methyl)azacyclobutan-3-yl)-5-(4-((7-ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl)piperazin-1-yl)pyridine-2-formamide (Compound 9) [ka]
[0134] Step 1: Compound 8J (191 mg, 0.44 mmol) and compound 4B (50 mg, 0.11 mmol) were added to ethanol (10 mL), then 1,2-dichloroethane (5 mL) was added, 3 drops of glacial acetic acid were added, and the mixture was reacted at room temperature for 1 hour. After that, sodium cyanoborohydride (50 mg, 0.8 mmol) was added and the mixture was reacted at room temperature for 1 hour. After spin drying, the mixture was separated and purified by a liquid-phase separation column (liquid-phase separation conditions: C18 reverse phase preparation column, mobile phase was deionized water (A) containing 0.1% ammonium bicarbonate, acetonitrile (B), gradient elution, B content = 5% to 50%, elution time 15 min, flow rate 12 mL / min, column temperature: 30 °C), and the title compound 9 (5 mg, yield 5.3%, retention time about 6.3 min) was obtained.
number
[0135] Example 10: N-(1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperidin-4-yl)-5-(4-((7-ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl)piperazin-1-yl)pyridine-2-formamide (compound 10) [ka]
[0136] Step 1: 1N (50 mg, 0.11 mmol) and compound 1O (30 mg, 0.11 mmol) were added to dimethyl sulfoxide (2 mL), then N,N-diisopropylethylamine (28 mg, 0.22 mmol) was added, and the mixture was reacted at 100 ° C for 2 h. The mixture was directly separated and purified by liquid-phase separation column (liquid-phase separation conditions: C18 reverse phase preparation column, mobile phase was deionized water (A) containing 0.1% ammonium bicarbonate, acetonitrile (B), gradient elution, B content = 5% to 50%, elution time 15 min, flow rate 12 mL / min, column temperature: 30 ° C.), and the title compound 10 (30 mg, yield 37.3%, retention time about 7.3 min) was obtained. 1H NMR(400MHz,CD3OD)δ 8.61(d,1H),8.34(d,1H),7.99(d,1H),7.88(d,2H),7.67(d,1H),7.49(d,1H),7.37(d,1H),7.24(d,1H),5.06(d,1H),4.56(s,2H),4.23 - 4.12(m,1H),4.09 - 4.00(m,2H),3.84 - 3.35(m,8H),3.24 - 3.11(m,2H),2.92 - 2.60(m,5H),2.15 - 2.00(m,3H),1.83 - 1.66(m,2H),1.35 - 1.23(m,3H).
number
[0137] Example 11: N-(1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)azacyclobutan-3-yl)-5-(4-((7-ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl)piperazin-1-yl)pyridine-2-formamide (Compound 11) [ka]
[0138] Step 1: 4B (50 mg, 0.11 mmol) and compound 1O (30 mg, 0.11 mmol) were added to dimethyl sulfoxide (2 mL), then N,N-diisopropylethylamine (28 mg, 0.22 mmol) was added, and the mixture was reacted at 100 ° C for 2 h. The mixture was directly separated and purified by liquid-phase separation column (liquid-phase separation conditions: C18 reverse phase preparation column, mobile phase was deionized water (A) containing 0.1% ammonium bicarbonate, acetonitrile (B), gradient elution, B content = 5% to 50%, elution time 15 min, flow rate 12 mL / min, column temperature: 30 ° C.) to obtain the title compound 11 (5 mg, yield 6.5%, retention time about 7.3 min). 1H NMR(400MHz,DMSO-d6)δ 11.83(s,1H),11.05(s,1H),9.12(d,1H),8.34(d,2H),7.85(d,1H),7.75(s,1H),7.69 - 7.61(m,2H),7.41(d,1H),6.81(s,1H),6.68(d,1H),5.10 - 4.86(m,2H),4.43 - 4.28(m,2H),4.18 - 4.02(m,2H),3.74 - 3.58(m,2H),3.44 - 3.33(m,4H),2.96 - 2.79(m,1H),2.69 - 2.52(m,8H),2.08 - 1.94(m,1H),1.29 - 0.97(m,3H).
number
[0139] Example 12: N-(1-(2-((3R,5R)-adamantan)-1-yl)acetyl)piperidin-4-yl)-5-(4-((7-ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl)piperazin-1-yl)pyridine-2-formamide (compound 12) [ka]
[0140] Step 1: 1N (50 mg, 0.11 mmol) and adamantane acetic acid (42 mg, 0.22 mmol) were added to N,N-dimethylformamide (2 mL), HATU (84 mg, 0.22 mmol), N,N-diisopropylethylamine (28 mg, 0.22 mmol) were added, and the mixture was reacted at room temperature for 1 h. The mixture was directly separated and purified by a liquid-phase separation column (liquid-phase separation conditions: C18 reversed-phase preparation column, mobile phase was deionized water (A) containing 0.1% ammonium bicarbonate, acetonitrile (B), gradient elution, B content = 5% to 50%, elution time 15 min, flow rate 12 mL / min, column temperature: 30 °C), to obtain the title compound 12 (30 mg, yield 42.3%, retention time about 7.1 min). 1 H NMR(400MHz,CD3OD)δ 8.62(d,1H),8.36(d,1H),8.00(d,1H),7.92(d,1H),7.88(s,1H),7.51(d,1H),4.65 - 4.51(m,3H),4.18 - 4.00(m,2H),3.88 - 3.40(m,8H),3.29 - 3.19(m,1H),2.88 - 2.74(m,1H),2.72 - 2.60(m,2H),2.31 - 2.13(m,2H),2.05 - 1.90(m,5H),1.78 - 1.64(m,12H),1.63 - 1.49(m,2H),1.33 - 1.23(m,3H).
number
[0141] Example 13: N-(1-(2-((3R,5R)-adamantan)-1-yl))acetyl)azacyclobutan-3-yl)-5-(4-((7-ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl)piperazin-1-yl)pyridine-2-formamide (compound 13) [ka]
[0142] Step 1: 4B (50 mg, 0.11 mmol) and adamantane acetic acid (42 mg, 0.22 mmol) were added to N,N-dimethylformamide (2 mL), HATU (84 mg, 0.22 mmol), N,N-diisopropylethylamine (28 mg, 0.22 mmol) were added, and the mixture was reacted at room temperature for 1 h. The mixture was directly separated and purified by a liquid-phase separation column (liquid-phase separation conditions: C18 reverse-phase preparation column, mobile phase was deionized water (A) containing 0.1% ammonium bicarbonate, acetonitrile (B), gradient elution, B content = 5% to 50%, elution time 15 min, flow rate 12 mL / min, column temperature: 30 °C), to obtain the title compound 13 (30 mg, yield 42%, retention time about 7.0 min). 1 H NMR(400MHz,CD3OD)δ 8.62(d,1H),8.38(d,1H),7.97(d,1H),7.90(s,1H),7.87(s,1H),7.49(d,1H),4.79 - 4.72(m,1H),4.61 - 4.50(m,3H),4.35 - 4.21(m,2H),4.07 - 3.98(m,1H),3.88 - 3.34(m,8H),2.77 - 2.61(m,2H),2.06 - 1.85(m,5H),1.79 - 1.56(m,12H),1.38 - 1.17(m,3H).
number
[0143] Example 14: N-(1'-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)-[1,3'-diazacyclobutan]-3-yl)-5-(4-((7-ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl)piperazin-1-yl)pyridine-2-formamide (compound 14) [ka]
[0144] Step 1: 4B (50 mg, 0.11 mmol) and 1Q (71 mg, 0.22 mmol) were added to ethanol (5 mL), then 1,2-dichloroethane (5 mL) was added, 3 drops of glacial acetic acid were added, and the mixture was reacted at 60 ° C for 12 hours, after which sodium cyanoborohydride (50 mg, 0.8 mmol) was added and the mixture was reacted at room temperature for 1 h. After spin drying, the mixture was separated and purified by a liquid-phase separation column (liquid-phase separation conditions: C18 reverse phase preparation column, mobile phase was deionized water (A) containing 0.1% ammonium bicarbonate, acetonitrile (B), gradient elution, B content = 5% to 50%, elution time 15 min, flow rate 12 mL / min, column temperature: 30 ° C), and the title compound 14 (20 mg, yield 24.1%, retention time about 6.5 min) was obtained. 1 H NMR(400MHz,CD3OD)δ 8.48(d,2H),8.29(d,1H),7.98(d,1H),7.82(s,1H),7.73(s,1H),7.61(d,1H),6.78(s,1H),6.62(d,1H),5.08 - 5.02(m,1H),4.94 - 4.91(m,1H),4.29 - 4.13(m,2H),4.13 - 4.02(m,1H),3.86 - 3.80(m,1H),3.75 - 3.68(m,3H),3.65 - 3.53(m,5H),2.94 - 2.79(m,3H),2.76 - 2.61(m,9H),2.14 - 2.06(m,1H),1.30 - 1.26(m,3H).
number
[0145] Example 15: N-(1-(1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)azacyclobutan-3-yl)piperidin-4-yl)-5-(4-((7-ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl)piperazin-1-yl)pyridine-2-formamide (compound 15) [ka]
[0146] Step 1: Compound 15A (1.0 g, 3.6 mmol) was dissolved in dimethyl sulfoxide (10 mL), azacyclobutan-3-ol hydrochloride (470 mg, 4.32 mmol) and N,N-diisopropylethylamine (936 mg, 7.2 mmol) were added, and the mixture was reacted at 100° C. for 2 h. The mixture was cooled to room temperature, water (50 mL) was added, and the mixture was extracted with ethyl acetate (50 mL x 3), washed with water (50 mL x 2), washed with saturated saline (50 mL x 1), dried over anhydrous sodium sulfate, and concentrated to obtain crude product 15B (1.2 g, yield 100.0%).
number
[0147] Step 2: Compound 15B (1.2 g, 3.6 mmol) was dissolved in dichloromethane (30 mL), Dess-Martin oxidant (3.1 g, 7.2 mmol) was added, and the mixture was reacted at room temperature for 16 hours. The mixture was washed with saturated sodium thiosulfate (50 mL x 1), saturated sodium bicarbonate (50 mL x 1), and saturated saline (50 mL x 1), dried over anhydrous sodium sulfate, and concentrated. The mixture was then separated and purified by silica gel column chromatography (methanol:dichloromethane (v / v) = 0:100 to 5:100) to obtain the title compound 15C (600 mg, yield 50.1%).
number
[0148] Step 3: Compound 15C (72 mg, 0.22 mmol) and 1N (50 mg, 0.11 mmol) were added to ethanol (5 mL), then 1,2-dichloroethane (5 mL) was added, 6 drops of glacial acetic acid were added, and the mixture was reacted at 80 ° C for 24 hours, after which sodium cyanoborohydride (50 mg, 0.8 mmol) was added and the mixture was reacted at room temperature for 1 h. After spin drying, the mixture was separated and purified by a liquid-phase separation column (liquid-phase separation conditions: C18 reverse phase preparation column, mobile phase was deionized water (A) containing 0.1% ammonium bicarbonate, acetonitrile (B), gradient elution, B content = 5% to 50%, elution time 15 min, flow rate 12 mL / min, column temperature: 30 ° C), and the title compound 15 (30 mg, yield 34.9%, retention time about 6.3 min) was obtained. 1H NMR(400MHz,CD3OD)δ8.63(d,1H),8.37(d,1H),8.00(d,1H),7.94(s,1H),7.87(s,1H),7.63 - 7.58(m,1H),7.54 - 7.49(m,1H),7.26(d,1H),6.86(d,1H),5.12 - 5.04(m,1H),4.66 - 4.56(m,4H),4.52 - 4.42(m,2H),4.28 - 4.15(m,2H),3.80 - 3.49(m,10H),3.29 - 3.05(m,2H),2.91 - 2.62(m,5H),2.34 - 1.86(m,5H),1.31 - 1.27(m,3H).
number
[0149] Example 16: N-(1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)nitrid-3-yl)-5-(4-((7-ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl)piperazin-1-yl)pyridine-2-formamide (Compound 16) [ka]
[0150] Step 1: Compound 4B (50 mg, 0.11 mmol) and 2-(2,6-dioxopiperidin-3-yl)-4-fluoroisoindoline-1,3-dione (36 mg, 0.13 mmol) were added to dimethyl sulfoxide (2 mL), followed by N,N-diisopropylethylamine (28 mg, 0.22 mmol) and reacted at 100 ° C for 1 h. The mixture was directly separated and purified by liquid-phase separation column (liquid-phase separation conditions: C18 reverse phase preparation column, mobile phase was deionized water (A) containing 0.1% ammonium bicarbonate, acetonitrile (B), gradient elution, B content = 5% to 50%, elution time 15 min, flow rate 12 mL / min, column temperature: 30 ° C), to obtain the title compound 16 (30 mg, yield 38.8%, retention time about 7.0 min). 1 H NMR(400MHz,DMSO-d6)δ 11.82(s,1H),11.04(s,1H),9.07(d,1H),8.40(s,1H),8.27(d,1H),7.84(d,1H),7.75(s,1H),7.63(s,1H),7.61 - 7.54(m,1H),7.40(d,1H),7.13(d,1H),6.81(d,1H),5.12 - 4.97(m,1H),4.90 - 4.76(m,1H),4.62 - 4.45(m,2H),4.33 - 4.13(m,2H),3.65(s,2H),3.40 - 3.32(m,4H),3.31 - 3.30(m,2H),2.97 - 2.76(m,1H),2.59 - 2.53(m,6H),2.00(d,1H),1.22 - 1.12(m,3H).
number
[0151] Example 17: N-(1-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxoisoindolin-5-yl)azacyclobutan-3-yl)-5-(4-((7-ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl)piperazin-1-yl)pyridine-2-formamide (compound 17) [ka]
[0152] Step 1: Compound 4B (50 mg, 0.11 mmol) and 2-(2,6-dioxopiperidin-3-yl)-5,6-difluoroindoline-1,3-dione (38 mg, 0.13 mmol) were added to dimethyl sulfoxide (2 mL), followed by N,N-diisopropylethylamine (28 mg, 0.22 mmol) and reacted at 100 ° C for 1 h. The mixture was directly separated and purified by liquid-phase separation column (liquid-phase separation conditions: C18 reverse phase preparation column, mobile phase was deionized water (A) containing 0.1% ammonium bicarbonate, acetonitrile (B), gradient elution, B content = 5% to 50%, elution time 15 min, flow rate 12 mL / min, column temperature: 30 ° C), to obtain the title compound 17 (31 mg, yield 39.2%, retention time about 7.1 min). 1 H NMR(400MHz,DMSO-d6)δ 11.83(s,1H),11.07(s,1H),9.08(d,1H),8.40(d,1H),8.24(d,1H),7.85(d,1H),7.75(s,1H),7.67 - 7.52(m,2H),7.40(d,1H),6.96(d,1H),5.11 - 5.03(m,1H),4.97 - 4.85(m,1H),4.52 - 4.41(m,2H),4.28 - 4.19(m,2H),3.65(s,2H),3.45 - 3.32(m,4H),3.31 - 3.31(m,2H),2.95 - 2.80(m,1H),2.60 - 2.53(m,6H),2.08 - 1.94(m,1H),1.20 - 1.16(m,3H).
number
[0153] Example 18: N-(1-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxoisoindolin-5-yl)piperidin-4-yl)-5-(4-((7-ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl)piperazin-1-yl)pyridine-2-formamide (Compound 18) [ka]
[0154] Step 1: Compound 1N (50 mg, 0.11 mmol) and 2-(2,6-dioxopiperidin-3-yl)-5,6-difluoroindoline-1,3-dione (38 mg, 0.13 mmol) were added to dimethyl sulfoxide (2 mL), followed by N,N-diisopropylethylamine (28 mg, 0.22 mmol) and reacted at 100 ° C for 1 h. The mixture was directly separated and purified by liquid-phase separation column (liquid-phase separation conditions: C18 reverse phase preparation column, mobile phase was deionized water (A) containing 0.1% ammonium bicarbonate, acetonitrile (B), gradient elution, B content = 5% to 50%, elution time 15 min, flow rate 12 mL / min, column temperature: 30 ° C), to obtain the title compound 18 (31 mg, yield 37.8%, retention time about 7.1 min). 1 H NMR(400MHz,DMSO-d6)δ 12.18(s,1H),11.09(s,1H),8.54(d,1H),8.41 - 8.30(m,2H),7.92(d,1H),7.79(d,2H),7.72(d,1H),7.55 - 7.45(m,2H),5.14 - 5.08(m,1H),4.53(s,2H),4.24 - 3.83(m,3H),3.68 - 3.59(m,2H),3.57 - 3.10(m,6H),3.09 - 3.00(m,2H),2.94 - 2.83(m,1H),2.72 - 2.52(m,4H),2.09 - 2.00(m,1H),1.94 - 1.76(m,4H),1.23 - 1.16(m,3H).
number
[0155] Example 19: N-(1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)piperidin-4-yl)-5-(4-((7-ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl)piperazin-1-yl)pyridine-2-formamide (Compound 19) [ka]
[0156] Step 1: 1N (50 mg, 0.11 mmol) and 2-(2,6-dioxopiperidin-3-yl)-4-fluoroisoindoline-1,3-dione (36 mg, 0.13 mmol) were added to dimethyl sulfoxide (2 mL), followed by N,N-diisopropylethylamine (28 mg, 0.22 mmol), and reacted at 100 ° C for 1 h. The mixture was directly separated and purified by liquid-phase separation column (liquid-phase separation conditions: C18 reversed-phase preparation column, mobile phase was deionized water (A) containing 0.1% ammonium bicarbonate, acetonitrile (B), gradient elution, B content = 5% to 50%, elution time 15 min, flow rate 12 mL / min, column temperature: 30 ° C), to obtain the title compound 19 (30 mg, yield 37.3%, retention time about 7.0 min). 1H NMR(400MHz,DMSO-d6)δ 12.17(s,1H),11.07(s,1H),8.54(s,1H),8.45 - 8.25(m,2H),7.92(d,1H),7.81(s,1H),7.77(s,1H),7.73 - 7.67(m,1H),7.50(d,1H),7.41 - 7.32(m,2H),5.15 - 5.01(m,1H),4.51(s,2H),4.04 - 3.97(m,3H),3.72(d,2H),3.49 - 3.12(m,6H),3.08 - 2.99(m,2H),2.94 - 2.81(m,1H),2.67 - 2.52(m,4H),2.10 - 1.99(m,1H),1.96 - 1.76(m,4H),1.24 - 1.14(m,3H).
number
[0157] Example 20: N-((3R)-1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)pyrrolidin-3-yl)-5-(4-((7-ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl)piperazin-1-yl)pyridine-2-formamide (compound 20) [ka]
[0158] Step 1: Compound 1L (0.5 g, 1.27 mmol) and (R)-3-aminopyrrolidine-1-carboxylic acid tert-butyl ester (283 mg, 1.5 mmol) were dissolved in DMF (5 mL), and benzotriazole-N,N,N',N'-tetramethyluronium hexafluorophosphate (570 mg, 1.5 mmol), N,N-diisopropylethylamine (330 mg, 2.54 mmol) were added, and the mixture was reacted at room temperature with stirring for 1 h. After the reaction was completed, water (10 ml) and ethyl acetate (10 mL) were added, the organic phase was separated, and the aqueous phase was extracted with ethyl acetate (10 mL x 2). The organic phases were combined, dried over anhydrous sodium sulfate, and concentrated to obtain crude product 20A (700 mg, 98.0%).
number
[0159] Step 2: Compound 20A (700 mg, 1.27 mmol) was dissolved in dichloromethane (6 mL), trifluoroacetic acid (2 mL) was added, and the mixture was reacted at room temperature for 30 min. After the reaction was completed, the mixture was concentrated, adjusted to pH>7 with triethylamine, and purified by C18 column chromatography (acetonitrile:0.1% aqueous ammonia solution (v / v)=50%) to obtain product 20B (400 mg, 68.2%).
number
[0160] Step 3: Compound 20B (50 mg, 0.11 mmol) and 2-(2,6-dioxopiperidin-3-yl)-5-fluoroisoindoline-1,3-dione (36 mg, 0.13 mmol) were added to dimethyl sulfoxide (2 mL), followed by N,N-diisopropylethylamine (28 mg, 0.22 mmol) and reacted at 100 ° C for 1 h. The mixture was directly separated and purified by liquid-phase separation column (liquid-phase separation conditions: C18 reverse phase preparation column, mobile phase was deionized water (A) containing 0.1% ammonium bicarbonate, acetonitrile (B), gradient elution, B content = 5% to 50%, elution time 15 min, flow rate 12 mL / min, column temperature: 30 ° C), to obtain the title compound 20 (45 mg, yield 57.1%, retention time about 7.0 min). 1 H NMR(400MHz,DMSO-d6)δ 11.81(s,1H),11.03(s,1H),8.61(d,1H),8.40(s,1H),8.26(s,1H),7.86(d,1H),7.75(s,1H),7.67 - 7.60(m,2H),7.41(d,1H),6.93(s,1H),6.84(d,1H),5.12 - 4.99(m,1H),4.79 - 4.54(m,1H),3.76 - 3.69(m,1H),3.65(s,2H),3.62 - 3.57(m,1H),3.54 - 3.41(m,2H),3.39 - 3.33(m,4H),2.94 - 2.81(m,1H),2.66 - 2.52(m,8H),2.33 - 2.24(m,1H),2.24 - 2.15(m,1H),2.06 - 1.96(m,1H),1.22 - 1.13(m,3H).
number
[0161] Example 21: N-((3S)-1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)pyrrolidin-3-yl)-5-(4-((7-ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl)piperazin-1-yl)pyridine-2-formamide (compound 21) [ka]
[0162] Step 1: Compound 1L (0.5 g, 1.27 mmol) and (S)-3-aminopyrrolidine-1-carboxylic acid tert-butyl ester (283 mg, 1.5 mmol) were dissolved in N,N-dimethylformamide (5 mL), and benzotriazole-N,N,N',N'-tetramethyluronium hexafluorophosphate (570 mg, 1.5 mmol), N,N-diisopropylethylamine (330 mg, 2.54 mmol) were added, and the mixture was reacted at room temperature for 1 hour with stirring. After the reaction was completed, water (10 ml) and ethyl acetate (10 mL) were added, the organic phase was separated, and the aqueous phase was extracted with ethyl acetate (10 mL x 2). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain crude product 21A (700 mg, 98.0%), which was directly used in the next step reaction without purification.
number
[0163] Step 2: Compound 21A (700 mg, 1.27 mmol) was dissolved in dichloromethane (6 mL), trifluoroacetic acid (2 mL) was added, and the mixture was reacted at room temperature for 30 min. After the reaction was completed, the mixture was concentrated, and the residue was adjusted to pH>7 with triethylamine. The mixture was then purified by C18 column chromatography (acetonitrile:0.1% aqueous ammonia solution=1:20 to 1:1) to obtain product 21B (400 mg, 68.2%).
number
[0164] Step 3: Compound 21B (50 mg, 0.11 mmol) and 2-(2,6-dioxopiperidin-3-yl)-5-fluoroisoindoline-1,3-dione (36 mg, 0.13 mmol) were added to dimethyl sulfoxide (2 mL), followed by N,N-diisopropylethylamine (28 mg, 0.22 mmol) and reacted at 100 ° C for 1 hour. The mixture was directly separated and purified by liquid-phase separation column (liquid-phase separation conditions: C18 reverse phase preparation column, mobile phase was deionized water (A) containing 0.1% ammonium bicarbonate, acetonitrile (B), gradient elution, B content = 5% to 50%, elution time 15 min, flow rate 12 mL / min, column temperature: 30 ° C), to obtain the title compound 21 (43 mg, yield 54.5%, retention time about 7.0 min). 1 H NMR(400MHz,DMSO-d6)δ 11.81(s,1H),11.04(s,1H),8.61(d,1H),8.40(s,1H),8.26(s,1H),7.86(d,1H),7.75(s,1H),7.71 - 7.58(m,2H),7.41(d,1H),6.93(s,1H),6.84(d,1H),5.17 - 4.92(m,1H),4.86 - 4.45(m,1H),3.84 - 3.68(m,1H),3.65(s,2H),3.61 - 3.57(m,1H),3.54 - 3.42(m,2H),3.36 - 3.33(m,4H),2.93 - 2.81(m,1H),2.62 - 2.52(m,8H),2.35 - 2.25(m,1H),2.23 - 2.14(m,1H),2.07 - 1.96(m,1H),1.23 - 1.13(m,3H).
number
[0165] Example 22: 2-(2,6-dioxopiperidin-3-yl)-5-((3aR,6aS)-5-(5-(4-((7-ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl)piperazin-1-yl)pyridine-2-formyl)hexahydropyrrolo[3,4-c]pyrrole-2(1H)-yl)isodihydroindole-1,3-dione (compound 22) [ka]
[0166] Step 1: Compound 1L (0.070 g, 0.18 mmol) and cis-2-BOC-hexahydropyrrole[3,4-C]pyrrole (56.6 mg, 0.27 mmol) were dissolved in N,N-dimethylformamide (3 mL), and benzotriazole-N,N,N',N'-tetramethyluronium hexafluorophosphate (82.1 mg, 0.22 mmol), N,N-diisopropylethylamine (69.7 mg, 0.54 mmol) were added, and the mixture was reacted at room temperature for 1 hour with stirring. After the reaction was completed, water (10 ml) and ethyl acetate (10 mL) were added, the organic phase was separated, and the aqueous phase was extracted with ethyl acetate (10 mL x 2). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to obtain crude product 22A (100.0 mg, 95.1%), which was directly used for the next step reaction without purification.
number
[0167] Step 2: Compound 22A (100.0 mg, 0.17 mmol) was dissolved in dichloromethane (3 mL), trifluoroacetic acid (1 mL) was added, and the mixture was reacted at room temperature for 30 min. After completion of the reaction, the mixture was directly concentrated to give product 22B, which was the trifluoroacetate salt (102.0 mg, 100%).
number
[0168] Step 3: Compound 22B (102.0 mg, 0.17 mmol) and 2-(2,6-dioxopiperidin-3-yl)-5-fluoroisoindoline-1,3-dione (72.0 mg, 0.26 mmol) were added to dimethyl sulfoxide (2 mL), then N,N-diisopropylethylamine (44.0 mg, 0.34 mmol) was added, and the mixture was reacted at 100°C for 1 hour. The mixture was directly separated and purified by liquid-phase separation column (liquid-phase separation conditions: C18 reverse-phase preparation column, mobile phase was deionized water (A) containing 0.1% ammonium bicarbonate, acetonitrile (B), gradient elution, B content = 5% to 50%, elution time 15 min, flow rate 12 mL / min, column temperature: 30°C) to obtain the title compound 22 (38.0 mg, yield 30.1%, retention time about 6.9 min). 1 H NMR(400MHz,DMSO-d6)δ 11.81(s,1H),11.04(s,1H),8.40(s,1H),8.26(d,1H),7.86(d,1H),7.75(s,1H),7.69 - 7.72(m,3H),7.37(d,1H),6.93(d,1H),6.84(d,1H),5.07 - 5.02(m,1H),4.09 - 4.06(m,1H),3.84 - 3.62(m,6H),3.53-3.48(m,1H),3.41 - 3.39(m,1H),3.15 - 3.09(m,2H),2.92 - 2.83(m,1H),2.62 - 2.52(m,12H),2.07 - 1.96(m,1H),1.23 - 1.13(m,3H).
number
[0169] Example 23: 2-(2,6-dioxopiperidin-3-yl)-5-(6-(5-(4-((7-ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl)piperazin-1-yl)pyridine-2-formyl)-2,6-diazaspiro[3.3]heptan-2-yl)isoindoline-1,3-dione (compound 23) [ka]
[0170] Step 1: Compound 1L (0.10 g, 0.25 mmol) and tert-butyl 2,6-diazaspiro[3.3]heptane-2-carboxylate tert-butyl oxalate ester (56.6 mg, 0.27 mmol) were dissolved in N,N-dimethylformamide (3 mL), benzotriazole-N,N,N',N'-tetramethyluronium hexafluorophosphate (82.1 mg, 0.22 mmol), N,N-diisopropylethylamine (86.5 mg, 0.30 mmol) were added, and the mixture was stirred at room temperature for 1 hour to react. After the reaction was completed, water (10 ml) and ethyl acetate (10 mL) were added, the organic phase was separated, the aqueous phase was extracted with ethyl acetate (10 mL x 2), the organic phase was combined, dried over anhydrous sodium sulfate, and concentrated to obtain crude product 23A (130.0 mg, 90.1%), which was directly used in the next step reaction without purification.
number
[0171] Step 2: Compound 23A (130.0 mg, 0.22 mmol) was dissolved in dichloromethane (3 mL), trifluoroacetic acid (1 mL) was added, and the mixture was reacted at room temperature for 30 min. After completion of the reaction, the mixture was directly concentrated to give product 23B, which was a trifluoroacetate salt (126.0 mg, 95%).
number
[0172] Step 3: Compound 23B (126.0 mg, 0.21 mmol) and 2-(2,6-dioxopiperidin-3-yl)-5-fluoroisoindoline-1,3-dione (75.0 mg, 0.27 mmol) were added to dimethyl sulfoxide (2 mL), then N,N-diisopropylethylamine (81.0 mg, 0.63 mmol) was added, and the mixture was reacted at 100 ° C for 1 hour. The mixture was directly separated and purified by liquid-phase separation column (liquid-phase separation conditions: C18 reverse phase preparation column, mobile phase was deionized water (A) containing 0.1% ammonium bicarbonate, acetonitrile (B), gradient elution, B content = 5% to 50%, elution time 15 min, flow rate 12 mL / min, column temperature: 30 ° C), and the title compound 23 (42.0 mg, yield 27.4%, retention time about 6.7 min) was obtained. 1 H NMR(400MHz,DMSO-d6)δ 11.81(s,1H),11.04(s,1H),8.40(s,1H),8.27(d,1H),7.80(d,1H),7.75(s, 1H),7.65(d,1H),7.62(s,1H),7.38(dd,1H),6.79(d,1H),6.67(dd,1H),5.08 - 5.03(m,1H),4.77(s,2H),4.26(s,2H),4.22(s,4H),3.65(s,2H),3.36 - 3.34(m,4H),2.92 - 2.83(m,1H),2.62 - 2.52(m,8H),2.02 - 1.99(m,1H),1.18 - 1.16(m,3H).
number
[0173] Example 24: N-(2-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)-2-azaspiro[3.3]heptan-6-yl)-5-(4-((7-ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl)piperazin-1-yl)pyridine-2-formamide (Compound 24) [ka]
[0174] Step 1: Compound 1L (0.2 g, 0.51 mmol) and 6-amino-2-azaspiro[3.3]heptane-2-carboxylic acid tert-butyl ester (108 mg, 0.51 mmol) were dissolved in DMF (5 mL), and benzotriazole-N,N,N',N'-tetramethyluronium hexafluorophosphate (232 mg, 0.61 mmol), N,N-diisopropylethylamine (99 mg, 0.77 mmol) were added, and the mixture was stirred at room temperature for 1 h to react. After the reaction was completed, water (10 ml) and ethyl acetate (10 mL) were added, the organic phase was separated, and the aqueous phase was extracted with ethyl acetate (10 mL x 2). The organic phases were combined, dried over anhydrous sodium sulfate, and concentrated to obtain crude product 24A (300 mg, 100.0%).
number
[0175] Step 2: Crude compound 24A (300 mg, 0.51 mmol) was dissolved in dichloromethane (6 mL), trifluoroacetic acid (2 mL) was added, and the reaction was carried out at room temperature for 30 min. After completion of the reaction, the mixture was concentrated to give crude product 24B (300 mg, 100.0%).
number
[0176] Step 3: Crude compound 24B (300 mg, 0.51 mmol) and 2-(2,6-dioxopiperidin-3-yl)-5-fluoroisoindoline-1,3-dione (140 mg, 0.51 mmol) were added to dimethyl sulfoxide (3 mL), followed by N,N-diisopropylethylamine (133 mg, 1.02 mmol) and reacted at 100 ° C for 1 h. Direct separation and purification by liquid-phase separation column (liquid-phase separation conditions: C18 reversed-phase preparation column, mobile phase was deionized water (A) containing 0.1% ammonium bicarbonate, acetonitrile (B), gradient elution, B content = 5% to 50%, elution time 15 min, flow rate 12 mL / min, column temperature: 30 ° C) to obtain the title compound 24 (46 mg, yield 12.1%, retention time about 7.5 min). 1 H NMR(400MHz,DMSO-d6)δ 11.83(s,1H),11.04(s,1H),8.63(d,1H),8.41(s,1H),8.28(s,1H),7.83(d,1H),7.75(s,1H),7.70 - 7.59(m,2H),7.40(d,1H),6.77(s,1H),6.64(d,1H),5.11 - 4.98(m,1H),4.45 - 4.35(m,1H),4.12(s,2H),3.99(s,2H),3.66(s,2H),3.39 - 3.32(m,4H),2.97 - 2.80(m,1H),2.63 - 2.53(m,10H),2.48 - 2.42(m,2H),2.10 - 1.96(m,1H),1.21 - 1.16(m,3H).
number
[0177] Example 25: N-((1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperidin-4-yl)methyl)-5-(4-((7-ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl)piperazin-1-yl)pyridine-2-formamide (Compound 25) [ka]
[0178] Step 1: Compound 1L (0.1 g, 0.25 mmol) and 4-(aminomethyl)piperidine-1-carboxylic acid tert-butyl ester (53 mg, 0.25 mmol) were dissolved in DMF (5 mL), and benzotriazole-N,N,N',N'-tetramethyluronium hexafluorophosphate (114 mg, 0.3 mmol), N,N-diisopropylethylamine (65 mg, 0.5 mmol) were added, and the mixture was reacted at room temperature with stirring for 1 h. After the reaction was completed, water (10 ml) and ethyl acetate (10 mL) were added, and the organic phase was separated. The aqueous phase was extracted with ethyl acetate (10 mL x 2). The organic phases were combined, dried over anhydrous sodium sulfate, and concentrated to obtain crude product 25A (150 mg, 100%).
number
[0179] Step 2: Crude compound 25A (150 mg, 0.25 mmol) was dissolved in dichloromethane (3 mL), trifluoroacetic acid (1 mL) was added, and the reaction was carried out at room temperature for 30 min. After completion of the reaction, the mixture was concentrated to give crude product 25B (160 mg, 100%).
number
[0180] Step 3: Crude compound 25B (160 mg, 0.25 mmol) and 2-(2,6-dioxopiperidin-3-yl)-5-fluoroisoindoline-1,3-dione (70 mg, 0.25 mmol) were added to dimethyl sulfoxide (3 mL), followed by N,N-diisopropylethylamine (65 mg, 0.5 mmol) and reacted at 100 °C for 1 h. The mixture was directly separated and purified by liquid-phase separation column (liquid-phase separation conditions: C18 reversed-phase preparation column, mobile phase was deionized water (A) containing 0.1% ammonium bicarbonate, acetonitrile (B), gradient elution, B content = 5% to 50%, elution time 15 min, flow rate 12 mL / min, column temperature: 30 °C) to obtain the title compound 25 (40 mg, yield 21.5%, retention time about 7.2 min). 1 H NMR(400MHz,DMSO-d6)δ 11.83(s,1H),11.05(s,1H),8.48(s,1H),8.41(s,1H),8.28(s,1H),7.84(d,1H),7.75(s,1H),7.71 - 7.56(m,2H),7.40(d,1H),7.30(s,1H),7.22(d,1H),5.12 - 4.97(m,1H),4.04(d,2H),3.66(s,2H),3.40 - 3.32(m,4H),3.31 - 3.30(m,2H),3.23 - 3.16(m,2H),3.00 - 2.81(m,3H),2.63 - 2.52(m,8H),2.06 - 1.97(m,1H),1.94 - 1.80(m,1H),1.80 - 1.67(m,2H),1.20 - 1.16(m,3H).
number
[0181] Example 26: N-(1-(1-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxoisoindolin-5-yl)azacyclobutan-3-yl)piperidin-4-yl)-5-(4-((7-ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl)piperazin-1-yl)pyridine-2-formamide (Compound 26) [ka]
[0182] Step 1: 1N (0.3 g, 0.76 mmol) and 3-aminoazacyclobutane-1-carboxylic acid tert-butyl ester (261 mg, 1.52 mmol) were dissolved in ethanol (5 mL), dichloroethane (5 mL) and glacial acetic acid (6 drops) were added, and the mixture was stirred at 80° C. for 24 h to react, and sodium cyanoborohydride (141 mg, 2.28 mmol) was added and reacted for 1 hour. After concentration, the mixture was purified by C18 column chromatography (acetonitrile: 0.1% trifluoroacetic acid solution (v / v) = 50%) to obtain product 26A (300 mg, 62.1%).
number
[0183] Step 2: Crude compound 26A (150 mg, 0.253 mmol) was dissolved in dichloromethane (3 mL), trifluoroacetic acid (1 mL) was added, and the reaction was carried out at room temperature for 30 min. After completion of the reaction, the mixture was concentrated to give crude product 26B (160 mg, 100.0%).
number
[0184] Step 3: Crude compound 26B (160 mg, 0.23 mol) and 2-(2,6-dioxopiperidin-3-yl)-5-fluoroisoindoline-1,3-dione (70 mg, 0.25 mmol) were added to dimethyl sulfoxide (3 mL), followed by N,N-diisopropylethylamine (65 mg, 0.5 mmol) and reacted at 100 ° C for 1 h. Direct separation and purification by liquid-phase separation column (liquid-phase separation conditions: C18 reversed-phase preparation column, mobile phase was deionized water (A) containing 0.1% ammonium bicarbonate, acetonitrile (B), gradient elution, B content = 5% to 50%, elution time 15 min, flow rate 12 mL / min, column temperature: 30 ° C) to obtain the title compound 26 (40 mg, yield 21.6%, retention time about 6.8 min). 1 H NMR(400MHz,DMSO-d6)δ 11.83(s,1H),11.07(s,1H),8.40(d,1H),8.27(d,1H),8.20(d,1H),7.83(d,1H),7.75(s,1H),7.66 - 7.55(m,2H),7.42 - 7.37(m,1H),6.92(d,1H),5.24 - 4.95(m,1H),4.32 - 4.18(m,2H),4.06 - 3.92(m,2H),3.88 - 3.74(m,1H),3.65(s,2H),3.37 - 3.31(m,4H),2.92 - 2.75(m,3H),2.58 - 2.53(m,6H),2.08 - 1.90(m,3H),1.84 - 1.74(m,2H),1.69 - 1.57(m,2H),1.20 - 1.16(m,3H).
number
[0185] Example 27: N-((1s,4s)-4-((2-(-2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)amino)cyclohexyl)-5-(4-((7-ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl)piperazin-1-yl)pyridine-2-formamide (Compound 27) [ka]
[0186] Step 1: 27A (500 mg, 2.33 mmol), 2-(2,6-dioxopiperidin-3-yl)-5-fluoroisodihydroindole-1,3-dione (640 mg, 2.33 mmol) and N,N-diisopropylethylamine (900 mg, 6.99 mmol) were added to dimethyl sulfoxide (5 ml) and reacted at 100 ° C for 1 h. The reaction solution was cooled to room temperature, water (30 ml) was added, extracted with ethyl acetate (15 ml × 2), the organic phase was washed with saturated sodium chloride solution, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The crude product was separated and purified by silica gel column chromatography (20 g silica gel column, eluent EA / PE = 0 ~ 60%) to obtain the title compound 27B (200 mg, 18%).
number
[0187] Step 2: 27B (200 mg, 0.43 mmol) was added to dichloromethane (9 ml), followed by the addition of trifluoroacetic acid (3 ml) and reacting at room temperature for 2 h. The reaction solution was concentrated under reduced pressure and dried to give crude product 27C (250 mg).
[0188] Step 3: Intermediate 1L (100 mg, 0.25 mmol), 27C (250 mg, 0.43 mmol), 2-(7-azabenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (210 mg, 0.55 mmol) and N,N-diisopropylethylamine (194 mg, 1.5 mmol) were added to N,N-dimethylformamide (3 ml) in sequence and reacted at room temperature for 5 h. The reaction solution was directly sent to HPLC for separation and purification, and after purification, it was concentrated under reduced pressure to remove acetonitrile, extracted with (dichloromethane:methanol=10:1), and the organic phase was concentrated under reduced pressure to obtain the title compound 27 (60 mg, 30%).
[0189] Separation method by preparative HPLC: 1. Equipment: waters 2767 preparative liquid, chromatography column: SunFire@ Prep C18 (19mm x 250mm) 2. The sample was dissolved in DMF and filtered through a 0.45μm filter to prepare the sample solution. 3. Preparative chromatography conditions: a. Composition of mobile phases A and B: Mobile phase A: acetonitrile, Mobile phase B: water (containing 0.1% ammonium acetate), b. Gradient elution, the content of mobile phase A is 5%-40%, c. Flow rate is 12mL / min, d. Elution time is 20min. 1 H NMR(400MHz,DMSO-d6)δ 11.84(s,1H),11.04(s,1H),8.41(d,1H),8.28(d,1H),8.01(d,1H),7.85(d, 1H),7.75(s,1H),7.63(s,1H),7.57(d,1H),7.41(dd,1H),7.03(s,1H),6.98 - 6.89(m,2H),5.03(dd,1H),3.96(s,1H),3.72-3.64(m,3H),3.37-3.33(m,4H),2.93 - 2.81(m,1H),2.63 - 2.51(m,8H),2.05 - 1.95(m,1H),1.80-1.70(m,6H),1.68 - 1.57(m,2H),1.18(t,3H).
number
[0190] Example 28: N-(7-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)-7-azaspiro[3.5]non-2-yl)-5-(4-((7-ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl)piperazin-1-yl)pyridine-2-formamide (Compound 28) [ka]
[0191] Step 1: Compound 1L (100 mg, 0.25 mmol) and 2-amino-7-azaspiro[3.5]nonane-7-carboxylic acid tert-butyl ester (73.2 mg, 0.3 mmol) were dissolved in DMF (5 mL), and benzotriazole-N,N,N',N'-tetramethyluronium hexafluorophosphate (114 mg, 0.3 mmol), N,N-diisopropylethylamine (64.5 mg, 0.5 mmol) were added, and the mixture was stirred at room temperature for 1 h to react. After the reaction was completed, water (10 ml) and ethyl acetate (10 mL) were added, the organic phase was separated, and the aqueous phase was extracted with ethyl acetate (10 mL x 2). The organic phases were combined, dried over anhydrous sodium sulfate, and concentrated to obtain crude product 28A (156 mg, 100.0%).
number
[0192] Step 2: Compound 28A (156 mg, 0.25 mmol) was dissolved in dichloromethane (6 mL), trifluoroacetic acid (2 mL) was added, and the mixture was reacted at room temperature for 30 min. After the reaction was completed, the mixture was concentrated, adjusted to pH>7 with triethylamine, and purified by C18 column chromatography (acetonitrile:0.1% aqueous ammonia solution (v / v)=50%) to obtain product 28B (100 mg, 77.2%).
number
[0193] Step 3: Compound 28B (100 mg, 0.19 mmol) and 2-(2,6-dioxopiperidin-3-yl)-5-fluoroisoindoline-1,3-dione (63 mg, 0.22 mmol) were added to dimethyl sulfoxide (2 mL), followed by N,N-diisopropylethylamine (49 mg, 0.38 mmol) and reacted at 100 ° C for 1 h. The mixture was directly separated and purified by liquid-phase separation column (liquid-phase separation conditions: C18 reverse phase preparation column, mobile phase was deionized water (A) containing 0.1% ammonium bicarbonate, acetonitrile (B), gradient elution, B content = 5% to 50%, elution time 15 min, flow rate 12 mL / min, column temperature: 30 ° C), to obtain the title compound 28 (60 mg, yield 41.0%, retention time about 7.1 min). 1 H NMR(400MHz,DMSO-d6)δ 11.83(s,1H),11.06(s,1H),8.59-8.57(d,1H),8.41(s,1H),8.26(s,1H),7.84-7.82(d,1H),7.75(s,1H),7.65 - 7.63(m,2H),7.41-7.38(d,1H),7.32(s,1H),7.26-7.23(d,1H),5.08 - 5.04(m,1H),4.52 - 4.42(m,1H),3.66(s,2H),3.48-3.47(m,2H),3.39 - 3.31(m,6H),2.93 - 2.84(m,1H),2.60 - 2.54(m,8H),2.23 - 2.21(t,2H),2.03 - 1.94(m,3H),1.69 - 1.64(m,4H),1.20 - 1.17(t,3H).
number
[0194] Example 29 3-((1-((1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperidin-4-yl)methyl)azacyclobutan-3-yl)amino)-5-(4-((7-ethyl-6-oxy-5,6-dihydro-1,5-naphthyridin-3-yl)methyl)piperazin-1-yl)-N-methylpyridine-2-formamide (Compound 29) [ka]
[0195] Step 1: 29A (9 g, 56.57 mmol) was added to ethanol (100 mL) and stirred, sulfuric acid (25 mL) was added, and the mixture was reacted at 70° C. for 2 hours. The system was then concentrated, diluted with ethyl acetate (200 mL), washed with saturated saline, and the organic phase was concentrated and then dried to obtain the title compound 29B (10 g, 94.5%).
number
[0196] Step 2: 29B (10 g, 53.43 mmol) and 1-tert-butoxycarbonyl-3-aminoazetidine (11 g, 64.12 mmol) were dissolved in DMF / DMSO (50 mL / 50 mL), potassium carbonate (2.2 g, 160.3 mmol) was added, and the mixture was reacted at 100° C. for 24 hours. Then, water (300 mL) was added to dilute the mixture, and the mixture was extracted with ethyl acetate (50 mL×3). The organic phases were combined and washed with saturated saline, dried over anhydrous sodium sulfate, and the organic phase was concentrated and separated by silica gel chromatography (PE:EA=1:0-1:1) to obtain the title compound 29C (4.6 g, 25.4%).
number
[0197] Step 3: 29C (4.6 g, 13.55 mmol), piperazine-1-carboxylic acid benzyl ester (3.6 g, 16.27 mmol) was dissolved in DMSO (50 mL), sodium carbonate (4.3 g, 40.66 mmol) was added, and the mixture was reacted at 100° C. overnight. Then, water (200 mL) was added to quench the reaction, and the mixture was extracted with ethyl acetate (50 mL×3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, spin-dried, and separated by silica gel chromatography column (PE:EA=1:0-1:1) to obtain the title compound 29D (4 g, 54.7%).
number
[0198] Step 4: 29D (2 g, 3.7 mmol) was dissolved in methanol (10 mL), and a solution of methylamine in water (10 mL, 40%) was added, and the mixture was reacted at room temperature for 4 hours. The suspension was concentrated, and a saturated ammonium chloride solution was added, and the mixture was extracted with dichloromethane. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and then spun to dryness to obtain the title compound 29E (1.6 mg, 82.3%).
number
[0199] Step 5: 29E (500 mg, 0.95 mmol) was dissolved in methanol (5 mL), Pd / C (200 mg) was added, and the mixture was reacted for 2 hours under a hydrogen gas environment. The mixture was filtered and then spin-dried to obtain the title compound 29F (300 mg, 80.6%).
number
[0200] Step 6: 1G (142 mg, 0.64 mmol) and 29F (300 mg, 0.77 mmol) were dissolved in anhydrous acetonitrile (10 mL), potassium iodide (11 mg, 0.06 mmol) and DIPEA (411 mg, 3.18 mmol) were added, and after nitrogen gas replacement, the mixture was reacted at 80 ° C. for 2 hours. Completion of the raw material reaction was detected by LCMS, the system was concentrated, a saturated solution of sodium bicarbonate (20 mL) was added, and the mixture was extracted with DCM (10 mL × 3). The organic phases were combined, dried over anhydrous sodium sulfate, concentrated, and then passed through a column (DCM: MeOH = 1: 0 to 10: 1) to obtain the title compound 29G (180 mg, 50.1%).
number
[0201] Step 7: 29G (180 mg, 0.31 mmol) was added to dichloromethane (3 mL), trifluoroacetic acid (1 mL) was added dropwise, and the mixture was stirred at room temperature for 2 hours. After spin drying, the mixture was purified by reverse phase chromatography column (water (5‰NH3·H2O):acetonitrile) to give the title compound 29H (140 mg, 95%).
number
[0202] Step 8: 29H (20mg, 0.04mmol) and 3C (24mg, 0.06mmol) were added to methanol, 1 drop of acetic acid was added, refluxed overnight, and sodium cyanoborohydride (34mg, 0.21mmol) was added. When the reaction was completed, it was concentrated and sent to HPLC for fractionation. Preparative HPLC separation method: 1. Equipment: waters 2767 preparative liquid, chromatography column: SunFire@ Prep C18 (19mm x 250mm) 2. The sample was filtered through a 0.45μm filter to prepare the sample liquid. 3. Preparative chromatography conditions: a. Composition of mobile phase A and B: mobile phase A: acetonitrile, mobile phase B: water (containing 0.5% ammonia water), b. Gradient elution, the content of mobile phase A is 5%-50%, c. Flow rate is 12mL / min, d elution time is 20min. The fraction was concentrated and lyophilized to give compound 29 (12 mg, 34.7%). 1 H NMR(400MHz,DMSO-d6)δ 12.09(s,1H),9.94(s,1H),8.93(dd,1H),8.51(s,1H),8.42 - 8.32(m,1H),7.85 - 7.63(m,4H),7.38 - 7.31(m,1H),7.14 - 6.95(m,1H),6.35 - 6.18(m,1H),5.13 - 5.00(m,1H),4.71 - 4.34(m,4H),4.19 - 3.98(m,5H),3.33 - 3.09(m,6H),3.04 - 2.82(m,5H),2.76(t,3H),2.65 - 2.51(m,6H),2.09 - 1.83(m,2H),1.82 - 1.67(m,2H),1.35 - 1.14(m,5H).
number
[0203] Example 30 3-((1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)nitrid-3-yl)amino)-5-(4-((7-ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl)piperazin-1-yl)-N-methylpyridine-2-formamide (compound 30) [ka]
[0204] Step 1: 29H (100mg, 0.21mmol), 2-(2,6-dioxopiperidin-3-yl)-5-fluoroisoindoline-1,3-dione (58mg, 0.21mmol) was dissolved in dimethylsulfoxide (3mL), DIPEA (81mg, 0.63mmol) was added, and the mixture was reacted at 100℃ for 2 hours, and then the mixture was directly sent to HPLC for fractionation. Preparative HPLC separation method: 1. Equipment: Waters 2767 Preparative Liquid, Chromatography Column: SunFire@Prep C18 (19mm×250mm) 2. The sample was filtered through a 0.45μm filter to prepare the sample liquid. 3. Conditions for preparative chromatography: a. Composition of mobile phases A and B: Mobile phase A: acetonitrile, Mobile phase B: water (containing 0.5% aqueous ammonia); b. Gradient elution, content of mobile phase A: 5%-50%; c. Flow rate: 12 mL / min; d Elution time: 20 min. The fraction was concentrated and freeze-dried to obtain compound 30 (30 mg, 19.5%). 1H NMR(400MHz,DMSO-d6)δ 11.83(s,1H),11.04(s,1H),8.88(d,1H),8.41(d,1H),8.34 - 8.27(m,1H),7.75(s,1H),7.70 - 7.60(m,3H),6.86(d,1H),6.72(dd,1H),6.30(d,1H),5.06(dd,1H),4.64 - 4.53(m,1H),4.53 - 4.45(m,2H),3.89 - 3.77(m,2H),3.66(s,2H),3.37 - 3.32(m,4H),2.94 - 2.81(m,1H),2.73(d,3H),2.62 - 2.52(m,8H),2.07 - 1.97(m,1H),1.19(t,3H).
number
[0205] Example 31 N-(1-(2-(2,6-dioxopiperidin-3-yl)-1-oxyisoindolin-5-yl)piperidin-4-yl)-5-(4-((7-ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl)piperazin-1-yl)pyridine-2-formamide (Compound 31) [ka]
[0206] Step 1: 31A (2.8 g, 18.4 mmol), azetin-3-yl carbamate tert-butyl ester (3.8 g, 22.1 mmol) was dissolved in dimethyl sulfoxide (40 mL), DIPEA (7.1 g, 55.2 mmol) was added, and the mixture was reacted at 100° C. for 2 hours. After the reaction was completed, the mixture was cooled and water (40 mL) was added to precipitate the product, which was filtered, washed with water to remove dimethyl sulfoxide, and dried to obtain the title compound 31B (6.6 g, crude, containing DMSO).
number
[0207] Step 2: 31B (6.6 g, containing DMSO) was added to methanol (50 mL), and sodium hydroxide solution (2.2 g was dissolved in 50 mL of water) was added, and the reaction was carried out at 50° C. for 2 hours. The completion of the reaction was detected by LCMS, and the methanol was concentrated, the pH was adjusted to 5 with 1 M hydrochloric acid solution, and the product was filtered and dried to obtain the title compound 31C (5.3 g, two-step yield 82.2%).
number
[0208] Step 3: 31C (5.3 g, 15.1 mmol) was added to dichloromethane (100 mL), and then tert-butyldimethylchlorosilane (4.6 g, 30.2 mmol) and imidazole (4.2 g, 61.0 mmol) were added, and the mixture was reacted at room temperature for 16 hours. Water (200 mL) was added, and the mixture was extracted with dichloromethane (50 mL x 3). The organic phases were combined, dried over anhydrous sodium sulfate, concentrated, and then separated by silica gel chromatography column (PE~PE:EA=3:1) to obtain the title compound 31D (7 g, 80.0%).
number
[0209] Step 4: 31D (7 g, 12.1 mmol) was dissolved in ethanol (70 mL), potassium carbonate (5.0 g, 36.3 mmol) was added, and the mixture was reacted at room temperature overnight. After the reaction was completed, the mixture was filtered to remove the solid, and the filtrate was spin-dried to give the title compound 31E (5.6 g, 99.7%).
number
[0210] Step 5: 31E (2g, 4.3mmol), 3-aminopiperidine-2,6-dione hydrochloride (848mg, 5.16mmol), HATU (2.7g, 8.6mmol) and triethylamine (1.3g, 13.0mmol) were added to dichloromethane (20mL) and stirred at room temperature overnight, then diluted with water (100mL) and extracted with dichloromethane (20mL x 3), the organic phases were combined, dried over anhydrous sodium sulfate, concentrated and then separated by silica gel chromatography column (EA:PE=0-100%) to obtain the title compound 31F (1.48g, 59.8%).
number
[0211] Step 6: 31F (1.48 g, 2.57 mmol) was dissolved in dichloromethane (20 mL), tetrabutylammonium fluoride (2.57 mL, 1 mol / L tetrahydrofuran solution) was added, stirred at room temperature for 2 hours, diluted with water (50 mL), and extracted with dichloromethane (15 mL×3), the organic phases were combined, dried over anhydrous sodium sulfate, and spin-dried to give the title compound 31G (680 mg, 57.3%).
number
[0212] Step 7: 31G (680 mg, 1.48 mmol), p-toluenesulfonyl chloride (422 mg, 2.21 mmol), and triethylamine (1.2 g, 11.8 mmol) were added to dichloromethane (10 mL), stirred at 40° C. for 16 h, and then diluted with water (50 mL), extracted with dichloromethane (15 mL×3), and the organic phase was dried over anhydrous sodium sulfate, concentrated, and then separated by silica gel chromatography column to obtain the title compound 31H (400 mg, 61.2%).
number
[0213] Step 8: 31H (200 mg, 0.45 mmol) was added to dichloromethane (6 mL), trifluoroacetic acid (2 mL) was added dropwise, stirred at room temperature for 2 h, and directly spun to dryness to give the title compound 31I (200 mg, containing TFA).
number
[0214] Step 9: 31I (200 mg, 0.45 mmol), 1L (180 mg, 0.45 mmol), HATU (345 mg, 0.9 mmol) and triethylamine (230 mg, 2.27 mmol) were added to dichloromethane (5 mL), stirred at room temperature overnight, filtered, the filter cake was washed with dichloromethane, the organic phase was concentrated and separated and purified by C18 reverse phase column (5‰ aqueous ammonia:acetonitrile) to give compound 31 (40 mg, 12.2%). 1 H NMR(400MHz,DMSO-d6)δ 8.40(d,1H),8.30 - 8.23(m,2H),7.85(d,1H),7.75(s,1H),7.62(d,1H),7.51(d,1H),7.40(dd,1H),7.07(dd,1H),7.03 - 6.99(m,1H),5.30(s,2H),4.56(dd,1H),4.08 - 3.95(m,1H),3.92 - 3.81(m,2H),3.65(s,2H),3.37 - 3.32(m,5H),2.97(t,2H),2.69 - 2.53(m,8H),2.09 - 1.91(m,2H),1.90 - 1.81(m,2H),1.78 - 1.64(m,2H),1.18(t,3H).
number
[0215] Example 32: N-((1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)azacyclobutan-3-yl)methyl)-5-(4-((7-ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl)piperazin-1-yl)pyridine-2-formamide (compound 32) [ka]
[0216] Step 1: 1L (150 mg, 0.37 mmol), 3-(aminomethyl)azacyclobutane-1-carboxylic acid tert-butyl ester (70 mg, 0.37 mmol), HATU (182 mg, 0.48 mmol), DIPEA (140 mg, 1.11 mmol), and DMF (3 mL) were added to the reaction flask and stirred at 25 °C for 5 h. After the reaction was completed, water (10 mL) was added, and the reaction solution was extracted three times with ethyl acetate (30 mL x 3), washed with saturated sodium chloride solution, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to give crude product 32A (202 mg, 48%).
number
[0217] Step 2: Compound 32A (202 mg, 0.36 mmol) was dissolved in dichloromethane (6 mL), trifluoroacetic acid (2 mL) was added, and the reaction was carried out at room temperature for 30 min. After the reaction was completed, the mixture was concentrated and concentrated under reduced pressure to obtain crude product 32B (150 mg, 90%).
number
[0218] Step 3: Compound 32B (143 mg, 0.31 mmol), 2-(2,6-dioxopiperidin-3-yl)-5-fluoroisoindoline-1,3-dione (86 mg, 0.31 mmol), DIPEA (120 mg, 0.93 mmol), and dimethyl sulfoxide (3 mL) were added to a reaction flask and stirred at 100 °C for 3 h. The reaction was monitored by LCMS, and the reaction system was directly separated after completion of the reaction, and the separation was performed by preparative HPLC separation method: 1. Equipment: waters 2767 preparative liquid, chromatography column: SunFire@ Prep C18 (19 mm x 250 mm). 2. The sample was filtered through a 0.45 μm filter to prepare the sample solution. 3. Conditions for preparative chromatography: a. Composition of mobile phase A and B: Mobile phase A: acetonitrile, Mobile phase B: water (containing 0.1% ammonium acetate), b. Gradient elution, content of mobile phase A is 10%-55%, c. Flow rate is 12 mL / min. Retention time is 7.0 min, and title compound 32 (40 mg, 20%) was obtained.
number
[0219] Example 33: N-((1s,3s)-3-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)cyclobutyl)-5-(4-((7-ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl)piperazin-1-yl)pyridine-2-formamide (compound 33) [ka]
[0220] Step 1: 1L (200 mg, 0.51 mmol), tert-butyl ((1s,3s)-3-aminocyclobutyl)carbamate (94.99 mg, 0.51 mmol), HATU (252 mg, 0.66 mmol), DIPEA (198 mg, 1.53 mmol), and DMF (4 mL) were added to the reaction flask and stirred at 25 °C for 5 h. After completion of the reaction, water (12 mL) was added, and the reaction solution was extracted three times with ethyl acetate (30 mL x 3), washed with saturated sodium chloride solution, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to give crude 33A (153 mg, 53%).
number
[0221] Step 2: Compound 33A (153 mg, 0.27 mmol) was dissolved in dichloromethane (6 mL), trifluoroacetic acid (2 mL) was added, and the mixture was reacted at room temperature for 30 min. After the reaction was completed, the mixture was concentrated and concentrated under reduced pressure to obtain crude product 33B (120 mg, 100%).
number
[0222] Step 3: Compound 33B (120 mg, 0.26 mmol), 2-(2,6-dioxopiperidin-3-yl)-4-fluoroisoindoline-1,3-dione (86 mg, 0.31 mmol), DIPEA (120 mg, 0.93 mmol), and dimethyl sulfoxide (3 mL) were added to a reaction flask and stirred at 100 °C for 3 h. The reaction was monitored by LCMS, and the reaction system was directly separated after completion of the reaction, and the separation was performed by preparative HPLC separation method: 1. Equipment: waters 2767 preparative liquid, chromatography column: SunFire@ Prep C18 (19 mm x 250 mm). 2. The sample was filtered through a 0.45 μm filter to prepare the sample solution. 3. Conditions for preparative chromatography: a. Composition of mobile phase A and B: Mobile phase A: acetonitrile, Mobile phase B: water (containing 0.1% ammonium acetate), b. Gradient elution, content of mobile phase A is 10%-55%, c. Flow rate is 12 mL / min. Retention time is 7.0 min, and the title compound 33 (12 mg, 6%) was obtained.
number
[0223] Example 34: N-((1r,4r)-4-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)amino)cyclohexyl)-5-(4-((7-ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl)piperazin-1-yl)pyridine-2-formamide (compound 34) [ka]
[0224] Step 1: 34A (517 mg, 2.41 mmol) was dissolved in dimethyl sulfoxide (10 ml), 2-(2,6-dioxopiperidin-3-yl)-5-fluoroisodihydroindole-1,3-dione (1 g, 3.62 mmol) was added, and the reaction system was placed in a 100 ° C oil bath pot and reacted for 1 h. After the reaction was completed, ethyl acetate (50 ml) was added to dilute the reaction system, and the organic phase was washed with water (10 ml). The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was quickly separated and purified by column chromatography (eluent ratio: MeOH:DCM = 0% ~ 10%) to obtain compound 34B (0.4 g, 35%).
number
[0225] Step 2: Compound 34B (0.4 g, 0.85 mmol) was placed in a reaction flask, dichloromethane (3 ml) / trifluoroacetic acid (1 ml) was added, and the mixture was reacted at room temperature for 2 h. After completion of the reaction, the mixture was directly concentrated to give crude compound 34C (0.3 g).
number
[0226] Step 3: Intermediate 1L (100mg, 0.25mmol) was dissolved in N,N-dimethylformamide (2ml), and compound 34C (141mg, 0.38mmol), 2-(7-azabenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (190mg, 0.5mmol) and N,N-diisopropylethylamine (130mg, 1mmol) were added to the reaction system, and the reaction was allowed to proceed overnight at room temperature. The reaction was monitored by LCMS, and the reaction system was directly separated after the reaction was completed. Separation HPLC separation method: 1. Equipment: waters 2767 separation liquid, chromatography column: SunFire@ Prep C18 (19mm x 250mm). 2. The sample was filtered through a 0.45μm filter to prepare the sample solution. 3. Conditions for preparative chromatography: a. Composition of mobile phase A and B: Mobile phase A: acetonitrile, Mobile phase B: water (containing 0.1% ammonium acetate), b. Gradient elution, the content of mobile phase A is 10% to 55%, c. Flow rate is 12 mL / min. Retention time is 7.0 min, and compound 34 (60 mg, 32%) is obtained.
number
[0227] Example 35: 2-(2,6-dioxopiperidin-3-yl)-5-(((1-(5-(4-((7-ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3)-yl)methyl)piperazin-1-yl)pyridine-2-formyl)piperidin-4-yl)methyl)amino)isodihydroindole-1,3-dione (compound 35) [ka]
[0228] Step 1: 35A (517 mg, 2.41 mmol) was dissolved in dimethyl sulfoxide (10 ml), 2-(2,6-dioxopiperidin-3-yl)-5-fluoroisodihydroindole-1,3-dione (1 g, 3.62 mmol) was added, and the reaction system was placed in a 100 ° C oil bath pot and reacted for 1 h. After the reaction was completed, ethyl acetate (50 ml) was added to dilute the reaction system, and the organic phase was washed with water (10 ml). The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was quickly separated and purified by column chromatography (eluent ratio: MeOH:DCM = 0% ~ 10%) to obtain compound 35B (0.25 g, 22%).
number
[0229] Step 2: Compound 35B (0.25 g, 0.53 mmol) was placed in a reaction flask, dichloromethane (3 ml) / trifluoroacetic acid (1 ml) was added, and the mixture was reacted at room temperature for 2 h. After completion of the reaction, the mixture was directly concentrated to give crude compound 35C (0.2 g).
number
[0230] Step 3: Intermediate 1L (100mg, 0.25mmol) was dissolved in N,N-dimethylformamide (2ml), and compound 35C (141mg, 0.38mmol), 2-(7-azabenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (190mg, 0.5mmol) and N,N-diisopropylethylamine (130mg, 1mmol) were added to the reaction system, and the reaction was allowed to proceed overnight at room temperature. The reaction was monitored by LCMS, and the reaction system was directly separated after the reaction was completed. Separation HPLC separation method: 1. Equipment: waters 2767 separation liquid, chromatography column: SunFire@ Prep C18 (19mm x 250mm). 2. The sample was filtered through a 0.45μm filter to prepare the sample solution. 3. Conditions for preparative chromatography: a. Composition of mobile phase A and B: Mobile phase A: acetonitrile, Mobile phase B: water (containing 0.1% ammonium acetate); b. Gradient elution, the content of mobile phase A is 10%-55%; c. Flow rate is 12 mL / min; d. Elution time is 20 min; Retention time is 7.0 min, and compound 35 (50 mg, 27%) was obtained.
number
[0231] Example 36: 2-(2,6-dioxopiperidin-3-yl)-5-(((1-(5-(4-((7-ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3)-yl)methyl)piperazin-1-yl)pyridine-2-formyl)azacyclobutan-3-yl)methyl)amino)isodihydroindole-1,3-dione (compound 36) [ka]
[0232] Step 1: 36A (517 mg, 2.41 mmol) was dissolved in dimethyl sulfoxide (10 ml), 2-(2,6-dioxopiperidin-3-yl)-5-fluoroisodihydroindole-1,3-dione (1 g, 3.62 mmol) was added, and the reaction system was placed in a 100 ° C oil bath pot and reacted for 1 h. After the reaction was completed, ethyl acetate (50 ml) was added to dilute the reaction system, and the organic phase was washed with water (10 ml). The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was quickly separated and purified by column chromatography (eluent ratio: MeOH:DCM = 0% ~ 10%) to obtain compound 36B (0.3 g, 26%).
number
[0233] Step 2: Compound 36B (0.25 g, 0.53 mmol) was placed in a 50 mL reaction flask, dichloromethane (3 ml) / trifluoroacetic acid (1 ml) was added, and the mixture was reacted at room temperature for 2 h. After completion of the reaction, the mixture was directly concentrated to give crude compound 36C (0.25 g).
number
[0234] Step 3: Intermediate 1L (100mg, 0.25mmol) was dissolved in N,N-dimethylformamide (2ml), and compound 36C (147mg, 0.38mmol), 2-(7-azabenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (190mg, 0.5mmol) and N,N-diisopropylethylamine (130mg, 1mmol) were added to the reaction system, and the reaction was allowed to proceed overnight at room temperature. The reaction was monitored by LCMS, and the reaction system was directly separated after the reaction was completed. Separation HPLC separation method: 1. Equipment: waters 2767 separation liquid, chromatography column: SunFire@ Prep C18 (19mm x 250mm). 2. The sample was filtered through a 0.45μm filter to prepare the sample solution. 3. Conditions for preparative chromatography: a. Composition of mobile phase A and B: Mobile phase A: acetonitrile, Mobile phase B: water (containing 0.1% ammonium acetate), b. Gradient elution, the content of mobile phase A is 10% to 55%, c. Flow rate is 12 mL / min, d elution time is 20 min. Retention time is 7.0 min, and compound 36 (78 mg, 42%) is obtained.
number
[0235] Example 37: N-((1s,3s)-3-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)amino)cyclobutyl)-5-(4-((7-ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl)piperazin-1-yl)pyridine-2-formamide (compound 37) [ka]
[0236] Step 1: tert-Butyl-cis-3-amino-1-cyclobutylcarbamate (500 mg, 2.68 mmol), 1O (1.11 g, 4.03 mmol), and N,N-diisopropylethylamine (1.04 g, 8.05 mmol) were placed together in a reaction flask, and dimethyl sulfoxide (15 mL) was added, followed by 100 o The mixture was heated to C and reacted for about 4 hours. After monitoring the completion of the reaction by TLC, the temperature was lowered to room temperature, saturated saline (80 mL) was added, the aqueous phase was extracted with ethyl acetate (20 mL x 6), the organic phase was dried over anhydrous sodium sulfate, filtered and concentrated, and the resulting residue was separated and purified by silica gel column chromatography (dichloromethane:methanol (v / v) = 100:5) to give 37A (300 mg, 25.3%) as a yellow solid.
number
[0237] Step 2: Compound 37A (150 mg, 0.339 mmol) was dissolved in dichloromethane (6 mL), trifluoroacetic acid (2 mL) was added at room temperature, and the reaction was continued at room temperature for 30 minutes after completion. After monitoring the completion of the reaction by TLC, it was directly concentrated under reduced pressure, dichloromethane (10 mL x 4) was added, and the mixture was sucked dry again to remove excess trifluoroacetic acid. The resulting foamy yellow solid 37B was used in the next step reaction without purification.
number
[0238] Step 3: Compound 1L (60 mg, 0.152 mmol), 37B (68 mg, 0.198 mmol), N,N-diisopropylethylamine (98.5 mg, 0.764 mmol), 2-(7-azabenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (116 mg, 0.305 mmol) were all placed in a reaction flask, and after adding dry N,N-dimethylformamide (5 mL), the mixture was reacted at room temperature for about 4 hours. After monitoring the completion of the reaction by TLC, it was directly purified by preparative liquid phase. The crude product was separated and purified by preparative HPLC, Method: 1. Equipment: waters 2767 preparative liquid, Chromatography column: SunFire@ Prep C18 (19 mm x 250 mm) 2. The sample was filtered through a 0.45 μm filter to prepare the sample solution. 3. Conditions for preparative chromatography: a. Composition of mobile phase A and B: Mobile phase A: acetonitrile, Mobile phase B: water (containing 0.5% ammonium acetate), b. Gradient elution, the content of mobile phase A is 5%-50%, c. Flow rate is 12 mL / min, d. Elution time is 10 min. Compound 37 (38 mg, 34.7%) was obtained.
number
[0239] Example 38: N-((1r,3r)-3-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)amino)cyclobutyl)-5-(4-((7-ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl)piperazin-1-yl)pyridine-2-formamide (compound 38) [ka]
[0240] Step 1: tert-Butyl-trans-3-amino-1-cyclobutylcarbamate (500 mg, 2.68 mmol), 1O (1.11 g, 4.03 mmol), and N,N-diisopropylethylamine (1.04 g, 8.05 mmol) were placed together in a reaction flask, and dimethyl sulfoxide (15 mL) was added, followed by 100 o The mixture was heated to C and reacted for about 4 hours. After monitoring the completion of the reaction by TLC, the temperature was lowered to room temperature, saturated saline (80 mL) was added, the aqueous phase was extracted with ethyl acetate (20 mL x 6), the organic phase was dried over anhydrous sodium sulfate, filtered and concentrated, and the resulting residue was separated and purified by silica gel column chromatography (dichloromethane:methanol (v / v) = 100:5) to give 38A (260 mg, 21.9%) as a yellow solid.
number
[0241] Step 2: Compound 38A (150 mg, 0.339 mmol) was dissolved in dichloromethane (6 mL), trifluoroacetic acid (2 mL) was added at room temperature, and the reaction was continued at room temperature for 30 min after completion. After monitoring the completion of the reaction by TLC, it was directly concentrated under reduced pressure, dichloromethane (10 mL x 4) was added, and sucked dry again to remove excess trifluoroacetic acid. The resulting foamy yellow solid 38B was used in the next step reaction without purification.
number
[0242] Step 3: Compound 1L (50 mg, 0.127 mmol), 38B (56.5 mg, 0.165 mmol), N,N-diisopropylethylamine (82.0 mg, 0.635 mmol), 2-(7-azabenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (96.6 mg, 0.254 mmol) were all placed in a reaction flask, and after adding dry N,N-dimethylformamide (5 mL), the mixture was reacted at room temperature for about 4 hours. After monitoring the completion of the reaction by TLC, it was directly purified by preparative liquid phase. The crude product was separated and purified by preparative HPLC, Method: 1. Equipment: waters 2767 preparative liquid, Chromatography column: SunFire@ Prep C18 (19 mm x 250 mm) 2. The sample was filtered through a 0.45 μm filter to prepare the sample solution. 3. Conditions for preparative chromatography: a. Composition of mobile phase A and B: Mobile phase A: acetonitrile, Mobile phase B: water (containing 0.5% ammonium acetate), b. Gradient elution, the content of mobile phase A is 5%-50%, c. Flow rate is 12 mL / min, d. Elution time is 10 min. Compound 38 (35 mg, 38.4%) was obtained.
number
[0243] Example 39: N-((1r,3r)-3-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)cyclobutyl)-5-(4-((7-ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl)piperazin-1-yl)pyridine-2-formamide (compound 39) [ka]
[0244] Step 1: 1L (150 mg, 0.38 mmol), tert-butyl ((1r,3r)-3-aminocyclobutyl)carbamate (71 mg, 0.38 mmol), HATU (187 mg, 0.49 mmol), DIPEA (150 mg, 1.16 mmol), and DMF (3 mL) were added to the reaction flask and stirred at 25 °C for 5 h. After completion of the reaction, water (12 mL) was added, and the reaction solution was extracted three times with ethyl acetate (30 ml x 3), washed with saturated sodium chloride solution, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to give crude 39A (150 mg, 70%).
number
[0245] Step 2: Compound 39A (150 mg, 0.27 mmol) was dissolved in dichloromethane (6 mL), trifluoroacetic acid (2 mL) was added, and the mixture was reacted at room temperature for 30 min. After the reaction was completed, the mixture was concentrated and concentrated under reduced pressure to obtain crude product 39B (98 mg, 79%).
number
[0246] Step 3: Compound 39B (98 mg, 0.21 mmol), 2-(2,6-dioxopiperidin-3-yl)-4-fluoroisoindoline-1,3-dione (58.43 mg, 0.21 mmol), DIPEA (81 mg, 0.63 mmol), and dimethyl sulfoxide (3 mL) were added to a reaction flask and stirred at 100 °C for 3 h. The reaction was monitored by LCMS, and the reaction system was directly separated after completion of the reaction, and the separation was performed by preparative HPLC separation method: 1. Equipment: waters 2767 separation liquid, chromatography column: SunFire@ Prep C18 (19 mm x 250 mm). 2. The sample was filtered through a 0.45 μm filter to prepare the sample solution. 3. Preparative chromatography conditions: a. Composition of mobile phases A and B: Mobile phase A: acetonitrile, mobile phase B: water (containing 0.1% ammonium acetate). b. Gradient elution, the content of mobile phase A is 10%-55%. c. Flow rate is 12 mL / min. Retention time is 7.0 min, and the title compound 39 (6 mg, 4%) was obtained.
number
[0247] Example 40: N-(2-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)-2-azaspiro[3.5]non-7-yl)-5-(4-((7-ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl)piperazin-1-yl)pyridine-2-formamide (compound 40) [ka]
[0248] Step 1: 1L (200 mg, 0.51 mmol), 2-BOC-7-amino-2-aza[3.5]nonane (120 mg, 0.51 mmol), HATU (250 mg, 0.66 mmol), DIPEA (200 mg, 1.53 mmol), and DMF (4 mL) were added to the reaction flask and stirred at 25 °C for 5 h. After the reaction was completed, water (12 mL) was added, and the reaction solution was extracted three times with ethyl acetate (30 ml x 3), washed with saturated sodium chloride solution, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain crude product 40A (300 mg, 95%).
number
[0249] Step 2: Compound 40A (155 mg, 0.25 mmol) was dissolved in dichloromethane (6 mL), trifluoroacetic acid (2 mL) was added, and the reaction was carried out at room temperature for 30 min. After the reaction was completed, the mixture was concentrated and concentrated under reduced pressure to obtain crude product 40B (110 mg, 85%).
number
[0250] Step 3: Compound 40B (170 mg, 0.33 mmol), 2-(2,6-dioxopiperidin-3-yl)-5-fluoroisoindoline-1,3-dione (100 mg, 0.36 mmol), DIPEA (120 mg, 0.93 mmol), and DMF (3 mL) were added to a reaction flask and stirred at 100 °C for 3 h. The reaction was monitored by LCMS, and the reaction system was directly separated after completion of the reaction, and the separation was performed by preparative HPLC separation method: 1. Equipment: waters 2767 preparative liquid, chromatography column: SunFire@ Prep C18 (19 mm x 250 mm). 2. The sample was filtered through a 0.45 μm filter to prepare the sample solution. 3. Conditions for preparative chromatography: a. Composition of mobile phase A and B: Mobile phase A: acetonitrile, Mobile phase B: water (containing 0.1% ammonium acetate) b. Gradient elution, the content of mobile phase A is 10% to 55% c. Flow rate is 12 mL / min. Retention time is 7.0 min, and the title compound 40 (20 mg, 8%) was obtained.
number
[0251] Example 41: N-((1s,3s)-3-((2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxoisoindolin-5-yl)amino)cyclobutyl)-5-(4-((7-ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl)piperazin-1-yl)pyridine-2-formamide (compound 41) [ka]
[0252] Step 1: 1L (300 mg, 0.76 mmol), tert-butyl ((1s,3s)-3-aminocyclobutyl)carbamate (71 mg, 0.38 mmol), HATU (190 mg, 0.50 mmol), DIPEA (150 mg, 1.16 mmol), and DMF (4 mL) were added to a reaction flask and stirred at 25 ° C for 5 h. After the reaction was completed, water (12 mL) was added, and the reaction solution was extracted three times with ethyl acetate (40 ml × 3), washed with saturated sodium chloride solution, dried over anhydrous sodium sulfate, concentrated under reduced pressure, and separated and purified by thin layer chromatography separation plate to obtain pale yellow purified product 41A (153 mg, 71.7%).
number
[0253] Step 2: Compound 41A (153 mg, 0.27 mmol) was dissolved in dichloromethane (6 mL), trifluoroacetic acid (2 mL) was added, and the mixture was reacted at room temperature for 30 min. After the reaction was completed, the mixture was concentrated and concentrated under reduced pressure to obtain crude product 41B (110 mg, 88%).
number
[0254] Step 3: Compound 41B (110 mg, 0.24 mmol), 2-(2,6-dioxopiperidin-3-yl)-5,6-difluoroindoline-1,3-dione (92 mg, 0.31 mmol), DIPEA (93 mg, 0.72 mmol), and DMF (3 mL) were added to a reaction flask and stirred at 100 °C for 3 h. The reaction was monitored by LCMS, and the reaction system was directly separated after completion of the reaction, and the separation was performed by preparative HPLC separation method: 1. Equipment: waters 2767 preparative liquid, chromatography column: SunFire@ Prep C18 (19 mm x 250 mm). 2. The sample was filtered through a 0.45 μm filter to prepare the sample solution. 3. Conditions for preparative chromatography: a. Composition of mobile phase A and B: Mobile phase A: acetonitrile, Mobile phase B: water (containing 0.1% ammonium acetate) b. Gradient elution, the content of mobile phase A is 10% to 55% c. Flow rate is 12 mL / min. Retention time is 7.0 min, and the title compound 41 (39 mg, 22%) was obtained.
number
[0255] Example 42: N-((1r,3r)-3-((2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxoisoindolin-5-yl)amino)cyclobutyl)-5-(4-((7-ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl)piperazin-1-yl)pyridine-2-formamide (compound 42) [ka]
[0256] Step 1: 1L (500 mg, 1.27 mmol), tert-butyl ((1r,3r)-3-aminocyclobutyl)carbamate (260 mg, 1.4 mmol), HATU (628 mg, 1.65 mmol), DIPEA (490 mg, 3.81 mmol), and DMF (4 mL) were added to a reaction flask and stirred at 25 °C for 5 h. After completion of the reaction, water (12 mL) was added, and the reaction solution was extracted three times with ethyl acetate (40 ml x 3), washed with saturated sodium chloride solution, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to give crude product 42A (480 mg, 67.3%).
number
[0257] Step 2: Compound 42A (480 mg, 0.85 mmol) was dissolved in dichloromethane (6 mL), trifluoroacetic acid (2 mL) was added, and the mixture was reacted at room temperature for 30 min. After the reaction was completed, the mixture was concentrated and concentrated under reduced pressure to obtain crude product 42B (370 mg, 94%).
number
[0258] Step 3: Compound 42B (185 mg, 0.4 mmol), 2-(2,6-dioxopiperidin-3-yl)-5,6-difluoroindoline-1,3-dione (130 mg, 0.44 mmol), DIPEA (155 mg, 1.2 mmol), and DMF (3 mL) were added to a reaction flask and stirred at 100 °C for 3 h. The reaction was monitored by LCMS, and the reaction system was directly separated after completion of the reaction, and the separation was performed by preparative HPLC separation method: 1. Equipment: waters 2767 preparative liquid, chromatography column: SunFire@ Prep C18 (19 mm x 250 mm). 2. The sample was filtered through a 0.45 μm filter to prepare the sample solution. 3. Conditions for preparative chromatography: a. Composition of mobile phase A and B: Mobile phase A: acetonitrile, Mobile phase B: water (containing 0.1% ammonium acetate) b. Gradient elution, content of mobile phase A is 10%-55% c. Flow rate is 12 mL / min. Retention time is 7.0 min, and title compound 42 (42 mg, 12%) was obtained.
number
[0259] Example 43: 2-(2,6-dioxopiperidin-3-yl)-5-(3-((5-(4-((7-ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-)yl)methyl)piperazin-1-yl)pyridin-2-yl)acetonitrilealkynyl)azacyclobutan-1-yl)isoindoline-1,3-dione (compound 43) [ka]
[0260] Step 1: 43A (5g, 21.11mmol), 3-acetonitrile alkynyl azacyclobutane-1-carboxylic acid tert-butyl ester (4.02g, 22.18mmol), bistriphenylphosphine palladium dichloride (0.74g, 1.06mmol), cuprous iodide (0.4g, 2.11mmol) and triethylamine (6.41g, 63.3mmol) were added to tetrahydrofuran (50ml) and reacted at room temperature for 16h after N2 replacement. Completion of the reaction was monitored by TLC, water (100ml) was added, extracted with ethyl acetate (100ml x 2), the organic phase was washed with saturated sodium chloride solution, dried over anhydrous sodium sulfate, filtered and concentrated, and the crude product was separated and purified by silica gel column chromatography (eluent EA / PE = 0-25%) to give the title compound 43B (5g, 70.24%).
number
[0261] Step 2: 43B (5 g, 14.83 mmol) was added to dichloromethane (40 ml), then trifluoroacetic acid (15 ml) was added, and the mixture was reacted at room temperature for 2 h. After monitoring the completion of the reaction, the reaction solution was directly concentrated under reduced pressure and dried to obtain 8 g of crude product, which was directly used in the next step reaction.
[0262] Step 3: The crude 43C (8 g), 2-(2,6-dioxopiperidin-3-yl)-5-fluoroisodihydroindole-1,3-dione (7.63 g, 21.72 mmol) and N,N-diisopropylethylamine (11.23 g, 86.88 mmol) were added to dimethyl sulfoxide (50 ml) and reacted at 100 ° C for 1 h, and the completion of the reaction was monitored by LCMS. The temperature was lowered to room temperature, water (200 ml) was added, and the mixture was extracted with dichloromethane (100 ml × 3), then washed with saturated sodium chloride solution, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The crude product was separated and purified by silica gel column chromatography (eluent EA / DCM = 0 ~ 50%) to obtain the title compound (4 g).
number
[0263] Step 4: 43D (2 g, 4.05 mmol), piperazine-1-carboxylic acid tert-butyl ester (1.51 g, 8.07 mmol), methanesulfonic acid (2-dicyclohexylphosphine-2',6'-diisopropoxy-1,1'-biphenyl) (2-amino-1,1'-biphenyl-2-yl) palladium (II) (0.17 g, 0.20 mmol) and cesium carbonate (2.64 g, 8.12 mmol) were added to dioxane (60 ml) and reacted at 100°C for 16 h after N2 replacement. The reaction was monitored by LC-MS. The temperature was lowered to room temperature, and the reaction solution was directly concentrated under reduced pressure, then added to DCM / MeOH=10:1 (60 ml), stirred, and filtered. The filtrate was concentrated under reduced pressure, and then separated and purified by silica gel column chromatography (eluent MeOH / DCM=0-10% purification) to obtain the title compound (0.35 g, 14%).
number
[0264] Step 5: 43E (0.35 g, 0.58 mmol) was added to dichloromethane (6 ml), then trifluoroacetic acid (2 ml) was added, and the mixture was reacted at room temperature for 2 h. After the reaction was completed, the mixture was concentrated and concentrated under reduced pressure to obtain crude product 43F (550 mg).
[0265] Step 6: 1G (0.1g, 0.45mmol), 43F (0.38g, 0.45mmol) were added to acetonitrile, then N,N-diisopropylethylamine (0.35g, 2.71mmol) and potassium iodide (0.015g, 0.09mmol) were added, and the mixture was heated to 80°C and reacted for 2h. The completion of the reaction was monitored. The reaction solution was directly sent to HPLC for separation and purification, and after purification, it was concentrated under reduced pressure to remove acetonitrile, extracted with (dichloromethane:methanol=10:1), and the organic phase was concentrated under reduced pressure to obtain the title compound (12mg, 4%). Separation method by preparative HPLC: 1. Equipment: waters 2767 preparative liquid, chromatography column: SunFire@ Prep C18 (19mm×250mm) 2. The sample was dissolved in DMF and filtered through a 0.45μm filter to prepare the sample solution. 3. Conditions for preparative chromatography: a. Composition of mobile phase A and B: Mobile phase A: acetonitrile, Mobile phase B: water (containing 0.1% ammonium acetate). b. Gradient elution, content of mobile phase A is 5%-40%. c. Flow rate is 12mL / min. d. Elution time is 20min. 1 H NMR(400MHz,DMSO-d6)δ 11.82(s,1H),11.05(s,1H),8.40(d,1H),8.25(d,1H),7.74(s,1H),7.68(d,1H),7.62(s,1 H),7.33(d,1H),7.26(dd,1H),6.87(d,1H),6.72(dd,1H),5.06(dd,1H),4.39(t,2H),4.10 - 4.02(m,2H),3.93-3.88(m,1H),3.64(s,2H),3.29 - 3.23(m,4H),2.94 - 2.82(m,1H),2.61-2.51(m,8H),2.03-1.99(m,1H),1.18(t,3H).
number
[0266] Example 44: 2-(2,6-dioxopiperidin-3-yl)-5-(4-((5-(4-((7-ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-)yl)methyl)piperazin-1-yl)pyridin-2-yl)acetonitrilealkynyl)piperidin-1-yl)isoindoline-1,3-dione (compound 44) [ka]
[0267] Step 1: 43A (5 g, 21.11 mmol), 4-acetonitrile alkynylpiperidine-1-carboxylic acid tert-butyl ester (4.64 g, 22.19 mmol), bistriphenylphosphine palladium dichloride palladium (0.74 g, 1.06 mmol), cuprous iodide (0.4 g, 2.11 mmol) and triethylamine (6.41 g, 63.3 mmol) were added to tetrahydrofuran (50 ml) and reacted at room temperature for 16 h after N2 replacement. Completion of the reaction was monitored by TLC, water (100 ml) was added, extracted with ethyl acetate (100 ml x 2), the organic phase was washed with saturated sodium chloride solution, dried over anhydrous sodium sulfate, filtered and concentrated, and the crude product was separated and purified by silica gel column chromatography (eluent EA / PE = 0-25%) to give the title compound (7 g, 90.78%).
[0268] Step 2: 44B (7 g, 19.16 mmol) was added to dichloromethane (45 ml), then trifluoroacetic acid (15 ml) was added, and the mixture was reacted at room temperature for 2 h. After monitoring the completion of the reaction, the reaction solution was directly concentrated under reduced pressure and dried to obtain 10 g of crude product, which was directly used in the next step reaction.
[0269] Step 3: Crude 44C (7 g, 18.46 mmol), 2-(2,6-dioxopiperidin-3-yl)-5-fluoroisodihydroindole-1,3-dione (3.57 g, 12.92 mmol) and N,N-diisopropylethylamine (14.31 g, 110.76 mmol) were added to dimethyl sulfoxide (50 ml) and reacted at 100 °C for 1 h, and the completion of the reaction was monitored by LCMS. The temperature was lowered to room temperature, water (200 ml) was added, extracted with dichloromethane (100 ml x 3), then washed with saturated sodium chloride solution, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The crude product was separated and purified by silica gel column chromatography (eluent EA / DCM = 0-50%) to obtain the title compound (3.5 g, 36%).
number
[0270] Step 4: 44D (2 g, 3.84 mmol), piperazine-1-carboxylic acid tert-butyl ester (1.07 g, 5.76 mmol), methanesulfonic acid (2-dicyclohexylphosphine-2',6'-diisopropoxy-1,1'-biphenyl) (2-amino-1,1'-biphenyl-2-yl) palladium (II) (0.16 g, 0.19 mmol) and cesium carbonate (2.5 g, 7.67 mmol) were added to dioxane (60 ml) and reacted at 100°C for 16 h after N2 replacement. The reaction was monitored by LC-MS. The temperature was lowered to room temperature, and the reaction solution was directly concentrated under reduced pressure, then added to DCM / MeOH=10:1 (60 ml), stirred, filtered, and the filtrate was concentrated under reduced pressure, then separated and purified by silica gel column chromatography (eluent MeOH / DCM=0-10% purification) to obtain the title compound (0.19 g, 7.9%).
number
[0271] Step 5: 44E (0.19 g, 0.3 mmol) was added to dichloromethane (6 ml), then trifluoroacetic acid (2 ml) was added, and the mixture was reacted at room temperature for 2 hours. The reaction solution was directly concentrated under reduced pressure and dried to give the title compound (0.24 g).
[0272] Step 6: 1G (0.1g, 0.45mmol), 44F (0.24g) were added to acetonitrile, then N,N-diisopropylethylamine (0.35g, 2.71mmol) and potassium iodide (0.015g, 0.09mmol) were added, and the mixture was heated to 80°C and reacted for 2h. The completion of the reaction was monitored. The reaction solution was directly sent to HPLC for separation and purification, and after purification, it was concentrated under reduced pressure to remove acetonitrile, extracted with (dichloromethane:methanol=10:1), and the organic phase was concentrated under reduced pressure to obtain the title compound (30mg, 9%). Separation method by preparative HPLC: 1. Equipment: waters 2767 preparative liquid, chromatography column: SunFire@ Prep C18 (19mm×250mm) 2. The sample was dissolved in DMF and filtered through a 0.45μm filter to prepare the sample solution. 3. Conditions for preparative chromatography: a. Composition of mobile phase A and B: Mobile phase A: acetonitrile, Mobile phase B: water (containing 0.1% ammonium acetate). b. Gradient elution, content of mobile phase A is 5%-40%. c. Flow rate is 12mL / min. d. Elution time is 20min. 1 H NMR(400MHz,DMSO-d6)δ 11.81(s,1H),11.05(s,1H),8.39(d,1H),8.21(d,1H),7.74(s,1H),7.67(d,1H),7.62(s,1H),7.36(d,1H),7.30 - 7.21(m,3H),5.06(dd,1H),3.84-3.80(m,2H),3.64(s,2H),3.37-3.30(m,2H),3.26-3.22(m,4H),2.99-2.93(m,1H),2.92 - 2.82(m,1H),2.63 - 2.51(m,8H),2.04-1.94(m,3H),1.74 - 1.62(m,2H),1.18(t,3H).
number
[0273] Example 45: N-((1s,4s)-4-((2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxoisoindolin-5-yl)amino)cyclohexyl)-5-(4-((7-ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl)piperazin-1-yl)pyridine-2-formamide (compound 45) [ka]
[0274] Step 1: 27A (0.7 g, 3.27 mmol), 2-(2,6-dioxopiperidin-3-yl)-5,6-difluoroisodihydroindole-1,3-dione (1.06 g, 3.6 mmol) and N,N-diisopropylethylamine (1.27 g, 9.81 mmol) were added to dimethyl sulfoxide (10 ml) and reacted at 100 ° C for 1 h. The reaction solution was cooled to room temperature, water (40 ml) was added, extracted with ethyl acetate (30 ml × 2), the organic phase was washed with saturated sodium chloride solution, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The crude product was separated and purified by silica gel column chromatography (20 g silica gel column, eluent EA / PE = 0 ~ 60%) to obtain the title compound (900 mg, 56%).
number
[0275] Step 2: 45B (300 mg, 0.61 mmol) was added to dichloromethane (6 ml), then trifluoroacetic acid (2 ml) was added, and the mixture was reacted at room temperature for 2 h. The reaction mixture was directly concentrated under reduced pressure and dried to give the title compound (0.35 g).
[0276] Step 3: 1L (145mg, 0.37mmol), 45C (350mg), 2-(7-azabenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (280mg, 0.74mmol) and N,N-diisopropylethylamine (200mg, 1.51mmol) were added to N,N-dimethylformamide (5ml) in sequence and reacted at room temperature for 5h. The reaction solution was directly sent to HPLC for separation and purification, and after purification, it was concentrated under reduced pressure to remove acetonitrile, extracted with (dichloromethane:methanol=10:1), and the organic phase was concentrated under reduced pressure to obtain the title compound (150mg, 53%). Separation method by preparative HPLC: 1. Equipment: waters 2767 preparative liquid, chromatography column: SunFire@ Prep C18 (19mm×250mm). 2. The sample was dissolved in DMF and filtered through a 0.45 μm filter to prepare a sample solution. 3. Conditions for preparative chromatography: a. Composition of mobile phases A and B: Mobile phase A: acetonitrile, Mobile phase B: water (containing 0.1% ammonium acetate). b. Gradient elution, with the content of mobile phase A ranging from 5% to 40%. c. Flow rate: 12 mL / min. d. Elution time: 20 min. 1 H NMR(400MHz,DMSO-d6)δ 11.84(s,1H),11.06(s,1H),8.41(d,1H),8.29(d,1H),8.10(d,1H),7.86(d,1H),7.75(s,1H),7.63(d,1H),7.58(d,1H),7.42(d d,1H),7.22(d,1H),6.51-6.47(m,1H),5.06(dd,1H),4.07-4.03(m,1H),3.80-3.74(m,1H),3.66(s,2H),3.37-3.33(m,4H),2.95 - 2.82(m,1H),2.63 - 2.51(m,8H),2.06 - 1.96(m,1H),1.89 - 1.63(m,8H),1.18(t,3H).
number
[0277] Example 46: 1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)-N-(5-(4-((7-ethyl-6-oxo-5,6-)dihydro-1,5-naphthyridin-3-yl)methyl)piperazin-1-yl)pyridin-2-yl)piperidine-4-formamide (compound 46) [ka]
[0278] Step 1: Compound 46A (3 g, 9.73 mmol) was added to methanol (50 mL), then 1,4-dioxane hydrochloride (6.06 g, 48.65 mmol) was added, reacted at room temperature overnight, filtered after completion of the reaction, washed, and the filter cake was collected to give compound 46B (2.0 g, 99%).
number
[0279] Step 2: Under the protection of nitrogen gas, compound 46B (0.5 g, 2.4 mmol) was placed in a flask and dimethyl sulfoxide (2 mL) was added. Then 7-(chloromethyl)-3-ethyl-1,2-dihydro-1,5-naphthyridin-2-one (0.53 g, 2.4 mmol), ethyldiisopropylamine (1.86 g, 14.4 mmol), and potassium iodide (0.08 g, 0.48 mmol) were added. The mixture was heated to 100°C and reacted at this temperature for 1 h. After the reaction was completed, the mixture was directly concentrated and the residue was quickly separated and purified by column chromatography (eluent ratio: MeOH:DCM = 0% to 10%) to obtain compound 46C (0.6 g, 63%).
number
[0280] Step 3: Compound 46C (600 mg, 1.52 mmol) was dissolved in methanol (10 mL), then palladium carbon (0.16 g, 1.52 mmol) and hydrazine hydrate (0.076 g, 1.52 mmol) were added, and the mixture was heated to 75° C. and reacted for 4 h. After the reaction was completed, the mixture was filtered, the organic phase was collected, and the residue was rapidly separated and purified by column chromatography (eluent ratio: MeOH:DCM=0%-10%) to obtain compound 46D (0.5 g, 90%).
number
[0281] Step 4: Compound 1O (500 mg, 1.81 mmol) and piperidine-4-carboxylic acid (0.23 g, 1.81 mmol) were added to dimethyl sulfoxide (10 mL), and then ethyldiisopropylamine (0.23 g, 1.81 mmol) was added. The mixture was heated to 100° C. and reacted overnight. After the reaction was completed, the mixture was directly concentrated and the residue was quickly separated and purified by column chromatography (eluent ratio: MeOH:DCM=0%-10%) to obtain compound 46E (0.49 g, 70%).
number
[0282] Step 5: Compound 46D (0.15 g, 0.41 mmol) and 46E (0.16 g, 0.41 mmol) were dissolved in DMF (5 mL), then 2-(7-aza-1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (0.19 g, 0.49 mmol) and ethyldiisopropylamine (0.16 g, 1.23 mmol) were added and reacted at room temperature for 1 h. The reaction was monitored by LCMS, and the reaction system was directly separated after the reaction was completed, and the separation was performed by preparative HPLC separation method: 1. Equipment: waters 2767 preparative liquid, chromatography column: SunFire@ Prep C18 (19 mm x 250 mm). 2. The sample was filtered through a 0.45 μm filter to prepare the sample solution. 3. Conditions for preparative chromatography: a. Composition of mobile phase A and B: Mobile phase A: acetonitrile, Mobile phase B: water (containing 0.1% ammonium acetate). b. Gradient elution, content of mobile phase A is 10%-55%. c. Flow rate is 12 mL / min. d. Elution time is 20 min. Retention time is 7.0 min, and compound 46 (50 mg, 17%) was obtained.
number
[0283] Example 47: 2-(1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperidin-4-yl)-N-(5-(4-((7-ethyl))-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl)piperazin-1-yl)pyridin-2-yl)acetamide (compound 47) [ka]
[0284] Step 1: Compound 1O (0.5 g, 1.81 mmol) and 4-piperidineacetic acid hydrochloride (0.33 g, 1.81 mmol) were added to dimethyl sulfoxide (10 mL), and then ethyldiisopropylamine (0.47 g, 3.62 mmol) was added. The mixture was heated to 100° C. and reacted overnight. After the reaction was completed, the mixture was directly concentrated and the residue was quickly separated and purified by column chromatography (eluent ratio: MeOH:DCM=0%-10%) to obtain compound 47B (0.5 g, 69%).
number
[0285] Step 2: Compound 46D (0.15 g, 0.41 mmol) and 47B (0.16 g, 0.41 mmol) were dissolved in DMF (5 mL), then 2-(7-aza-1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (0.19 g, 0.49 mmol) and ethyldiisopropylamine (0.16 g, 1.23 mmol) were added and reacted at room temperature for 1 h. The reaction was monitored by LCMS, and the reaction system was directly separated after completion of the reaction, and the separation was performed by preparative HPLC separation method: 1. The equipment was a waters 2767 preparative liquid, chromatography column: SunFire@ Prep C18 (19 mm x 250 mm). 2. The sample was filtered through a 0.45 μm filter to prepare the sample solution. 3. Conditions for preparative chromatography: a. Composition of mobile phase A and B: Mobile phase A: acetonitrile, Mobile phase B: water (containing 0.1% ammonium acetate). b. Gradient elution, content of mobile phase A is 10%-55%. c. Flow rate is 12 mL / min. d. Elution time is 20 min. Retention time is 7.0 min, and compound 47 (60 mg, 20%) is obtained.
number
[0286] Example 48: N-(1-(2-(2,6-dioxopiperidin-3-yl)-3-oxyisoindolin-5-yl)piperidin-4-yl)-5-(4-((7-ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl)piperazin-1-yl)pyridine-2-formamide (Compound 48) [ka]
[0287] Step 1: Methyl 5-bromo-2-methylbenzoate (5.00 g, 21.8 mmol), bromosuccinimide (4.28 g, 24.0 mmol), and dibenzoyl peroxide (1.06 g, 4.37 mmol) were placed together in a reaction flask, and dry carbon tetrachloride (150 mL) was added, followed by 80 o The mixture was heated to C and reacted overnight. After monitoring the completion of the reaction by TLC, water (200 mL) was added, the organic phase was separated, the aqueous phase was extracted with dichloromethane (50 mL x 3), the organic phase was combined, dried over anhydrous sodium sulfate, filtered and concentrated, and the resulting residue was separated and purified by silica gel column chromatography (petroleum ether: ethyl acetate (v / v) = 100: 2) to obtain compound 48B (4.9 g, 72.9%) as a colorless oil.
[0288] Step 2: Compound 48B (2.00 g, 6.49 mmol) was dissolved in N,N-dimethylformamide (50 mL), and N,N-diisopropylethylamine (2.51 g, 19.5 mmol) and 3-amino-2,6-piperidinedione hydrochloride (1.28 g, 7.79 mmol) were added thereto in that order, and the resulting mixture was cooled to 80° C. o The temperature was raised to C and the reaction was continued for about 30 hours. After monitoring the completion of the reaction by TLC, water (50 mL) was added, stirred for 5 minutes, and then directly filtered. The solid was washed with a 5% methanol-containing dichloromethane solution (20 mL x 3). The solid obtained was silver gray after drying, and was the crude product of compound 48C (1.39 g, 66.2%).
number
[0289] Step 3: Compound 48C (100 mg, 0.310 mmol), Pd-G3-Ruphos (25.3 mg, 0.0310 mmol), 4-tert-butoxycarbonylaminopiperidine (80.6 mg, 0.403 mmol) and cesium carbonate (302 mg, 0.929 mmol) were all placed in a microwave reaction tube, and dried 1,4-dioxane (6 mL) was added, followed by heating in a microwave reactor for 120 min. o The mixture was heated to C and reacted for 2 hours. After monitoring the completion of the reaction by TLC, the solvent was directly sucked dry. The solid residue was separated and purified by silica gel column chromatography (dichloromethane:methanol (v / v) = 10:1) to give a yellow-brown mixture 48D (110 mg).
number
[0290] Step 4: A mixture of compound 48D (110 mg) was dissolved in dichloromethane (3 mL), trifluoroacetic acid (1 mL) was added at room temperature, and stirring was continued for 30 minutes at room temperature. After monitoring the completion of the reaction by TLC, the solvent was directly sucked dry, ethyl acetate (10 mL) and water (5 mL) were added again, the aqueous phase and the organic phase were separated, the organic phase was washed with water (2 mL x 3), the aqueous phase was combined, backwashed once with ethyl acetate (5 mL), and the aqueous phase was lyophilized to obtain a crude trifluoroacetate salt of compound 48E (33 mg) as a tan solid.
number
[0291] Step 5: Compound 1L (50 mg, 0.127 mmol), trifluoroacetate of 48E (69.7 mg, 0.153 mmol), 2-(7-azabenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (96.8 mg, 0.254 mmol) and N,N-diisopropylethylamine (82.1 mg, 0.636 mmol) were placed in a round-bottom flask, and N,N-dimethylformamide (5 mL) was added thereto, followed by stirring at room temperature for about 2 hours to cause a reaction. After monitoring the completion of the reaction by TLC, water (30 mL) was added, and the aqueous phase was extracted with 10% methanol in dichloromethane (5 mL×8). The organic phases were combined, dried over anhydrous sodium sulfate, filtered and concentrated, and the resulting residue was separated and purified by thick silica gel plate (dichloromethane:ethyl acetate:methanol (v / v / v)=10:1:1) to give compound 48 (14 mg, 15.4%).
number
[0292] Example 49: N-(1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperidin-4-yl)-1'-(7-ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl)-1',2',3',6'-tetrahydro-[3,4'-bipyridine]-6-formamide (Compound 49) [ka]
[0293] Step 1: Compound 49A (1g, 5mmol) and 2-(2,6-dioxopiperidin-3-yl)-5-fluoroisoindoline-1,3-dione (1.38g, 5mmol) were dissolved in dimethylsulfoxide (20mL), N,N-diisopropylethylamine (1.29g, 10mmol) was added, and the mixture was reacted at 100°C for 1h. After the reaction was completed, water (20ml) and ethyl acetate (60mL) were added, and the organic phase was separated, washed with water (10mL x 2), extracted, washed with saturated saline (10mL x 1), dried over anhydrous sodium sulfate, concentrated, and separated and purified by silica gel column chromatography (eluent ratio: methanol: dichloromethane (v / v) = 0% to 10%) to obtain product 49B (1.8g, 78.1%).
number
[0294] Step 2: Compound 49B (200 mg, 0.44 mmol) was dissolved in dichloromethane (6 mL), trifluoroacetic acid (2 mL) was added, and the mixture was reacted at room temperature for 30 min. After completion of the reaction, the mixture was concentrated to give crude product 49C (200 mg, 100.0%).
number
[0295] Step 3: Compound 1G (1.48 g, 6.66 mmol) and methyl 1',2',3',6'-tetrahydro-[3,4'-bipyridine]-6-carboxylate hydrochloride (1.69 g, 6.66 mmol) were dissolved in acetonitrile (30 mL), potassium iodide (150 mg) and N,N-diisopropylethylamine (8.6 g, 66.6 mmol) were added, and the mixture was reacted at 80°C overnight. After the reaction was completed, the mixture was concentrated, and the product was separated and purified by silica gel column chromatography (eluent ratio: methanol:dichloromethane (v / v) = 0% to 10%) to obtain product 49D (1.5 g, 55.3%).
number
[0296] Step 4: Compound 49D (1.5 g, 3.7 mmol) and lithium hydroxide (0.444 g, 18.5 mmol) were dissolved in a mixed solvent of methanol (10 mL) and water (10 mL), and reacted at room temperature for 2 hours. After the reaction was completed, the pH was adjusted to 3-4 with 4N hydrochloric acid, and the product was separated and purified by C18 column chromatography (eluent ratio: acetonitrile: 0.5% trifluoroacetic acid water (v / v) = 0%-50%) to obtain product 49E (1.3 g, 90.1%).
number
[0297] Step 5: Compound 49E (100 mg, 0.26 mmol), benzotriazole-N,N,N',N'-tetramethyluronium hexafluorophosphate (114 mg, 0.3 mmol), compound 49C (200 mg, 0.44 mmol) and N,N-diisopropylethylamine (65 mg, 0.5 mmol) were dissolved in DMF (2 mL) and reacted at room temperature for 1 hour. After the reaction was completed, the mixture was directly separated and purified by a liquid-phase separation column (liquid-phase separation conditions: C18 reversed-phase separation column, mobile phase was deionized water (A) containing 0.1% ammonium bicarbonate, acetonitrile (B), gradient elution, B content = 5% to 50%, elution time 15 min, flow rate 12 mL / min, column temperature: 30 °C), to obtain the title compound 49 (50 mg, yield 26.5%, retention time about 7.5 min). 1 H NMR(400MHz,DMSO-d6)δ11.83(s,1H),11.05(s,1H),8.68(s,1H),8.61(d,1H),8.41(d,1H),8.04 - 7.97(m,2H),7.75(s,1H),7.67(d,2H),7.35(d,1H),7.30 - 7.25(m,1H),6.41(s,1H),5.18 - 4.94(m,1H),4.21 - 4.01(m,3H),3.72(s,2H),3.22 - 3.03(m,4H),2.96 - 2.82(m,1H),2.74 - 2.67(m,2H),2.63 - 2.51(m,6H),2.05 - 1.97(m,1H),1.91 - 1.84(m,2H),1.80 - 1.68(m,2H),1.20 - 1.17(m,3H).
number
[0298] Example 50: N-(1-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxoisoindolin-5-yl)piperidin-4-yl)-1'-(7-ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl)-1',2',3',6'-tetrahydro-[3,4'-bipyridine]-6-formamide (compound 50) [ka]
[0299] Step 1: Compound 49A (1g, 5mmol) and 2-(2,6-dioxopiperidin-3-yl)-5,6-difluoroisoindoline-1,3-dione (1.47g, 5mmol) were dissolved in dimethylsulfoxide (20mL), N,N-diisopropylethylamine (1.29g, 10mmol) was added, and the mixture was reacted at 100°C for 1h. After the reaction was completed, water (20ml) and ethyl acetate (60mL) were added, and the organic phase was separated, washed with water (10mL x 2), extracted, washed with saturated saline (10mL x 1), dried over anhydrous sodium sulfate, concentrated, and separated and purified by silica gel column chromatography (eluent ratio: methanol: dichloromethane (v / v) = 0% to 10%) to obtain product 50A (1.7g, 72.4%).
number
[0300] Step 2: Compound 50A (200 mg, 0.42 mmol) was dissolved in dichloromethane (6 mL), trifluoroacetic acid (2 mL) was added, and the mixture was reacted at room temperature for 30 minutes. After completion of the reaction, the mixture was concentrated to give crude product 50B (200 mg, 100.0%).
number
[0301] Step 3: Compound 49E (100 mg, 0.26 mmol), benzotriazole-N,N,N',N'-tetramethyluronium hexafluorophosphate (114 mg, 0.3 mmol), compound 50B (200 mg, 0.42 mmol) and N,N-diisopropylethylamine (65 mg, 0.5 mmol) were dissolved in DMF (2 mL) and reacted at room temperature for 1 hour. After the reaction was completed, the mixture was directly separated and purified by a liquid-phase separation column (liquid-phase separation conditions: C18 reversed-phase separation column, mobile phase was deionized water (A) containing 0.1% ammonium bicarbonate, acetonitrile (B), gradient elution, B content = 5% to 50%, elution time 15 min, flow rate 12 mL / min, column temperature: 30 °C), to obtain the title compound 50 (48 mg, yield 24.7%, retention time about 7.4 min). 1 H NMR(400MHz,DMSO-d6)δ11.82(s,1H),11.08(s,1H),8.71(s,1H),8.65(d,1H),8.41(d,1H),8.04 - 7.97(m,2H),7.76 - 7.69(m,2H),7.65(s,1H),7.49(d,1H),6.42(s,1H),5.21 - 4.91(m,1H),4.11 - 3.96(m,1H),3.73(s,2H),3.68 - 3.59(m,2H),3.22 - 3.14(m,2H),3.10 - 3.00(m,2H),2.95 - 2.83(m,1H),2.75 - 2.67(m,2H),2.62 - 2.52(m,6H),2.06 - 2.01(m,1H),1.93 - 1.85(m,4H),1.19 - 1.18(m,3H).
number
[0302] Example 51: N-((3S)-1-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxoisoindolin-5-yl)pyrrolidin-3-yl)-5-(4-((7-ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl)piperazin-1-yl)pyridine-2-formamide (compound 51) [ka]
[0303] Step 1: Compound 21B (50 mg, 0.11 mmol) and 2-(2,6-dioxopiperidin-3-yl)-5,6-difluoroisoindoline-1,3-dione (38 mg, 0.13 mmol) were added to dimethyl sulfoxide (2 mL), followed by N,N-diisopropylethylamine (28 mg, 0.22 mmol) and reacted at 100 ° C for 1 h. The mixture was directly separated and purified by liquid-phase separation column (liquid-phase separation conditions: C18 reverse phase preparation column, mobile phase was deionized water (A) containing 0.1% ammonium bicarbonate, acetonitrile (B), gradient elution, B content = 5% to 50%, elution time 15 min, flow rate 12 mL / min, column temperature: 30 ° C), to obtain the title compound 51 (35 mg, yield 43.3%, retention time about 7.0 min). 1 H NMR(400MHz,DMSO-d6)δ11.84(s,1H),11.06(s,1H),8.61(d,1H),8.40(d,1H),8.26(d,1H),7.86(d,1H),7.75(s,1H),7.66 - 7.56(m,2H),7.45 - 7.36(m,1H),7.07(d,1H),5.13 - 5.01(m,1H),4.68 - 4.50(m,1H),3.93 - 3.79(m,1H),3.75 - 3.57(m,5H),3.41 - 3.32(m,4H),2.96 - 2.80(m,1H),2.63 - 2.52(m,8H),2.26 - 1.98(m,3H),1.22 - 1.13(m,3H).
number
[0304] Example 52: N-(2-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxoisoindolin-5-yl)-2-azaspiro[3.3]heptan-6-yl)-5-(4-((7-ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl)piperazin-1-yl)pyridine-2-formamide (compound 52) [ka]
[0305] Step 1: Crude compound 24B (300 mg, 0.51 mmol) and 2-(2,6-dioxopiperidin-3-yl)-5,6-difluoroindoline-1,3-dione (150 mg, 0.51 mmol) were added to dimethyl sulfoxide (3 mL), followed by N,N-diisopropylethylamine (133 mg, 1.02 mmol) and reacted at 100 ° C for 1 h. Direct separation and purification by liquid-phase separation column (liquid-phase separation conditions: C18 reversed-phase preparation column, mobile phase was deionized water (A) containing 0.1% ammonium bicarbonate, acetonitrile (B), gradient elution, B content = 5% to 50%, elution time 15 min, flow rate 12 mL / min, column temperature: 30 ° C) gave the title compound 52 (50 mg, yield 12.8%, retention time about 7.4 min). 1H NMR(400MHz,DMSO-d6)δ 11.84(s,1H),11.07(s,1H),8.62(d,1H),8.41(d,1H),8.27(d,1H),7.82(d,1H),7.75(s,1H),7.65 - 7.55(m,2H),7.39(d,1H),6.89(d,1H),5.13 - 4.98(m,1H),4.42 - 4.30(m,1H),4.25(s,2H),4.12(s,2H),3.66(s,2H),3.38 - 3.32(m,4H),2.93 - 2.82(m,1H),2.63 - 2.51(m,10H),2.46 - 2.40(m,2H),2.05 - 1.95(m,1H),1.20 - 1.17(m,3H).
number
[0306] Example 53: N-((3S)-1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)pyrrolidin-3-yl)-1'-(7-ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl)-1',2',3',6'-tetrahydro-[3,4'-bipyridine]-6-formamide (compound 53) [ka]
[0307] Step 1: Compound 49E (0.5 g, 1.28 mmol) and (S)-3-aminopyrrolidine-1-carboxylic acid tert-butyl ester (283 mg, 1.5 mmol) were dissolved in DMF (5 mL), and benzotriazole-N,N,N',N'-tetramethyluronium hexafluorophosphate (570 mg, 1.5 mmol), N,N-diisopropylethylamine (330 mg, 2.54 mmol) were added, and the mixture was reacted by stirring at room temperature for 1 h. After the reaction was completed, water (10 ml) and ethyl acetate (10 mL) were added, the organic phase was separated, and the aqueous phase was extracted with ethyl acetate (10 mL x 2). The organic phases were combined, dried over anhydrous sodium sulfate, and concentrated to give crude product 53A (750 mg, 100.0%).
number
[0308] Step 2: Compound 53A (700 mg, 1.28 mmol) was dissolved in dichloromethane (6 mL), trifluoroacetic acid (2 mL) was added, and the mixture was reacted at room temperature for 30 min. After the reaction was completed, the mixture was concentrated, adjusted to pH>7 with triethylamine, and purified by C18 column chromatography (acetonitrile:0.1% aqueous ammonia solution (v / v)=50%) to obtain product 53B (400 mg, 68.2%).
number
[0309] Step 3: Compound 53 B (100 mg, 0.22 mmol) and 2-(2,6-dioxopiperidin-3-yl)-5-fluoroisoindoline-1,3-dione (61 mg, 0.22 mmol) were added to DMF (3 mL), followed by N,N-diisopropylethylamine (57 mg, 0.44 mmol) and reacted at 100 ° C for 2 h. The mixture was directly separated and purified by liquid-phase separation column (liquid-phase separation conditions: C18 reverse phase preparation column, mobile phase was deionized water (A) containing 0.1% ammonium bicarbonate, acetonitrile (B), gradient elution, B content = 5% to 50%, elution time 15 min, flow rate 12 mL / min, column temperature: 30 ° C), to obtain the title compound 53 (45 mg, yield 28.7%, retention time about 7.0 min). 1 H NMR(400MHz,DMSO-d6)δ 11.82(s,1H),11.04(s,1H),8.94(d,1H),8.67(s,1H),8.41(d,1H),8.02(s,2H),7.76(s,1H),7.65(d,2H),6.93(d,1H),6.89 - 6.78(m,1H),6.42(s,1H),5.12 - 4.96(m,1H),4.76 - 4.52(m,1H),3.80 - 3.67(m,3H),3.67 - 3.57(m,1H),3.55 - 3.44(m,2H),3.17(s,2H),2.97 - 2.81(m,1H),2.77 - 2.65(m,2H),2.63 - 2.52(m,6H),2.36 - 2.14(m,2H),2.08 - 1.97(m,1H),1.20 - 1.17(m,3H).
number
[0310] Example 54: N-((3S)-1-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxoisoindolin-5-yl)pyrrolidin-3-yl)-1'-(7-ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl)-1',2',3',6'-tetrahydro-[3,4'-bipyridine]-6-formamide (compound 54) [ka]
[0311] Step 1: Compound 53 B (100 mg, 0.22 mmol) and 2-(2,6-dioxopiperidin-3-yl)-5,6-difluoroindoline-1,3-dione (65 mg, 0.22 mmol) were added to DMF (3 mL), followed by N,N-diisopropylethylamine (57 mg, 0.44 mmol) and reacted at 100 ° C for 2 h. The mixture was directly separated and purified by liquid-phase separation column (liquid-phase separation conditions: C18 reversed-phase preparation column, mobile phase was deionized water (A) containing 0.1% ammonium bicarbonate, acetonitrile (B), gradient elution, B content = 5% to 50%, elution time 15 min, flow rate 12 mL / min, column temperature: 30 ° C), to obtain the title compound 54 (45 mg, yield 28.0%, retention time about 7.0 min). 1 H NMR(400MHz,DMSO-d6)δ 11.81(s,1H),11.06(s,1H),8.93(d,1H),8.67(s,1H),8.41(d,1H),8.12 - 7.91(m,2H),7.75(s,1H),7.66 - 7.55(m,2H),7.08(d,1H),6.42(s,1H),5.14 - 5.00(m,1H),4.69 - 4.50(m,1H),3.95 - 3.83(m,1H),3.77 - 3.53(m,5H),3.17(s,2H),2.94 - 2.81(m,1H),2.74 - 2.65(m,2H),2.63 - 2.51(m,6H),2.26 - 2.13(m,2H),2.06 - 1.97(m,1H),1.20 - 1.16(m,3H).
number
[0312] Example 55: N-(2-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)-2-azaspiro[3.3]heptan-6-yl)-1'-(7-ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl)-1',2',3',6'-tetrahydro-[3,4'-bipyridine]-6-formamide (compound 55) [ka]
[0313] Step 1: Compound 49E (0.5 g, 1.28 mmol) and 6-amino-2-azaspiro[3.3]heptane-2-carboxylic acid tert-butyl ester (318 mg, 1.5 mmol) were dissolved in DMF (5 mL), and benzotriazole-N,N,N',N'-tetramethyluronium hexafluorophosphate (570 mg, 1.5 mmol), N,N-diisopropylethylamine (330 mg, 2.54 mmol) were added, and the mixture was stirred at room temperature for 1 h to react. After the reaction was completed, water (10 ml) and ethyl acetate (10 mL) were added, the organic phase was separated, the aqueous phase was extracted with ethyl acetate (10 mL x 2), the organic phase was combined, dried over anhydrous sodium sulfate, and concentrated to obtain crude product 55A (750 mg, 100.0%).
number
[0314] Step 2: Compound 55A (750 mg, 1.28 mmol) was dissolved in dichloromethane (6 mL), trifluoroacetic acid (2 mL) was added, and the mixture was reacted at room temperature for 30 min. After the reaction was completed, the mixture was concentrated, adjusted to pH>7 with triethylamine, and purified by C18 column chromatography (acetonitrile:0.1% aqueous ammonia solution (v / v)=50%) to obtain product 55B (300 mg, 48.3%).
number
[0315] Step 3: Compound 55 B (150 mg, 0.31 mmol) and 2-(2,6-dioxopiperidin-3-yl)-5-fluoroisoindoline-1,3-dione (86 mg, 0.31 mmol) were added to DMF (3 mL), followed by N,N-diisopropylethylamine (80 mg, 0.62 mmol) and reacted at 100 ° C for 2 h. Direct separation and purification by liquid-phase separation column (liquid-phase separation conditions: C18 reversed-phase preparation column, mobile phase was deionized water (A) containing 0.1% ammonium bicarbonate, acetonitrile (B), gradient elution, B content = 5% to 50%, elution time 15 min, flow rate 12 mL / min, column temperature: 30 ° C) to obtain the title compound 55 (35 mg, yield 15.2%, retention time about 7.0 min). 1 H NMR(400MHz,DMSO-d6)δ 11.83(s,1H),11.06(s,1H),8.96(d,1H),8.71(d,1H),8.42(d,1H),8.04 - 7.94(m,2H),7.77(s,1H),7.64(d,2H),6.77(d,1H),6.64(d,1H),6.43(s,1H),5.15 - 4.97(m,1H),4.51 - 4.35(m,1H),4.13(s,2H),4.00(s,2H),3.73(s,2H),3.17(s,2H),2.97 - 2.81(m,1H),2.75 - 2.64(m,2H),2.61 - 2.53(m,7H),2.50 - 2.46(m,3H),2.10 - 1.85(m,1H),1.21 - 1.17(m,3H).
number
[0316] Example 56: N-(2-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxoisoindolin-5-yl)-2-azaspiro[3.3]heptan-6-yl)-1'-(7-ethyl-6-oxy-5,6-dihydro-1,5-naphthyridin-3-yl)methyl)-1',2',3',6'-tetrahydro-[3,4'-bipyridine]-6-formamide (compound 56) [ka]
[0317] Step 1: Compound 55 B (150 mg, 0.31 mmol) and 2-(2,6-dioxopiperidin-3-yl)-5,6-difluoroindoline-1,3-dione (91 mg, 0.31 mmol) were added to DMF (3 mL), followed by N,N-diisopropylethylamine (80 mg, 0.62 mmol) and reacted at 100 ° C for 2 h. Direct separation and purification by liquid-phase separation column (liquid-phase separation conditions: C18 reversed-phase preparation column, mobile phase was deionized water (A) containing 0.1% ammonium bicarbonate, acetonitrile (B), gradient elution, B content = 5% to 50%, elution time 15 min, flow rate 12 mL / min, column temperature: 30 ° C) to obtain the title compound 56 (40 mg, yield 17.0%, retention time about 7.0 min). 1H NMR(400MHz,DMSO-d6)δ 11.84(s,1H),11.07(s,1H),8.94(d,1H),8.70(s,1H),8.42(d,1H),8.05 - 7.92(m,2H),7.77(s,1H),7.65(s,1H),7.59(d,1H),6.89(d,1H),6.43(s,1H),5.15 - 5.02(m,1H),4.46 - 4.36(m,1H),4.26(s,2H),4.13(s,2H),3.73(s,2H),3.17(s,2H),2.94 - 2.84(m,1H),2.77 - 2.68(m,2H),2.61 - 2.53(m,7H),2.50 - 2.43(m,3H),2.07 - 1.97(m,1H),1.21 - 1.17(m,3H).
number
[0318] Example 57: N-(1-(1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperidin-4-yl)-1H-pyrazol-4-yl)-5-(4-((7-ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl)piperazin-1-yl)pyridine-2-formamide (compound 57) [ka]
[0319] Step 1: Intermediate 1L (100mg, 0.25mmol) was dissolved in N,N-dimethylformamide (2ml), and compound 57A (102mg, 0.38mmol), 2-(7-azabenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (190mg, 0.5mmol) and N,N-diisopropylethylamine (130mg, 1mmol) were added to the reaction system, and the reaction was allowed to proceed overnight at room temperature. The reaction was monitored by LCMS, and the reaction system was directly separated after the reaction was completed. Separation HPLC separation method: 1. Equipment: waters 2767 separation liquid, chromatography column: SunFire@ Prep C18 (19mm x 250mm) 2. The sample was filtered through a 0.45μm filter to prepare the sample solution. 3. Conditions for preparative chromatography: a. Composition of mobile phase A and B: Mobile phase A: acetonitrile, Mobile phase B: water (containing 0.1% ammonium acetate). b. Gradient elution, content of mobile phase A is 10%-55%. c. Flow rate is 12 mL / min. Retention time is 7.0 min, and compound 57B (100 mg, 41%) is obtained.
number
[0320] Step 2: Compound 57B (0.1 g, 0.16 mmol) was placed in a reaction flask, dichloromethane (3 ml) / trifluoroacetic acid (1 ml) was added, and the mixture was reacted at room temperature for 2 h. After completion of the reaction, the mixture was directly concentrated to give crude compound 57C (0.1 g).
number
[0321] Step 3: The crude product 57C (100 mg, 0.16 mmol) from the previous step was dissolved in N-methylpyrrolidone (5 ml), 2-(2,6-dioxopiperidin-3-yl)-5-fluoroisodihydroindole-1,3-dione (88 mg, 0.32 mmol) was added, and the reaction system was reacted in a microwave at 150 ° C for 1 h. After the reaction was completed, the reaction system was directly separated and separated by preparative HPLC separation method: 1. Equipment: waters 2767 separation liquid, chromatography column: SunFire@ Prep C18 (19 mm × 250 mm) 2. The sample was filtered through a 0.45 μm filter to prepare the sample liquid. 3. Preparative chromatography conditions: a. Composition of mobile phases A and B: Mobile phase A: acetonitrile, mobile phase B: water (containing 0.1% ammonium acetate). b. Gradient elution, the content of mobile phase A is 10% to 55%. c. The flow rate was 12 mL / min. Retention time was 7.0 min, and compound 57 (50 mg, 40%) was obtained.
number
[0322] Example 58: N-(1-(1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperidin-4-yl)-1H-pyrazol-4-yl)-1'-((7-ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl)-1',2',3',6'-tetrahydro-[3,4'-bipyridine]-6-formamide (compound 58) [ka]
[0323] Step 1: Intermediate 49E (100 mg, 0.26 mmol) was dissolved in N,N-dimethylformamide (2 ml), and compound 57A (104 mg, 0.38 mmol), 2-(7-azabenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (198 mg, 0.52 mmol) and N,N-diisopropylethylamine (135 mg, 1.04 mmol) were added to the reaction system, and the reaction was allowed to proceed overnight at room temperature. The reaction was monitored by LCMS, and the reaction system was directly separated after the reaction was completed. Separation HPLC separation method: 1. Equipment: waters 2767 separation liquid, chromatography column: SunFire@ Prep C18 (19 mm x 250 mm). 2. The sample was filtered through a 0.45 μm filter to prepare the sample solution. 3. Conditions for preparative chromatography: a. Composition of mobile phase A and B: Mobile phase A: acetonitrile, Mobile phase B: water (containing 0.1% ammonium acetate). b. Gradient elution, content of mobile phase A is 10%-55%. c. Flow rate is 12 mL / min. Retention time is 7.0 min, and compound 58A (100 mg, 60%) is obtained.
number
[0324] Step 2: Compound 58A (0.1 g, 0.16 mmol) was placed in a reaction flask, dichloromethane (3 ml) / trifluoroacetic acid (1 ml) was added, and the mixture was reacted at room temperature for 2 h. After completion of the reaction, the mixture was directly concentrated to give crude compound 58B (0.1 g).
number
[0325] Step 3: The crude product 58B (100 mg, 0.16 mmol) from the previous step was dissolved in N-methylpyrrolidone (5 ml), 2-(2,6-dioxopiperidin-3-yl)-5-fluoroisodihydroindole-1,3-dione (88 g, 0.32 mmol) was added, and the reaction system was reacted in a microwave at 150 °C for 1 h. After the reaction was completed, the reaction system was directly separated and used for preparative HPLC separation method: 1. Equipment: waters 2767 preparative liquid, chromatography column: SunFire@ Prep C18 (19 mm × 250 mm). 2. The sample was filtered through a 0.45 μm filter to prepare the sample liquid. 3. Preparative chromatography conditions: a. Composition of mobile phases A and B: Mobile phase A: acetonitrile, mobile phase B: water (containing 0.1% ammonium acetate). b. Gradient elution, the content of mobile phase A is 10% to 55%. c) Flow rate was 12 mL / min. Retention time was 7.0 min, and compound 58 (50 mg, 40%) was obtained.
number
[0326] Example 59: N-((1r,3r)-3-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)cyclobutyl)-5-(4-((7)-ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl)piperazin-1-yl)pyridine-2-formamide (compound 59) [ka]
[0327] Step 1: 59A (500mg, 2.67mmol) was dissolved in anhydrous tetrahydrofuran (10ml), and 2-(2,6-dioxopiperidin-3-yl)-5-hydroxyisodihydroindole-1,3-dione (733mg, 2.67mmol) and triphenylphosphine (839mg, 3.2mmol) were added under nitrogen gas, and the reaction system was placed in an oil bath at 60℃, and diethyl azodicarboxylate (557mg, 3.2mmol) was added, and the reaction was continued at 60℃ for 3h. After the reaction was completed, water (20ml) was added to quench the reaction, and the mixture was extracted with ethyl acetate (20ml×3). The organic phases were combined, and the organic phase was dried over anhydrous sodium sulfate, filtered, and the residue was rapidly separated and purified by column chromatography (eluent ratio: ethyl acetate: petroleum ether=0%~20%) to obtain compound 59B (0.3g, 25%).
number
[0328] Step 2: Compound 59B (0.3 g, 0.68 mmol) was placed in a reaction flask, dichloromethane (3 ml) / trifluoroacetic acid (1 ml) was added, and the mixture was reacted at room temperature for 2 h. After completion of the reaction, the mixture was directly concentrated to give crude compound 59C (0.4 g).
number
[0329] Step 3: Intermediate 1L (272 mg, 0.68 mmol) was dissolved in N,N-dimethylformamide (5 ml), and crude compound 59C, 2-(7-azabenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (517 mg, 1.36 mmol) and N,N-diisopropylethylamine (354 mg, 2.72 mmol) were added to the reaction system, and the reaction was allowed to proceed overnight at room temperature. The reaction was monitored by LCMS, and the reaction system was directly separated after the reaction was completed. Separation HPLC separation method: 1. Equipment: waters 2767 preparative liquid, chromatography column: SunFire@ Prep C18 (19 mm x 250 mm). 2. The sample was filtered through a 0.45 μm filter to prepare the sample solution. 3. Conditions for preparative chromatography: a. Composition of mobile phase A and B: Mobile phase A: acetonitrile, Mobile phase B: water (containing 0.1% ammonium acetate). b. Gradient elution, content of mobile phase A is 10%-55%. c. Flow rate is 12 mL / min. d. Elution time is 20 min. Retention time is 7.0 min, and compound 59 (180 mg, 37%) was obtained.
number
[0330] Example 60 N-((1s,3s)-3-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)cyclobutyl)-5-(4-((7-ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl)piperazin-1-yl)pyridine-2-formamide (Compound 60) [ka]
[0331] Step 1: 60A (1.46 g, 5.34 mmol), ((1r,3r)-3-hydroxycyclobutyl)carbamate tert-butyl ester (1 g, 5.34 mmol), triphenylphosphine (2.1 g, 8.01 mmol) and diethyl azodicarboxylate (1.4 g, 8.03 mmol) were added to tetrahydrofuran (20 ml), and after N2 replacement, the mixture was reacted at 60 ° C for 16 h. The reaction mixture was cooled to room temperature, water (30 ml) was added, and the mixture was extracted with ethyl acetate (30 ml × 2), the organic phase was washed with saturated sodium chloride solution, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The crude product was separated and purified by silica gel column chromatography (20 g silica gel column, eluent EA / PE = 0 ~ 60%) to obtain the title compound (500 mg, 21%).
number
[0332] Step 2: 60B (500 mg, 1.13 mmol) was added to dichloromethane (9 ml), then trifluoroacetic acid (3 ml) was added, and the mixture was reacted at room temperature for 2 h. After the reaction was completed, the mixture was directly concentrated to give crude compound 60C (0.65 g).
[0333] Step 3: 1L (130mg, 0.33mmol), 60C (150mg, 0.33mmol), 2-(7-azabenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (190mg, 0.5mmol) and N,N-diisopropylethylamine (210mg, 1.62mmol) were added to N,N-dimethylformamide (5ml) in sequence and reacted at room temperature for 5h. The reaction solution was directly sent to HPLC for separation and purification, and after purification, it was concentrated under reduced pressure to remove acetonitrile, extracted with (dichloromethane:methanol=10:1), and the organic phase was concentrated under reduced pressure to obtain the title compound (30mg, 12.65%). Separation method by preparative HPLC: 1. Equipment: waters 2767 preparative liquid, chromatography column: SunFire@ Prep C18 (19mm×250mm). 2. The sample was dissolved in DMF and filtered through a 0.45 μm filter to prepare a sample solution. 3. Conditions for preparative chromatography: a. Composition of mobile phases A and B: Mobile phase A: acetonitrile, Mobile phase B: water (containing 0.1% trifluoroacetic acid). b. Gradient elution, with the content of mobile phase A ranging from 5% to 40%. c. Flow rate: 12 mL / min. d. Elution time: 20 min. 1 H NMR(400MHz,DMSO-d6)δ 11.82(s,1H),11.04(s,1H),8.44 - 8.36(m,2H),8.27(d,1H),7.81(d,1H),7.78 - 7.72(m,2H),7.63(d,1H),7.38(dd,1H),7.21 - 7.14(m,2H),5.11(dd,1H),4.51-4.43(m,1H),4.27 - 4.12(m,1H),3.65(s,2H),3.34-3.30(m,4H),2.99 - 2.86(m,1H),2.79 - 2.64(m,3H),2.57-2.54(m,8H),2.49-2.45(m,1H),2.06 - 1.94(m,1H),1.19(t,3H).
number
[0334] Example 61: N-(1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperidin-4-yl)-5-(4-((7-ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl)piperazin-1-yl)-N-methylpyridine-2-formamide (Compound 61) [ka]
[0335] Step 1: Compound 4-aminopiperidine-1-carboxylic acid tert-butyl ester (1.0 g, 4.99 mmol) and ethyl trifluoroacetate (3.55 g, 24.95 mmol) were dissolved in methanol (10 mL), reacted at 50° C. overnight, and concentrated to obtain crude product 61B (1.5 g, 100.0% yield).
number
[0336] Step 2: Compound 61B (1.5 g, 4.99 mmol) was dissolved in DMF (15 mL), and NaH (60%, 400 mg, 10.12 mmol) was added at 0° C. and reacted for 10 min. Then, iodomethane (1.44 g, 10.12 mmol) was added and reacted at room temperature for 30 min. Ethyl acetate (50 mL) was added, and the mixture was washed with water (30 mL×2), washed with saturated saline (30 mL), dried over anhydrous sodium sulfate, and concentrated to give crude product 61C (1.6 g, 100.0% yield).
number
[0337] Step 3: Compound 61C (1.6 g, 4.99 mmol) was dissolved in methanol (10 mL), water (10 mL) was added, and then sodium hydroxide (1.03 g, 25.8 mmol) was added. The mixture was reacted at 50° C. for 2 hours, extracted with dichloromethane (20 mL×2), washed with saturated saline (20 mL), dried over anhydrous sodium sulfate, and concentrated to give crude product 61D (0.5 g, 45.3% yield).
number
[0338] Step 4: Compound 1L (0.918 g, 2.33 mmol) and compound 61D (500 mg, 2.33 mmol) were dissolved in DMF (10 mL), and benzotriazole-N,N,N',N'-tetramethyluronium hexafluorophosphate (0.89 g, 2.33 mmol) and N,N-diisopropylethylamine (0.45 mg, 3.47 mmol) were added, and the mixture was reacted by stirring at room temperature for 1 h. After the reaction was completed, water (20 ml) and ethyl acetate (50 mL) were added, and the organic phase was separated, washed with water (20 mL x 2), washed with saturated saline (20 mL), dried over anhydrous sodium sulfate, and concentrated to obtain crude product 61E (1.0 g, 72.5%).
number
[0339] Step 5: Compound 61E (1.0 g, 1.7 mmol) was dissolved in dichloromethane (9 mL), trifluoroacetic acid (3 mL) was added, and the mixture was stirred at room temperature for 1 h to react. After the reaction was completed, the pH was adjusted to 7-8 with triethylamine, and the mixture was purified by C18 column chromatography (acetonitrile: 0.1% aqueous ammonia solution (v / v) = 40%) to obtain product 61F (300 mg, 36.1%).
number
[0340] Step 6: Compound 61F (100 mg, 0.2 mmol) and 2-(2,6-dioxopiperidin-3-yl)-5-fluoroisoindoline-1,3-dione (55 mg, 0.2 mmol) were added to dimethyl sulfoxide (3 mL), followed by N,N-diisopropylethylamine (52 mg, 0.4 mmol) and reacted at 100 ° C for 2 h. The mixture was directly separated and purified by liquid-phase separation column (liquid-phase separation conditions: C18 reverse phase preparation column, mobile phase was deionized water (A) containing 0.1% ammonium bicarbonate, acetonitrile (B), gradient elution, B content = 5% to 50%, elution time 15 min, flow rate 12 mL / min, column temperature: 30 ° C.), to obtain the title compound 61 (40 mg, yield 26.8%, retention time about 7.5 min). 1 H NMR(400MHz,DMSO-d6)δ 11.84(s,1H),11.06(s,1H),8.40(d,1H),8.26(s,1H),7.75(s,1H),7.72 - 7.61(m,2H),7.50 - 7.42(m,1H),7.42 - 7.21(m,3H),5.10 - 5.03(m,1H),4.26 - 3.96(m,3H),3.65(s,2H),3.33 - 3.31(m,4H),3.17 - 3.04(m,1H),2.94 - 2.76(m,5H),2.63 - 2.51(m,8H),2.06 - 1.98(m,1H),1.89 - 1.70(m,4H),1.20 - 1.16(m,3H).
number
[0341] Example 62: N-(1-(3-(2,4-dioxotetrahydropyrimidin-1(2H)-phenyl)piperidin-4-yl)-5-(4-((7-ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl)piperazin-1-yl)pyridine-2-formamide (Compound 62) [ka]
[0342] Step 1: Compound 4-aminopiperidine-1-carboxylic acid tert-butyl ester (10.0 g, 50 mmol) and 1-fluoro-3-nitrobenzene (7.05 g, 50 mmol) were dissolved in dimethyl sulfoxide (100 mL), N,N-diisopropylethylamine (12.9 g, 100 mmol) was added, and the mixture was reacted at 150° C. for 24 hours. Ethyl acetate (400 mL) was added, and the mixture was washed with water (100 mL×2), washed with saturated saline (100 mL), dried over anhydrous sodium sulfate, concentrated, and then purified by silica gel column chromatography (petroleum ether:ethyl acetate (v / v)=100:30) to obtain product 62B (6 g, yield 37.5%).
number
[0343] Step 2: Compound 62B (6 g, 18.7 mmol) was dissolved in methanol (60 mL), and palladium hydroxide carbon (1.2 g) was added. Hydrogen gas was then added and the mixture was reacted at 50° C. overnight. The mixture was filtered and concentrated to give crude product 62C (5.8 g, 100.0% yield).
number
[0344] Step 3: Compound 62C (4 g, 13.7 mmol) was dissolved in toluene (40 mL), acrylic acid (1.48 g, 20.6 mmol) was added, and the reaction was carried out at 100° C. overnight and used directly in the next step.
number
[0345] Step 4: Acetic acid (40 mL) was added to the reaction solution obtained in the previous step, followed by the addition of urea (1.2 g, 20.6 mmol), and the mixture was reacted at 100 °C overnight. The mixture was concentrated and then purified by silica gel column chromatography (petroleum ether:ethyl acetate (v / v) = 100:20) to obtain product 62E (0.4 g, two-step yield 7.5%).
number
[0346] Step 5: Compound 62E (0.4 g, 1.0 mmol) was dissolved in dichloromethane (9 mL), trifluoroacetic acid (3 mL) was added, and the mixture was stirred at room temperature for 1 h to react, and then concentrated to give product 62F (410 mg, 100.0%).
number
[0347] Step 6: Compound 1L (0.1 g, 0.25 mmol) and compound 62F (101 mg, 0.25 mmol) were dissolved in DMF (3 mL), and benzotriazole-N,N,N',N'-tetramethyluronium hexafluorophosphate (114 mg, 0.3 mmol) and N,N-diisopropylethylamine (65 mg, 0.5 mmol) were added, and the mixture was stirred at room temperature for 1 h to react. The mixture was then directly separated and purified by a liquid-phase separation column (liquid-phase separation conditions: C18 reversed-phase separation column, the mobile phase was deionized water (A) containing 0.1% ammonium bicarbonate, acetonitrile (B), gradient elution, B content = 5% to 50%, elution time 15 min, flow rate 12 mL / min, column temperature: 30 °C), to obtain the title compound 62 (30 mg, yield 18.1%, retention time about 7.1 min). 1H NMR(400MHz,DMSO-d6)δ11.84(s,1H),10.28(s,1H),8.41(d,1H),8.36 - 8.23(m,2H),7.85(d,1H),7.75(s,1H),7.63(s,1H),7.47 - 7.37(m,1H),7.25 - 7.12(m,1H),6.91(s,1H),6.84(d,1H),6.71(d,1H),4.01 - 3.85(m,1H),3.78 - 3.72(m,2H),3.71 - 3.64(m,4H),3.39 - 3.38(m,4H),2.89 - 2.76(m,2H),2.74 - 2.64(m,2H),2.59 - 2.52(m,6H),1.92 - 1.81(m,2H),1.80 - 1.66(m,2H),1.22 - 1.14(m,3H).
number
[0348] Example 63: N-(1-(3-(2,4-dioxotrihydropyridine-1(2H)-phenyl)piperidin-4-yl)-1'-(7-ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl)-1',2',3',6'-tetrahydro-[3,4'-bipyridine]-6-formamide (Compound 63) [ka]
[0349] Step 1: Compound 49E (0.1 g, 0.27 mmol) and 62F (108 mg, 0.27 mmol) were dissolved in DMF (3 mL), and benzotriazole-N,N,N',N'-tetramethyluronium hexafluorophosphate (103 mg, 0.27 mmol) and N,N-diisopropylethylamine (70 mg, 0.54 mmol) were added, and the mixture was reacted at room temperature with stirring for 1 h. The mixture was then directly separated and purified by a liquid-phase separation column (liquid-phase separation conditions: C18 reversed-phase separation column, the mobile phase was deionized water (A) containing 0.1% ammonium bicarbonate, acetonitrile (B), gradient elution, B content = 5% to 50%, elution time 15 min, flow rate 12 mL / min, column temperature: 30 °C, and the title compound 63 (35 mg, yield 19.6%, retention time about 7.3 min) was obtained. 1 H NMR(400MHz,DMSO-d6)δ12.17(s,1H),10.28(s,1H),8.74(s,1H),8.64 - 8.54(m,2H),8.10 - 8.02(m,2H),7.81(s,2H),7.26 - 7.21(m,1H),6.94(s,1H),6.87(d,1H),6.74(d,1H),6.41(s,1H),4.59(s,2H),4.05 - 3.97(m,1H),3.91(s,2H),3.79 - 3.65(m,5H),3.43 - 3.26(m,1H),2.92 - 2.79(m,4H),2.72 - 2.66(m,2H),2.61 - 2.55(m,2H),1.93 - 1.74(m,4H),1.24 - 1.15(m,3H).
number
[0350] Example 64: N-(1-(3-(2,4-dioxotetrahydropyrimidin-1(2H)-phenyl)piperidin-4-yl)-5-(4-((7-ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl)piperazin-1-yl)pyridine-2-formamide (Compound 64) [ka]
[0351] Step 1: Compound 62C (1.0 g, 3.44 mmol) and 3-bromopiperidine-2,6-dione (0.65 g, 3.44 mmol) were dissolved in DMF (10 mL), sodium bicarbonate (0.86 g, 10.32 mmol) was added, and the mixture was reacted at 80° C. for 24 hours. Ethyl acetate (50 mL) was added, and the mixture was washed with water (20 mL×2), washed with saturated saline (10 mL), dried over anhydrous sodium sulfate, and concentrated. The mixture was then purified by silica gel column chromatography (petroleum ether:ethyl acetate (v / v)=100:20) to obtain product 64A (350 mg, yield 25.3%).
number
[0352] Step 2: Compound 64A (0.35 g, 0.9 mmol) was dissolved in hydrogen chloride-dioxane (3 mL), reacted at room temperature for 1 hour, and concentrated to give crude product 64B (0.3 g, 100.0% yield).
number
[0353] Step 3: Compound 1L (0.1 g, 0.25 mmol) and compound 64B (90 mg, 0.25 mmol) were dissolved in DMF (3 mL), and benzotriazole-N,N,N',N'-tetramethyluronium hexafluorophosphate (114 mg, 0.3 mmol) and N,N-diisopropylethylamine (65 mg, 0.5 mmol) were added. The mixture was stirred at room temperature for 1 h and reacted. The mixture was then directly separated and purified by a liquid-phase separation column (liquid-phase separation conditions: C18 reversed-phase separation column, the mobile phase was deionized water (A) containing 0.1% ammonium bicarbonate, acetonitrile (B), gradient elution, B content = 5% to 50%, elution time 15 min, flow rate 12 mL / min, column temperature: 30 °C), to obtain the title compound 64 (35 mg, yield 20.7%, retention time about 7.3 min). 1 H NMR(400MHz,DMSO-d6)δ11.82(s,1H),10.73(s,1H),8.40(d,1H),8.33 - 8.16(m,2H),7.85(d,1H),7.75(s,1H),7.63(s,1H),7.42 - 7.30(m,1H),6.96 - 6.84(m,1H),6.29(s,1H),6.21(d,1H),6.14(d,1H),5.59(d,1H),4.37 - 4.25(m,1H),4.00 - 3.85(m,1H),3.64(s,2H),3.60(d,2H),3.38 - 3.31(m,4H),2.80 - 2.67(m,3H),2.65 - 2.52(m,7H),2.16 - 2.04(m,1H),1.90 - 1.66(m,5H),1.20 - 1.15(m,3H).
number
[0354] Example 65: N-(1-(3-((2,6-dioxopiperidin-3-yl)amino)phenyl)piperidin-4-yl)-1'-(7-ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl)-1',2',3',6'-tetrahydro-[3,4'-bipyridine]-6-formamide (Compound 65) [ka]
[0355] Step 1: Compound 49E (0.1 g, 0.27 mmol) and 64B (91 mg, 0.27 mmol) were dissolved in DMF (3 mL), and benzotriazole-N,N,N',N'-tetramethyluronium hexafluorophosphate (103 mg, 0.27 mmol) and N,N-diisopropylethylamine (70 mg, 0.54 mmol) were added. The mixture was stirred at room temperature for 1 h and reacted. The mixture was then directly separated and purified by liquid-phase separation column (liquid-phase separation conditions: C18 reversed-phase separation column, mobile phase: deionized water (A) containing 0.1% ammonium bicarbonate, acetonitrile (B), gradient elution, B content = 5% to 50%, elution time 15 min, flow rate 12 mL / min, column temperature: 30 °C) to obtain the title compound 65 (35 mg, yield 19.2%, retention time about 7.2 min). 1 H NMR(400MHz,DMSO-d6)δ11.82(s,1H),10.74(s,1H),8.70(s,1H),8.56(d,1H),8.41(d,1H),8.05 - 7.96(m,2H),7.75(s,1H),7.65(s,1H),6.97 - 6.84(m,1H),6.42(s,1H),6.30(s,1H),6.22(d,1H),6.13(d,1H),5.60(d,1H),4.37 - 4.27(m,1H),4.05 - 3.87(m,1H),3.72(s,2H),3.62(d,2H),3.22 - 3.12(m,2H),2.82 - 2.65(m,5H),2.63 - 2.52(m,5H),2.16 - 2.05(m,1H),1.91 - 1.68(m,5H),1.21 - 1.15(m,3H).
number
[0356] Example 66: N-((1r,4r)-4-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)cyclohexyl)-5-(4-((7-ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl)piperazin-1-yl)pyridine-2-formamide (Compound 66) [ka]
[0357] Step 1: Under the protection of nitrogen gas, compound 66A (1.0 g, 4.64 mmol) and compound 4-hydroxythalidomide (1.27 g, 0.64 mmol) were dissolved in dry tetrahydrofuran (20 ml), cooled to 0°C, triphenylphosphine (1.83 g, 6.98 mmol) was added, and after completion, the temperature was controlled at 0°C, diethyl azodicarboxylate (1.29 g, 7.42 mmol) was added dropwise, and after completion of the dropwise addition, the temperature was returned to room temperature, and 3 After reacting for 0 min, the mixture was heated to 60°C and reacted for 15 hours. After the reaction was completed, water (50 ml) was added to quench the reaction, and the mixture was extracted twice with ethyl acetate (50 ml x 2). The organic phases were combined, washed with saturated saline, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated. The residue was then separated and purified by silica gel column chromatography (petroleum ether:ethyl acetate (v / v) = 4:1) to obtain the title compound 66B (0.82 g, 37.5%).
[0358] Step 2: Compound 66B (0.82 g, 1.74 mmol) was dissolved in dichloromethane (10 mL), trifluoroacetic acid (3 mL) was added, and the mixture was reacted at room temperature for 30 min. After completion of the reaction, the mixture was directly concentrated to give the trifluoroacetate salt of compound 66C (0.84 g, 99%).
[0359] Step 3: Under the protection of nitrogen gas, compound 66C (0.13g, 0.33mmol) was dissolved in N,N-dimethylformamide (5ml), cooled to 0℃, and compound 1L (0.16g, 0.33mmol), N,N-diisopropylethylamine (0.17g, 1.32mmol), 2-(7-azabenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (0.15g, 0.40mmol) were added, and the temperature was raised to 25℃ after completion and reacted for 1 hour. After the reaction was completed, the reaction liquid was put into water (20ml) and extracted with dichloromethane (50mL×3). The organic phase was combined, washed with saturated saline, dried with anhydrous sodium sulfate, filtered, the filtrate was concentrated, and the concentrated residue was separated and purified. Separation method by preparative HPLC: 1. Equipment: waters 2767 preparative liquid, chromatography column: SunFire@ Prep C18 (19mm x 250mm). 2. The sample was filtered through a 0.45μm filter to prepare the sample solution. 3. Conditions for preparative chromatography: a. Composition of mobile phases A and B: Mobile phase A: acetonitrile, Mobile phase B: water (containing 0.1% TFA). b. Gradient elution, content of mobile phase A is 5%-50%. c. Flow rate is 12mL / min. d Elution time is 20min. Retention time is 8.8min, and compound 66 (75mg, 30.4%) was obtained. 1 H NMR(400MHz,DMSO-d6)δ 11.83(s,1H),11.09(s,1H),8.40(s,1H),8.28(d,1H),8.16(d,1H),7.84(d,2H), 7.75(s,1H),7.63(s,1H),7.49(d,1H),7.43-7.39(m,2H),5.13-5.09(m,1H),4.9 0-4.88(m,1H),3.93-3.89(m,1H),3.66(s,2H),3.46-3.42(m,4H),2.92-2.86(m, 1H),2.62-2.53(m,8H),2.03-1.93(m,3H),1.80-1.66(m,6H),1.20-1.17(m,3H).
number
[0360] Example 67: N-((1s,4s)-4-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)cyclohexyl)-5-(4-((7-ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl)piperazin-1-yl)pyridine-2-formamide (Compound 67) [ka]
[0361] Step 1: Under the protection of nitrogen gas, compound 67A (1.0 g, 4.64 mmol) and 4-hydroxythalidomide (1.27 g, 0.64 mmol) were dissolved in dry tetrahydrofuran (20 ml), cooled to 0°C, triphenylphosphine (1.83 g, 6.98 mmol) was added, and after completion, the temperature was controlled at 0°C, and diethyl azodicarboxylate (1.29 g, 7.42 mmol) was added dropwise, and after completion of the dropwise addition, the temperature was returned to room temperature and 30 ml was added. After reacting in, the mixture was heated to 60°C and reacted for 15 hours. After the reaction was completed, water (50ml) was added to quench the reaction, and the mixture was extracted twice with ethyl acetate (50ml x 2). The organic phases were combined, washed with saturated saline, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated. The residue was then separated and purified by silica gel column chromatography (petroleum ether:ethyl acetate (v / v) = 4:1) to obtain the title compound 67B (0.52g, 23.8%).
[0362] Step 2: Compound 67B (0.52 g, 1.1 mmol) was dissolved in dichloromethane (10 mL), trifluoroacetic acid (3 mL) was added, and the mixture was reacted at room temperature for 30 min. After completion of the reaction, the mixture was directly concentrated to give the trifluoroacetate salt of compound 67C (0.52 g, 97%).
[0363] Step 3: Under the protection of nitrogen gas, compound 67C (0.13g, 0.33mmol) was dissolved in N,N-dimethylformamide (5ml), cooled to 0℃, and compound 1L (0.16g, 0.33mmol), N,N-diisopropylethylamine (0.17g, 1.32mmol), 2-(7-azabenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (0.15g, 0.40mmol) were added, and the temperature was raised to 25℃ after completion and reacted for 1 hour. After the reaction was completed, the reaction liquid was put into water (20ml) and extracted with dichloromethane (50mL×3). The organic phase was combined, washed with saturated saline, dried with anhydrous sodium sulfate, filtered, the filtrate was concentrated, and the concentrated residue was separated and purified. Separation method by preparative HPLC: 1. Equipment: waters 2767 preparative liquid, chromatography column: SunFire@ Prep C18 (19mm x 250mm). 2. The sample was filtered through a 0.45μm filter to prepare the sample solution. 3. Conditions for preparative chromatography: a. Composition of mobile phases A and B: Mobile phase A: acetonitrile, Mobile phase B: water (containing 0.1% TFA). b. Gradient elution, with the content of mobile phase A being 5%-50%. c. Flow rate is 12mL / min. d. Elution time is 20min. Retention time is 8.6min, and compound 67 (40mg, 16.2%) was obtained. 1 H NMR(400MHz,DMSO-d6)δ 11.83(s,1H),11.09(s,1H),8.40(s,1H),8.28(d,1H),8.14(d,1H),7.86-7.81(m, 2H),7.75(s,1H),7.63(s,1H),7.45(d,1H),7.42-7.35(m,2H),5.14-5.09(m,1H), 4.65-4.62(m,1H),3.87-3.83(m,1H),3.66(s,2H),3.38-3.33(m,4H),2.94-2.86( m,1H),2.62-2.50(m,8H),2.14-1.90(m,5H),1.67-1.51(m,4H),1.20-1.17(m,3H).
number
[0364] Example 68: 1-(1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperidin-4-yl)-N-(5-(4-((7-ethyl))-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl)piperazin-1-yl)pyridin-2-yl)-1H-pyrazole-4-formamide (Compound 68) [ka]
[0365] Step 1: Compound 68A (0.5 g, 3.54 mmol) and 1-Boc-4-methanesulfonyloxypiperidine (0.99 g, 3.54 mmol) were dissolved in DMF (10 mL), and cesium carbonate (2.31 g, 7.08 mmol) was added. The temperature was raised to 90 ° C. and the mixture was reacted overnight. After the reaction was completed, ethyl acetate (50 ml) was added to dilute the reaction system, and the organic phase was washed with water (10 ml). The organic phase was dried over anhydrous sodium sulfate and filtered. The residue after filtration and concentration was quickly separated and purified by column chromatography (eluent ratio: MeOH:DCM = 0% ~ 10%) to obtain compound 68B (0.9 g, 79%).
number
[0366] Step 2: Compound 68B (0.9 g, 2.78 mmol) was dissolved in methanol (3 mL) and tetrahydrofuran (3 mL), lithium hydroxide (0.27 g, 11.29 mmol) was added, and the mixture was heated to 60° C. and reacted for 2 h. The mixture was cooled to room temperature and the pH was adjusted to 4 with 1 M HCl. A white solid precipitated and was filtered to obtain 68C (0.7 g, 85%) as a white solid.
number
[0367] Step 3: Compound 68C (0.4 g, 1.35 mmol) and 46D (0.59 g, 1.62 mmol) were dissolved in DMF (5 mL), then 2-(7-azabenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (0.62 g, 1.62 mmol) and N,N-diisopropylethylamine (0.52 g, 4.05 mmol) were added and reacted at room temperature overnight. After the reaction was completed, ethyl acetate (30 ml) was added to dilute the reaction system, the organic phase was washed with water (10 ml), the organic phase was dried over anhydrous sodium sulfate, filtered, and the residue after filtration and concentration was quickly separated and purified by column chromatography (eluent ratio: MeOH:DCM = 0% to 10%) to obtain compound 68D (0.2 g, 23%).
number
[0368] Step 4: Compound 68D (0.2 g, 0.31 mmol) was dissolved in trifluoroacetic acid (0.6 mL) and dichloromethane (1.8 mL) and reacted at room temperature for 2 h. After the reaction was completed, the mixture was directly concentrated to give crude compound 68E (0.15 g).
number
[0369] Step 5: Under the protection of nitrogen gas, compound 68E (0.15 g, 0.28 mmol) and 2-(2,6-dioxo-piperidin-3-yl)-5-fluoro-isoindoline-1,3-dione (0.077 g, 0.28 mmol) were dissolved in dimethyl sulfoxide (5 mL), heated to 100 ° C, and reacted for 2 h. The reaction was monitored by LCMS, and the reaction system was directly separated after the reaction was completed, and the separation was performed by preparative HPLC separation method: 1. Equipment: waters 2767 separation liquid, chromatography column: SunFire@ Prep C18 (19 mm × 250 mm). 2. The sample was filtered through a 0.45 μm filter to prepare the sample solution. 3. Preparative chromatography conditions: a. Composition of mobile phases A and B: Mobile phase A: acetonitrile, mobile phase B: water (containing 0.1% ammonium acetate). b. Gradient elution, the content of mobile phase A is 10%-55%. c. Flow rate is 12 mL / min. d. Elution time is 20 min. Retention time is 7.0 min, and compound 68 (50 mg, 22%) was obtained.
number
[0370] Example 69 N-(1-(5-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)pyrimidin-2-yl)piperidin-4-yl)-5-(4-((7-ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl)piperazin-1-yl)pyridine-2-formamide (Compound 69) [ka]
[0371] Step 1: 69A (5 g, 31.34 mmol), piperidin-4-yl carbamate tert-butyl ester (7.5 g, 37.5 mmol) was dissolved in DMF (50 mL), triethylamine (9.5 g, 93.88 mmol) was added, and the reaction was allowed to proceed overnight at room temperature. After completion of the reaction was monitored by TLC, water (200 mL) was added, filtered and dried to give the title compound 69B (10 g, 98.7%).
number
[0372] Step 2: 69B (10 g, 0.25 mmol) was added to methanol (10 mL), palladium on carbon (5 g) was added, and the reaction was stirred under H2 environment for 12 h, after which it was filtered and spin-dried to give the title compound 69C (8 g, 88.2%).
number
[0373] Step 3: 69C (3 g, 10.23 mmol) and acrylic acid (1.47 g, 20.45 mmol) were added to toluene (30 mL) and reacted overnight at 100 °C under nitrogen gas protection, and the system was spun dry to give crude 69D, which was used directly in the next step reaction.
number
[0374] Step 4: 69D and urea (614 mg, 10.24 mmol) were added to acetic acid (30 mL), the reaction was stirred at 100° C. overnight, and it was concentrated, separated and purified by reverse phase column to give the title compound 69E (180 mg, 6.1% yield for two steps).
number
[0375] Step 5: 69E (180 mg, 0.62 mmol), 1L (244 mg, 0.62 mmol), HATU (236 mg, 0.62 mmol) and DIPEA (400 mg, 3.10 mmol) were added to DMF (5 mL), stirred at room temperature for 2 h, and then sent to HPLC for separation. Separation method by preparative HPLC: 1. Equipment: waters 2767 preparative liquid, chromatography column: SunFire@ Prep C18 (19 mm x 250 mm). 2. The sample was filtered through a 0.45 μm filter to prepare the sample liquid. 3. Preparative chromatography conditions: a. Composition of mobile phase A and B: Mobile phase A: acetonitrile, mobile phase B: water (containing 0.1% TFA). b. Gradient elution, the content of mobile phase A is 5%-50%. c. Flow rate is 12 mL / min. d Elution time is 20 min. The pH of the fraction was adjusted to 7-8 by adding sodium bicarbonate, and the fraction was extracted with dichloromethane and concentrated to give compound 69 (130 mg, 31.5%). 1H NMR(400MHz,DMSO-d6)δ 11.83(s,1H),10.42(s,1H),8.40(d,1H),8.34(s,2H),8.29 - 8.22(m,2H),7.85(d,1H),7.75(s,1H),7.62(s,1H),7.40(dd,1H),4.70 - 4.56(m,2H),4.15 - 3.96(m,1H),3.72(t,2H),3.65(s,2H),3.37 - 3.32(m,4H),3.05(t,2H),2.71(t,2H),2.60 - 2.52(m,6H),1.89 - 1.77(m,2H),1.65 - 1.49(m,2H),1.18(t,3H).
number
[0376] Example 70 N-(1-(3-((2,6-dioxopiperidin-3-yl)amino)phenyl)piperidin-4-yl)-6-fluoro-5-(4-((5-fluoro-2-methyl-3-oxo-3,4-dihydroquinolin-6-yl)methyl)piperazin-1-yl)pyridine-2-formamide (Compound 70) [ka]
[0377] Step 1: Compound 70A (2.0 g, 9.6 mmol) was dissolved in anhydrous dichloromethane (10 mL), triphenylphosphine (7.5 g, 28.8 mmol) was added, and a solution of carbon tetrabromide (9.5 g, 28.8 mmol) in anhydrous dichloromethane (5 mL) was added at 0° C., and the mixture was reacted at room temperature for 30 min. After filtration, the filter cake was dried to obtain product 70B (1.8 g, yield 69.2%).
number
[0378] Step 2: Compound 70B (1.8 g, 6.67 mmol) was dissolved in acetonitrile (15 mL), and 6-fluoro-5-(piperazin-1-yl)pyridine carboxylate methyl salt (1.83 g, 6.67 mmol), potassium iodide (180 mg) and N,N-diisopropylethylamine (4.3 g, 33.35 mmol) were added, reacted at 50° C. for 3 hours, filtered, and the filter cake was dried to obtain crude product 70C (2.4 g, yield 85.6%).
number
[0379] Step 3: Compound 70C (2.4 g, 5.6 mmol) was dissolved in methanol (24 mL), water (24 mL) and lithium hydroxide (1.2 g, 28 mmol) were added, and the mixture was reacted at room temperature for 1 hour. The mixture was then adjusted to pH=3-4 with 6N hydrochloric acid, filtered, and the filter cake was dried to obtain crude product 70D (2.1 g, yield 91.2%).
number
[0380] Step 4: Compound 70D (0.1 g, 0.24 mmol) and compound 64B (81 mg, 0.24 mmol) were dissolved in DMF (3 mL), and benzotriazole-N,N,N',N'-tetramethyluronium hexafluorophosphate (114 mg, 0.3 mmol) and N,N-diisopropylethylamine (65 mg, 0.5 mmol) were added, and the mixture was reacted at room temperature for 1 h by stirring. The mixture was then directly separated and purified by a liquid-phase separation column (liquid-phase separation conditions: C18 reversed-phase separation column, the mobile phase was deionized water (A) containing 0.1% ammonium bicarbonate, acetonitrile (B), gradient elution, B content = 5% to 50%, elution time 15 min, flow rate 12 mL / min, column temperature: 30 °C, and the title compound 70 (35 mg, yield 20.8%, retention time about 7.5 min) was obtained. 1H NMR(400MHz,DMSO-d6)δ12.42(s,1H),10.74(s,1H),8.23(d,1H),7.85(d,1H),7.59 - 7.41(m,2H),7.34 - 7.25(m,1H),6.93 - 6.86(m,1H),6.29(s,1H),6.21(d,1H),6.14 - 6.08(m,1H),5.60(d,1H),4.40 - 4.22(m,1H),3.95 - 3.81(m,1H),3.70(s,2H),3.62(d,2H),3.23 - 3.10(m,4H),2.78 - 2.67(m,3H),2.63 - 2.53(m,5H),2.41(s,3H),2.14 - 2.06(m,1H),1.90 - 1.68(m,5H).
number
[0381] Example 71 N-(1-(3-(2,4-dioxotetrahydropyrimidin-1(2H)-phenyl)piperidin-4-yl)-6-fluoro-5-(4-((5-fluoro-2-methyl-3-oxo-3,4-dihydroquinolin-6-yl)methyl)piperazin-1-yl)pyridine-2-formamide (Compound 71) [ka]
[0382] Step 1: Compound 70D (0.1 g, 0.24 mmol) and compound 62F (92 mg, 0.24 mmol) were dissolved in DMF (3 mL), and benzotriazole-N,N,N',N'-tetramethyluronium hexafluorophosphate (114 mg, 0.3 mmol) and N,N-diisopropylethylamine (65 mg, 0.5 mmol) were added. The mixture was stirred at room temperature for 1 h and reacted. The mixture was then directly separated and purified by a liquid-phase separation column (liquid-phase separation conditions: C18 reversed-phase separation column, the mobile phase was deionized water (A) containing 0.1% ammonium bicarbonate, acetonitrile (B), gradient elution, B content = 5% to 50%, elution time 15 min, flow rate 12 mL / min, column temperature: 30 °C), to obtain the title compound 71 (35 mg, yield 21.2%, retention time about 7.6 min). 1 H NMR(400MHz,DMSO-d6)δ12.34(s,1H),10.26(s,1H),8.24(d,1H),8.00 - 7.79(m,1H),7.68 - 7.48(m,2H),7.38 - 7.15(m,2H),6.90(s,1H),6.87 - 6.78(m,1H),6.75 - 6.62(m,1H),4.02 - 3.87(m,1H),3.79 - 3.66(m,6H),3.21 - 3.10(m,4H),2.85 - 2.72(m,2H),2.71 - 2.65(m,2H),2.64 - 2.55(m,4H),2.41(s,3H),1.86 - 1.71(m,4H).
number
[0383] Example 72 N-(1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperidin-4-yl)-6-fluoro-5-(4-((5-fluoro-2-methyl-3-oxo-3,4-dihydroquinolin-6-yl)methyl)piperazin-1-yl)pyridine-2-formamide (Compound 72) [ka]
[0384] Step 1: Compound 70D (0.1 g, 0.24 mmol) and compound 49C (109 mg, 0.24 mmol) were dissolved in DMF (3 mL), and benzotriazole-N,N,N',N'-tetramethyluronium hexafluorophosphate (114 mg, 0.3 mmol) and N,N-diisopropylethylamine (65 mg, 0.5 mmol) were added, and the mixture was stirred at room temperature for 1 h to react. The mixture was then directly separated and purified by a liquid-phase separation column (liquid-phase separation conditions: C18 reverse phase separation column, the mobile phase was deionized water (A) containing 0.1% ammonium bicarbonate, acetonitrile (B), gradient elution, B content = 5% to 50%, elution time 15 min, flow rate 12 mL / min, column temperature: 30 °C, and the title compound 72 (40 mg, yield 22.2%, retention time about 7.1 min) was obtained. 1 H NMR(400MHz,DMSO-d6)δ 12.43(s,1H),11.06(s,1H),8.28(d,1H),7.85(d,1H),7.67(d,1H),7.62 - 7.45(m,2H),7.34(s,1H),7.31 - 7.21(m,2H),5.16 - 5.00(m,1H),4.08(d,3H),3.69(s,2H),3.19 - 3.03(m,6H),2.93 - 2.83(m,1H),2.66 - 2.54(m,6H),2.41(s,3H),2.07 - 1.97(m,1H),1.86 - 1.64(m,4H).
number
[0385] Example 73 N-(1-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxoisoindolin-5-yl)piperidin-4-yl)-6-fluoro-5-(4-((5-fluoro-2-methyl-3-oxo-3,4-dihydroquinolin-6-yl)methyl)piperazin-1-yl)pyridine-2-formamide (Compound 73) [ka]
[0386] Step 1: Compound 70D (0.1 g, 0.24 mmol) and compound 50B (113 mg, 0.24 mmol) were dissolved in DMF (3 mL), and benzotriazole-N,N,N',N'-tetramethyluronium hexafluorophosphate (114 mg, 0.3 mmol) and N,N-diisopropylethylamine (65 mg, 0.5 mmol) were added. The mixture was stirred at room temperature for 1 h to react, and then separated and purified directly by liquid-phase separation column (liquid-phase separation conditions: C18 reversed-phase separation column, mobile phase: deionized water (A) containing 0.1% ammonium bicarbonate, acetonitrile (B), gradient elution, B content = 5% to 50%, elution time 15 min, flow rate 12 mL / min, column temperature: 30 °C), to obtain the title compound 73 (45 mg, yield 24.3%, retention time about 7.2 min). 1 H NMR(400MHz,DMSO-d6)δ 12.41(s,1H),11.08(s,1H),8.31(d,1H),7.86(d,1H),7.71(d,1H),7.60 - 7.52(m,1H),7.48(d,2H),7.28 - 7.17(m,1H),5.14 - 5.07(m,1H),4.06 - 3.94(m,1H),3.74 - 3.55(m,4H),3.23 - 3.11(m,4H),3.10 - 2.96(m,2H),2.94 - 2.82(m,1H),2.67 - 2.52(m,6H),2.40(s,3H),2.10 - 1.98(m,1H),1.94 - 1.75(m,4H).
number
[0387] Example 74: N-(1-(4-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)phenyl)piperidin-4-yl)-6-fluoro-5-(4-((5-fluoro-2-methyl-)3-oxo-3,4-dihydroquinoxalin-6-yl)methyl)piperazin-1-yl)pyridine-2-formamide (Compound 74) [ka]
[0388] Step 1: 74A (20 g, 0.1 mol) was dissolved in N-methylpyrrolidone (250 ml), 1-fluoro-4-nitrobenzene (16.93 g, 0.2 mol) and potassium carbonate (13.82 g, 0.3 mol) were added, and the mixture was reacted for 3 h in an oil bath at 80 ° C. After the reaction was completed, the mixture was cooled to room temperature, water (700 ml) was added to quench the reaction, the aqueous phase was extracted with ethyl acetate (500 ml × 2), the organic phase was combined, dried over anhydrous sodium sulfate, and concentrated to obtain crude compound 74B (30 g).
number
[0389] Step 2: Crude compound 74B (30 g) from the previous step was dissolved in methanol (300 ml) and 10% Pd / C (3 g) was added, hydrogen gas was replaced three times, and the reaction was carried out for 16 h in a hydrogen gas atmosphere at 60° C. After the reaction was completed, the mixture was cooled to room temperature and filtered, and the filtrate was collected, spin-dried, and concentrated to give crude compound 74C (25 g).
number
[0390] Step 3: Compound 74C (5 g, 17.18 mmol) was dissolved in toluene (70 ml), and allyl alcohol (1.86 g, 25.77 mmol) was added and reacted for 15 h in an oil bath pot at 110° C. After the reaction was completed, the mixture was directly spin-dried and concentrated to obtain crude compound 74D (7 g).
number
[0391] Step 4: Crude compound 74D (7 g) from the previous step was dissolved in acetic acid / toluene (30 ml / 30 ml), urea (5.16 g, 85.9 mmol) was added, and the mixture was reacted in an oil bath at 110 °C for 15 h. After the reaction was completed, the mixture was directly spun and concentrated, and the residue was quickly separated and purified by column chromatography (eluent ratio: EA / PE = 0% to 20%) to give compound 74E (2.75 g, 41% yield for two steps).
number
[0392] Step 5: Compound 74E (2.75 g, 7.08 mmol) was placed in a flask, dichloromethane (15 ml) / trifluoroacetic acid (5 ml) was added, and the mixture was reacted at room temperature for 2 hours. After the reaction was completed, the pH was adjusted to alkaline with a saturated aqueous solution of sodium bicarbonate, and the aqueous phase was extracted with dichloromethane / methanol = 10 / 1. The organic phases were combined, dried over anhydrous sodium sulfate, and concentrated to obtain crude compound 74F (1.91 g).
number
[0393] Step 6: 70D (150 mg, 0.36 mmol) was dissolved in N,N-dimethylformamide (2 ml), and compound 74F (134 mg, 0.36 mmol), 2-(7-azabenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (2744 mg, 0.72 mmol) and N,N-diisopropylethylamine (141 mg, 1.08 mmol) were added to the reaction system, and the reaction was allowed to proceed overnight at room temperature. The reaction was monitored by LCMS, and the reaction system was directly separated after the reaction was completed. Separation HPLC separation method: 1. Equipment: waters 2767 separation liquid, chromatography column: SunFire@ Prep C18 (19 mm x 250 mm). 2. The sample was filtered through a 0.45 μm filter to prepare the sample solution. 3. Conditions for preparative chromatography: a. Composition of mobile phase A and B: Mobile phase A: acetonitrile, Mobile phase B: water (containing 0.1% ammonium acetate). b. Gradient elution, content of mobile phase A is 10%-55%. c. Flow rate is 12 mL / min. Retention time is 7.0 min, and compound 74 (95 mg, 39%) is obtained.
number
[0394] Example 75 N-(1-(2-(2,6-dioxopiperidin-3-yl)-1-oxyisoindolin-5-yl)piperidin-4-yl)-6-fluoro-5-(4-((5-fluoro-2-methyl-3-oxo-3,4-dihydroquinolin-6-yl)methyl)piperazin-1-yl)pyridine-2-formamide (Compound 75) [ka]
[0395] Step 1: 31I (180 mg, 0.53 mmol), 70D (218 mg, 0.53 mmol), HATU (200 mg, 0.53 mmol) and DIPEA (339 mg, 2.63 mmol) were added to DMF (5 mL), stirred at room temperature for 2 h, and then sent to HPLC for separation. Separation method by preparative HPLC: 1. Equipment: waters 2767 preparative liquid, chromatography column: SunFire@ Prep C18 (19 mm × 250 mm). 2. The sample was filtered through a 0.45 μm filter to prepare the sample liquid. 3. Preparative chromatography conditions: a. Composition of mobile phase A and B: Mobile phase A: acetonitrile, mobile phase B: water (containing 0.1% TFA). b. Gradient elution, the content of mobile phase A is 5% to 50%. c. Flow rate is 12 mL / min. d Elution time is 20 min. The pH of the fraction was adjusted to 7-8 by adding sodium bicarbonate, and the fraction was extracted with dichloromethane and then concentrated to give compound 75 (70 mg, 18.0%). 1 H NMR(400MHz,DMSO-d6)δ 10.67(s,1H),8.25(d,1H),7.88 - 7.82(m,1H),7.56 - 7.44(m,3H),7.24(t,1H),7.06(d,1H),7.01(s,1H),5.30(s,2H),4.57(dd,1H),4.09 - 3.96(m,1H),3.69(s,2H),3.25 - 3.13(m,6H),2.95(t,2H),2.65 - 2.56(m,4H),2.41(s,3H),2.11 - 1.90(m,4H),1.89 - 1.66(m,4H).
number
[0396] Biological Test Examples 1. MDA-MB-436 cell activity test experiment Breast cancer cells MDA-MB-436 were purchased from ATCC, and cultured in a medium of Leibovitz's L-15 + 10% FBS at 37 °C in a CO2-free incubator. On the first day, exponentially growing cells were collected, and the cell suspension was adjusted to 4000 cells / 135 μL using the medium. The cell suspension was added to a 96-well cell culture plate at 135 μL per well and incubated overnight. The next day, different concentrations of compounds were added, and the cells were placed in an incubator and incubated for 7 days. After the culture was completed, 75 μL of CTG solution that had been dissolved and equilibrated to room temperature was added per well according to the instructions of the CellTiter-Glo kit (Promega, G7573), mixed uniformly for 2 minutes on a microwell plate shaker, and left at room temperature for 10 minutes, after which the fluorescence signal value was measured using an Envision2104 plate reader (PerkinElmer). The inhibition rate was calculated using the formula (1), where RLU is the ratio of RLU to the inhibition rate. compound is the reading of the drug-treated group, and RLU control is the mean value of the vehicle control group, RLU blank The IC was calculated using GraphPad Prism (SoftBank). 50 values were calculated.
number
[0397] Results: The compounds of the present invention have a significant inhibitory effect on breast cancer cells MDA-MB-436, and IC 50 IC values are less than 100 nM and 50 IC values are less than 50 nM and 50 Values are less than 20 nM and optimal IC 50 The value is less than 10 nM. The maximum inhibition rate of breast cancer cells MDA-MB-436 at 10 μM reaches 70% or more, even 80% or more, even 90%, and optimally 95% or more. Here, the results of some examples are shown in Table 1.
[0398] [Table 2]
[0399] Conclusion: The compounds of the present invention have good inhibitory activity.
[0400] 2. PARP1, PARP2 and PARP7 enzyme activity inhibition experiment PARP1, PARP2 and PARP7 chemiluminescence detection kits were all purchased from BPS Bioscience. The histone solution in the kit was diluted 5-fold with 1×PBS, 25 μL of the histone dilution was taken and placed in a microwell plate and incubated at 4°C overnight. After the incubation was completed, the plate was washed three times with PBST (0.05% Tween-20), 25 μL of the mounting solution was taken and placed in a microwell plate and incubated at 25°C for 90 minutes, and after the incubation was completed, the plate was washed three times with PBST. A mixed solution of 2.5 μL of compounds at different concentrations diluted with test buffer and 5 μL of 2.5× substrate was placed in the microwell plate. PARP1, PARP2 and PARP7 enzymes were diluted to 0.33, 0.23 and 5.00 ng / μL, respectively, 5 μL was taken and placed in a microwell plate, and the reaction system was incubated at 25°C for 60 minutes. After the incubation was completed, the plate was washed three times with PBST. Streptavidin-HRP was diluted 2000-fold with the mounting solution, and 25 μL was taken and placed in a microwell plate and incubated at 25° C. for 30 minutes. After the incubation, the plate was washed three times with PBST, and ELISA ECL substrate A and substrate B were mixed uniformly at 1:1 (v / v), and 25 μL was taken and placed in a microwell plate, and the chemiluminescence value was read using a BMG microplate reader.
[0401] formula
number
[0402] [Table 3]
[0403] Conclusion: Compound 10 of the present invention showed much weaker inhibitory effects on PARP2 and PARP7 enzyme activities than on PARP1 in vitro, demonstrating good selectivity for inhibiting PARP1.
[0404] 3. Detection of PARP1 protein expression level in MDA-MB-231 cells MDA-MB-231 cells were placed in DMEM complete medium (supplemented with 10% FBS and 1% dual antibodies) and incubated for 37 o C, 5% CO2. Cells in the logarithmic growth phase were harvested and cultured at a cell density of 5 × 10 5The cells were adjusted to 1000 / well and added to a 6-well cell culture plate at a volume of 1mL / well. The compounds to be detected were adjusted to twice the final concentration, and 1mL of compounds at different concentrations was added to the treatment wells, and 0.2% DMSO-containing medium was added to the control wells, and incubated at 37°C and 5% CO2 for 24 hours. The cells were collected in a 1.5mL centrifuge tube, and 25μL of RIPA lysis solution (containing 1X protease inhibitor mixture) was added and dissolved on ice for 15 minutes, then centrifuged at 12000 rpm and 4°C for 10 minutes, the supernatant was collected, and the protein content was measured by the BCA method. The protein sample to be measured was diluted to 0.8mg / mL, and PARP1 was detected using a fully automated protein expression quantitative analyzer (ProteinSimple), and the internal standard protein was β-actin (both antibodies were from CST). The original data was processed using the software of the fully automated protein expression quantitative analyzer (Compass for SW), and the peak area and PARP1 expression rate relative to the control group were calculated. DC was calculated using a four-parameter nonlinear fitting model in Graphpad 8.3.0 software. 50 values were calculated.
[0405] Results: The compounds of the present invention have significant inhibitory effects on MDA-MB-231 cells and DC 50 Values are less than 10 nM and DC 50 The IC value is less than 5 nM and 50 Values are less than 2 nM, optimally IC 50 The value is less than 1 nM. Here, the results of some examples are shown in Table 3.
[0406] [Table 4]
[0407] 4. Detection of PARP2 protein expression level in MDA-MB-231 cells MDA-MB-231 cells were cultured in DMEM complete medium (supplemented with 10% FBS and 1% dual antibodies) at 37°C and 5% CO2. Cells in the logarithmic growth phase were harvested and the cell density was adjusted to 5 × 10 5 The cells were adjusted to 1000 / well, added to a 6-well cell culture plate at a volume of 1mL / well, and cultured overnight in an incubator at 37°C and 5% CO2. The next day, the target compounds were adjusted to twice the final concentration, and 1mL of compounds at different concentrations was added to the treatment wells, and 0.2% DMSO-containing medium was added to the control wells, and incubated at 37°C and 5% CO2 for 24 hours. The cells were collected in a 1.5mL centrifuge tube, and 25μL of RIPA lysis solution (containing 1X protease inhibitor mixture) was added, and the cells were lysed on ice for 15 minutes, then centrifuged at 12000 rpm and 4°C for 10 minutes, the supernatant was collected, and the protein content was measured by the BCA method. The target protein sample was diluted to 2mg / mL, and PARP2 was detected using a fully automated protein expression quantitative analyzer (ProteinSimple), and the internal standard protein was β-actin (both antibodies were from CST). The raw data was processed using the software of the automated protein expression quantitative analyzer (Compass for SW), and the peak area and the PARP2 expression ratio relative to the control group were calculated. DC was calculated using a four-parameter nonlinear fitting model in Graphpad 8.3.0 software. 50 values were calculated.
[0408] [Table 5]
[0409] Conclusion: Compound 10 of the present invention was shown to have a much weaker degradation activity against PARP2 protein in MDA-MB-231 cells than against PARP1, demonstrating good selectivity for degradation of PARP1.
[0410] 5. Detection of PARP1 protein expression level in MDA-MB-436 cells MDA-MB-436 cells were cultured in DMEM complete medium (15% FBS; 10 μg / mL insulin; 16 μg / mL glutathione and 1% double antibody) at 37°C under CO2-free conditions. Cells in the logarithmic growth phase were harvested and the cell density was adjusted to 2 × 10 5 The cells were adjusted to 1 / well and added to a 6-well cell culture plate at a volume of 1mL / well. The compounds to be detected were adjusted to twice the final concentration, and 1mL of compounds at different concentrations was added to the treatment wells, and 0.2% DMSO-containing medium was added to the control wells, and incubated at 37°C for 24 hours. The cells were collected in a 1.5mL centrifuge tube, and 25μL of RIPA lysis solution (containing 1X protease inhibitor mixture) was added, and the cells were dissolved on ice for 15 minutes, then centrifuged at 12000 rpm and 4°C for 10 minutes, the supernatant was collected, and the protein content was measured by the BCA method. The protein sample to be measured was diluted to 0.8mg / mL, and PARP1 was detected using a fully automated protein expression quantitative analyzer (ProteinSimple), and the internal standard protein was β-actin (both antibodies were from CST). The original data was processed using the software of the fully automated protein expression quantitative analyzer (Compass for SW), and the peak area and PARP1 expression rate relative to the control group were calculated.
[0411] MDA-MB-436 cells were cultured in L-15 complete medium (15% FBS; 10 μg / mL insulin; 16 μg / mL glutathione and 1% double antibody) at 37°C in the absence of CO2. Cells in the logarithmic growth phase were harvested and the cell density was adjusted to 2 × 10 5The cells were adjusted to 1000 / well, added to a 6-well cell culture plate at a volume of 1mL / well, and cultured overnight. The next day, the target compound was adjusted to twice the final concentration, and 1mL of the compound at different concentrations was added to the treatment well, and 0.2% DMSO-containing medium was added to the control well, and incubated at 37°C for 24 hours. The cells were collected in a 1.5mL centrifuge tube, and 25μL of RIPA lysis solution (containing 1X protease inhibitor mixture) was added, and the cells were dissolved on ice for 15 minutes, then centrifuged at 12000 rpm and 4°C for 10 minutes, the supernatant was collected, and the protein content was measured by the BCA method. The target protein sample was diluted to 0.8mg / mL, and PARP1 was detected using a fully automated protein expression quantitative analyzer (ProteinSimple), and the internal standard protein was β-actin (both antibodies were from CST). The original data was processed using the software of the fully automated protein expression quantitative analyzer (Compass for SW), and the peak area and PARP1 expression rate relative to the control group were calculated. DC was calculated using a four-parameter nonlinear fitting model in Graphpad 8.3.0 software. 50 values were calculated.
[0412] Results: The compounds of the present invention have a significant inhibitory effect on MDA-MB-436 cells, and at 100 nM, the maximum degradation rate of PARP1 protein in breast cancer cells MDA-MB-436 reaches 70% or more, even 80% or more, and optimally reaches 90% or more. Here, the DC 50 The value was 0.014 nM, and the results of some examples are shown in Table 5.
[0413] [Table 6]
[0414] 6. Detection of PARP2 protein expression level in MDA-MB-436 cells MDA-MB-436 cells were cultured in L-15 complete medium (15% FBS; 10 μg / mL insulin; 16 μg / mL glutathione and 1% double antibody) at 37°C in the absence of CO2. Cells in the logarithmic growth phase were harvested and the cell density was adjusted to 2 × 10 5 The cells were adjusted to 1 / well, added to a 6-well cell culture plate at a volume of 1mL / well, and cultured overnight. The next day, the target compound was adjusted to twice the final concentration, and 1mL of the compound at different concentrations was added to the treatment well, and 0.2% DMSO-containing medium was added to the control well, and incubated at 37°C for 24 hours. The cells were collected in a 1.5mL centrifuge tube, and 25μL of RIPA lysis solution (containing 1X protease inhibitor mixture) was added, and the cells were dissolved on ice for 15 minutes, then centrifuged at 12000 rpm and 4°C for 10 minutes, the supernatant was collected, and the protein content was measured by the BCA method. The target protein sample was diluted to 2mg / mL, and PARP2 was detected using a fully automated protein expression quantitative analyzer (ProteinSimple), and the internal standard protein was β-actin (both antibodies were from CST). The original data was processed using the software of the fully automated protein expression quantitative analyzer (Compass for SW), and the peak area and PARP2 expression rate relative to the control group were calculated. DC was calculated using a four-parameter nonlinear fitting model in Graphpad 8.3.0 software. 50 values were calculated.
[0415] [Table 7]
[0416] Conclusion: Compound 10 of the present invention was shown to have a much weaker degradation activity against PARP2 protein in MDA-MB-436 cells than against PARP1, demonstrating good selectivity for degradation of PARP1.
[0417] 7. Pharmacokinetic study in rats 7.1 Test animals: male SD rats, approximately 220 g, 6-8 weeks old, 6 rats / compound. Purchased from Chengdu Dashuo Experimental Animal Co., Ltd.
[0418] 7.2 Experimental Design: On the day of the experiment, 12 SD rats were randomly divided into groups according to their weight. They were fasted for 12-14 hours without water restriction one day before administration, and fed 4 hours after administration.
[0419] [Table 8]
[0420] Before and after administration, 0.15 mL of blood was collected from the orbit under isoflurane anesthesia, placed in an EDTAK2 centrifuge tube, and centrifuged at 5000 rpm and 4°C for 10 min to collect plasma. The blood collection times for the intravenous group and intragastric administration group were 0 min, 5 min, 15 min, 30 min, 1 h, 2 h, 4 h, 6 h, 8 h, and 24 h. Before analytical detection, all samples were stored at -80°C, and quantitative analysis was performed on the samples by LC-MS / MS. Here, the test results of some examples are as shown in Table 8.
[0421] [Table 9]
[0422] Conclusion: Compound 10 and compound 58 have good in vivo pharmacokinetic characteristics in rats.
[0423] 8. Pharmacokinetic study in mice 8.1 Test animals: male ICR mice, 20-25g, 18 mice / compound. Purchased from Chengdu Dashuo Experimental Animal Co., Ltd.
[0424] 8.2 Study design: On the day of the study, 36 ICR mice were randomly divided into groups according to weight. They were fasted for 12-14 hours without water restriction one day before administration, and fed 4 hours after administration.
[0425] [Table 10]
[0426] Before and after administration, 0.06 mL of blood was collected from the orbit under isoflurane anesthesia, placed in an EDTAK2 centrifuge tube, and spun at 5,000 rpm for 4 o The samples were centrifuged at 4°C for 10 min, and plasma was collected. The blood was collected at 0, 5, 15, and 30 min, and 1, 2, 4, 6, 8, and 24 h for both the intravenous and intragastric administration groups. All samples were stored at −80°C for 10 min before analysis. o C and quantitative analysis was performed on the samples by LC-MS / MS.
[0427] [Table 11]
[0428] Conclusion: Compound 10 and compound 58 have good in vivo pharmacokinetic characteristics in mice.
[0429] 9. Mouse MDA-MB-436 subcutaneous in vivo tumor model Human breast cancer MDA-MB-436 cells were cultured in Leibovitz's L-15 medium (containing 10 μg / mL insulin, 16 μg / mL glutathione, 10% fetal bovine serum, and 1% double antibody) at 37°C. The cells were passaged twice a week by general digestion using pancreatin. When the cell saturation was 80% to 90% and the required number was reached, the cells were harvested, counted, and then inoculated. 0.2 mL (10 × 10 6 100 pieces) of MDA-MB-436 cells (containing Matrigel, volume ratio 1:1) were subcutaneously inoculated into the right back of BALB / c nude mice (provided by Beijing Weitong Lihua Laboratory Animal Technology Co., Ltd.), and the average tumor volume was approximately 180 mm 3 When the tumor volume reached 100 mg / kg, the animals were divided into groups and drug administration was started (referred to as Day 0). The vehicle group was administered 5% DMSO, 30% PEG400 and 65% of 20% sulfobutyl-β-cyclodextrin solution, and the administration group was administered 1 or 10 mg / kg of compound 10, with an administration frequency of once a day, an administration cycle of 29 days, and a drug-free observation period of 14 days. After grouping, the tumor diameter was measured twice a week using a vernier, and the calculation formula for tumor volume was:
number
number
[0430] Test results: after 28 days of administration, the TGI of 1 and 10mg / kg compound 10 groups was 47.14% and 111% respectively; after withdrawal, the animal tumors of 1mg / kg compound 10 group continued to grow, and the tumor volume was equal to that of the vehicle group on the 43rd day after administration; after withdrawal, the animal tumor volume of 10mg / kg compound 10 group was much smaller than the tumor volume at the time of grouping, that is, tumor growth was very slow. The animal weight of compound 10 administration group did not decrease significantly.
[0431] Conclusion: In the mouse MDA-MB-436 subcutaneous in vivo xenograft tumor model, compound 10 of the present invention has excellent efficacy in inhibiting tumor growth and inducing tumor regression, and is well tolerated.
Claims
1. A PARP-1 decomposing agent of formula (I), a stereoisomer, deuterated product, solvate, pharma- ceutically acceptable salt or co-crystal thereof, [Formula 1] ULM is the E3 ubiquitin ligase binding moiety; L is a bond or chemical linking moiety that covalently couples the PTM and ULM; the PTM is a PARP-1 binding moiety; The PTM has a structure of formula (I-1), (I-2), (I-3) or (I-4), and the L forms a single bond covalent bond with the PTM by replacing any one of H in (I-1), (I-2), (I-3) or (I-4), or L is R 4 and R 5 and are covalently attached to the PTM by forming, together with the N atom to which they are attached, a 4-10 membered heterocycloalkyl group containing 1-2 N atoms and 0-2 heteroatoms selected from S and O; [chemical 2] X 1 , X 2 , X 3 , X 4 and X 5 are independently N or CR 6 and Ring A is a 4-12 membered heterocycloalkyl group containing 1-2 N atoms and 0-2 heteroatoms selected from S and O; R 1 is H, C 1-4 Alkyl group, halogen, CN or C 3-6 and cycloalkyl groups, the alkyl and cycloalkyl groups optionally being selected from halogen, OH, C 1-4 Alkoxy group, NH 2 and COOH; R 2 is H, C 1-4 Alkyl group, C 1-4 Alkoxy groups, halogens, OH or NH 2wherein the alkyl and alkoxy groups are optionally selected from halogen, OH, NH 2 , COOH and C 3-6 substituted with 1 to 3 groups selected from cycloalkyl groups; R 3 is H, C 1-4 Alkyl group, halogen, C 1-4 Alkoxy group or NH 2 wherein the alkyl and alkoxy groups are optionally selected from halogen, OH, NH 2 , COOH and C 3-6 substituted with 1 to 3 groups selected from cycloalkyl groups; R 4 is H, C 1-4 Alkyl group, C 3-6 Cycloalkyl groups or 4-7 membered heterocycloalkyl groups containing 1-3 heteroatoms selected from N, S and O, said alkyl groups, cycloalkyl groups and heterocycloalkyl groups optionally being halogen, OH, NH 2 , COOH and C 3-6 substituted with 1 to 3 groups selected from cycloalkyl groups; R 5 is H, C 1-4 Alkyl group or C 3-6 Cycloalkyl groups, the alkyl and cycloalkyl groups being optionally halogen, OH, NH 2 and COOH; or Optionally, R 4 and R 5 together with the N atom to which they are attached form a 4-10 membered heterocycloalkyl group containing 1-3 heteroatoms selected from N, S and O, said heterocycloalkyl group optionally containing halogen, OH, NH 2 , COOH and C 3-6 substituted with 1 to 3 groups selected from cycloalkyl groups; Each R 6 are independently H, C 1-4 Alkyl group, C 1-4 Alkoxy group, halogen, CN or C 3-6A cycloalkyl group, said alkyl group or cycloalkyl group optionally being selected from the group consisting of halogen, OH, NH 2 , COOH, or a stereoisomer, deuterated form, solvate, pharma- ceutically acceptable salt or co-crystal thereof.
2. The PARP-1 degrading agent has a structure of formula (II), (III), (IV), (V), (VI) or (VII): [C3] wherein Ring A is a 4-12 membered monocyclic heterocycloalkyl group, spirocyclic heterocycloalkyl group, bridged cyclic heterocycloalkyl group or fused cyclic heterocycloalkyl group containing 1-2 N atoms and 0-2 heteroatoms selected from S and O; M is -NR 5 -or- [C4] Ring B is a 4-10 membered heterocycloalkyl group containing 1-2 N atoms and 0-2 heteroatoms selected from S and O, and * is the connecting end to the left side; Each R L are independently -NR N -, C 1-3 Alkylene group, —CO—, —O—, —S—, C 3-6 Cycloalkylene groups, phenyl groups, 5- to 6-membered heteroaryl groups containing 1 to 3 heteroatoms selected from N, S, and O, 4- to 10-membered heterocycloalkylene groups containing 1 to 3 heteroatoms selected from N, S, and O, C 2-6 Alkenylene group, C 2-6 and an alkynylene group, wherein the alkylene group, alkenylene group, alkynylene group, cycloalkylene group, phenyl group, heteroaryl group, and heterocycloalkylene group are optionally selected from the group consisting of 1-4 Alkyl groups, halogens, CN, C 1-4 Alkoxy groups and halogenated C 1-4 substituted with 1 to 3 groups selected from alkoxy groups; The condition is -M-(R L)n-, two identical -NR N -, -O- or -S- is not present, R N is H or C 1-4 is an alkyl group, n is an integer from 0 to 10, ULM is U1, U2, U3, U4, U5, U6, U7: [C5] is selected from m is 1, 2 or 3; R 7 is H, halogen, CN, NH 2 , O.H., C. 1-4 Alkyl group or C 1-4 an alkoxy group, the alkyl or alkoxy group optionally being selected from the group consisting of halogen, CN, NH 2 and OH; R 8 , R 9 is H or taken together to form =O, a stereoisomer, deuterated product, solvate, pharma- ceutically acceptable salt or cocrystal thereof according to claim 1.
3. The PARP-1 decomposing agent has the formula (II-1), (III-1), (IV-1), (II-2), (III-2), (IV-2), (V-1), (VI-1), (VII-1), (V-2), (VI-2) or (VII-2): [C6] [C7] The PARP-1 decomposing agent according to claim 2, or a stereoisomer, deuterated product, solvate, pharma- ceutically acceptable salt or cocrystal thereof, having the structure:
4. X 5 is CH or N, R 1 is H or C 1-3 an alkyl group, the alkyl group being optionally selected from F, Cl, Br, I, OH, NH 2and COOH; R 2 is H, C 1-3 Alkyl group, C 1-3 an alkoxy group, F, Cl, Br or I; R 3 is H, C 1-3 Alkyl group, C 1-3 an alkoxy group, F, Cl, Br or I; n is 1, 2, 3, 4, 5, 6 or 7; R 5 is H, Ring B is a 4-10 membered monocyclic or spirocyclic heterocycloalkyl group containing 1-2 N atoms and 0-2 heteroatoms selected from S and O; Each R L are independently -NH-, C 1-3 Alkylene group, —CO—, —O—, C 3-6 Cycloalkylene groups, phenyl groups, 5- to 6-membered heteroaryl groups containing 1 to 3 heteroatoms selected from N, S, and O, 4- to 10-membered heterocycloalkylene groups containing 1 to 3 heteroatoms selected from N, S, and O, C 2-6 Alkenylene group, C 2-6 and an alkynylene group, wherein the alkylene group, alkenylene group, alkynylene group, phenyl group, heteroaryl group, cycloalkylene group and heterocycloalkylene group are optionally selected from the group consisting of 1-3 Alkyl groups, F, Cl, Br, I, CN, C 1-3 Alkoxy groups and halogenated C 1-3 substituted with 1 to 3 groups selected from alkoxy groups; The condition is -M-(R L ) in n-, there are no two identical —NH— or —O— groups connected thereto; R 7 is H, C 1-3 an alkyl group, F, Cl, Br or I; R 8 , R 9 is H or ═O, The PARP-1 decomposing agent, its stereoisomer, deuterated product, solvate, pharma- ceutically acceptable salt or cocrystal according to claim 3, wherein m is 1 or 2.
5. -M-(R L ) n- or -(R L ) n- is [C8] and * is a linking end to the left side.
6. The decomposition agent is [C9] [C10] [C11] is selected from one of the structures: Here, in each of the above structures, [C12] The PARP-1 decomposing agent according to claim 1, or a stereoisomer, deuterated product, solvate, pharma- ceutically acceptable salt or cocrystal thereof,
7. The PARP-1 decomposing agent of claim 1, wherein the decomposing agent is selected from one of the structures in Table A, a stereoisomer, deuterated product, solvate, pharma- ceutically acceptable salt or co-crystal thereof.
8. A pharmaceutical composition comprising the PARP-1 decomposing agent according to any one of claims 1 to 7, its stereoisomer, deuterated product, solvate, pharma- ceutically acceptable salt or cocrystal, and a pharma- ceutically acceptable carrier and / or excipient.
9. Use of the PARP-1 decomposing agent according to any one of claims 1 to 7, its stereoisomer, deuterated product, solvate, pharma- ceutically acceptable salt or cocrystal, or the composition according to claim 8, in the manufacture of a medicament for treating / preventing a PARP-1 mediated disease.
10. The use according to claim 9, wherein the PARP-1 mediated disease is breast cancer, ovarian cancer, uterine cancer or cervical cancer.
11. A pharmaceutical composition or formulation comprising 1 to 1500 mg of a compound according to any one of claims 1 to 7, a stereoisomer, deuterated form, solvate or a pharma- ceutically acceptable salt thereof, and a pharma- ceutically acceptable carrier and / or excipient.
12. 13. A method for treating a disease in a mammal, said method comprising administering to a subject a therapeutically effective amount of a compound according to any one of claims 1 to 7, its stereoisomer, deuterated form, solvate or pharma- ceutically acceptable salt, said therapeutically effective amount being preferably 1 to 1500 mg, and said disease being preferably breast cancer, ovarian cancer, uterine cancer or cervical cancer.
Citation Information
Patent Citations
Compound for inducing PARP-1 degradation based on CRBN ligand as well as preparation method and application of compound
CN110563703A
PARP1 protein degradation agent and application thereof in tumor resistance
CN111606969A
Quinolinone derivatives as PARP inhibitors
JP2011500758A
Compounds and methods for enhancing target protein degradation
JP2018512449A
Targeted protein degradation compounds, their antitumor applications, their intermediates and applications of intermediates
JP2021521163A
